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Background: Traditionally, patients are encouraged to attend dental recall appointments at regular
6-month intervals, irrespective of their risk of developing dental disease. Stakeholders lack evidence
of the relative effectiveness and cost-effectiveness of different recall strategies and the optimal recall
interval for maintenance of oral health.
Objectives: To test effectiveness and assess the cost–benefit of different dental recall intervals over a
4-year period.
Design: Multicentre, parallel-group, randomised controlled trial with blinded clinical outcome assessment
at 4 years and a within-trial cost–benefit analysis. NHS and participant perspective costs were combined
with benefits estimated from a general population discrete choice experiment. A two-stratum trial design
was used, with participants randomised to the 24-month interval if the recruiting dentist considered
them clinically suitable. Participants ineligible for 24-month recall were randomised to a risk-based or
6-month recall interval.
Setting: UK primary care dental practices.
Participants: Adult, dentate, NHS patients who had visited their dentist in the previous 2 years.
Interventions: Participants were randomised to attend for a dental check-up at one of three dental
recall intervals: 6-month, risk-based or 24-month recall.
Main outcomes: Clinical – gingival bleeding on probing; patient – oral health-related quality of life;
economic – three analysis frameworks: (1) incremental cost per quality-adjusted life-year gained,
(2) incremental net (societal) benefit and (3) incremental net (dental health) benefit.
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Results: A total of 2372 participants were recruited from 51 dental practices; 648 participants were
eligible for the 24-month recall stratum and 1724 participants were ineligible. There was no evidence
of a significant difference in the mean percentage of sites with gingival bleeding between intervention
arms in any comparison. For the eligible for 24-month recall stratum: the 24-month (n = 138) versus
6-month group (n = 135) had an adjusted mean difference of –0.91 (95% confidence interval –5.02
to 3.20); the risk-based (n = 143) versus 6-month group had an adjusted mean difference of –0.98
(95% confidence interval –5.05 to 3.09); the 24-month versus risk-based group had an adjusted mean
difference of 0.07 (95% confidence interval –3.99 to 4.12). For the overall sample, the risk-based
(n = 749) versus 6-month (n = 737) adjusted mean difference was 0.78 (95% confidence interval
–1.17 to 2.72). There was no evidence of a difference in oral health-related quality of life between
intervention arms in any comparison. For the economic evaluation, under framework 1 (cost per
quality-adjusted life-year) the results were highly uncertain, and it was not possible to identify the
optimal recall strategy. Under framework 2 (net societal benefit), 6-month recalls were the most
efficient strategy with a probability of positive net benefit ranging from 78% to 100% across the
eligible and combined strata, with findings driven by the high value placed on more frequent recall
services in the discrete choice experiment. Under framework 3 (net dental health benefit), 24-month
recalls were the most likely strategy to deliver positive net (dental health) benefit among those eligible
for 24-month recall, with a probability of positive net benefit ranging from 65% to 99%. For the combined
group, the optimal strategy was less clear. Risk-based recalls were more likely to be the most efficient
recall strategy in scenarios where the costing perspective was widened to include participant-incurred
costs, and in the Scottish subgroup.
Limitations: Information regarding factors considered by dentists to inform the risk-based interval and
the interaction with patients to determine risk and agree the interval were not collected.
Conclusions: Over a 4-year period, we found no evidence of a difference in oral health for participants
allocated to a 6-month or a risk-based recall interval, nor between a 24-month, 6-month or risk-based
recall interval for participants eligible for a 24-month recall. However, people greatly value and are
willing to pay for frequent dental check-ups; therefore, the most efficient recall strategy depends on
the scope of the cost and benefit valuation that decision-makers wish to consider.
Future work: Assessment of the impact of risk assessment tools in informing risk-based interval
decision-making and techniques for communicating a variable recall interval to patients.
Trial registration: Current Controlled Trials ISRCTN95933794.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health
Technology Assessment programme [project numbers 06/35/05 (Phase I) and 06/35/99 (Phase II)] and
will be published in full in Health Technology Assessment; Vol. 24, No. 60. See the NIHR Journals Library
website for further project information.
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Plain English summary
Traditionally, dentists have encouraged both patients at low risk and patients at high risk of developingdental disease to attend their dental practices for regular 6-month ‘check-ups’. There is, however,
little evidence available for either patients or dentists to use when deciding on the best dental recall
interval (i.e. time between dental check-ups) for maintaining oral health.
In this study, we wanted to find out, for adult patients who regularly attend the dentist, what interval
of time between dental check-ups maintains optimum oral health and represents value for money.
A total of 2372 adults who regularly attended 51 different dental practices across Scotland, Northern
Ireland, England and Wales were involved. Patients aged 18 years or over who received all or part
of their care as NHS patients were randomly allocated to groups to receive a check-up either every
6 months, at an individualised recall interval based on their own risk of oral disease (risk-based
recall), or every 24 months (if considered at low risk by their dentist). The recruited adults completed
questionnaires at their first trial appointment and then every year of the 4-year study. Their attendance
at recall appointments was recorded and they received a clinical assessment taken by study staff at the
end of their involvement at year 4.
After 4 years, there was no evidence of a difference in the oral health of patients allocated to a
6-month or variable risk-based recall interval. For patients considered by their dentists to be suitable
for a 24-month recall interval, there was no difference between those in the 24-month, 6-month or
risk-based recall intervals. However, people greatly value and are willing to pay for frequent dental
check-ups. The recall strategy that offers the best value for money to patients and the NHS, therefore,
depends on what people and decision-makers wish to value within a health-care system.
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Scientific summary
Background
Traditionally, patients have been encouraged to attend dental recall appointments at regular intervals
of 6 months between appointments, irrespective of the individual’s risk of developing dental disease.
This recommendation of a 6-month recall interval has become established practice in primary dental care
in many countries; however, there is a weak evidence base underpinning this recommendation. There
has been a longstanding international debate regarding the clinical effectiveness and cost-effectiveness
of recall intervals for routine dental check-up examinations. The need for primary research has been
highlighted in the Health Technology Assessment Group’s systematic review of routine dental check-ups,
which found little evidence to support or refute the practice of encouraging 6-month dental check-ups
in adults. The more recent Cochrane review on recall interval found only one trial, which was assessed
as having a high risk of bias, with 185 participants and concluded that there was insufficient evidence to
draw any conclusions regarding the potential beneficial or harmful effects of altering the recall interval
between dental check-ups. The limited evidence from recent observational studies also supports the
need for research. Many Clinical Commissioning Groups in England are now seeking to secure adherence
to the National Institute for Health and Care Excellence recall interval guideline as part of their clinical
governance responsibilities when commissioning dental primary care services. However, the lack of
direct evidence behind differing recall strategies complicates the adoption process, while uncertainty
remains within Clinical Commissioning Groups and among dentists as to how best to implement the
guidance in practice. There is, therefore, an urgent need to assess the relative effectiveness and value
for money of different dental recall intervals in a robust, sufficiently powered randomised controlled
trial in primary dental care.
The trial protocol was published in BMC Oral Health [Clarkson JE, Pitts NB, Bonetti, D, Boyers D,
Braid H, Elford R, et al. INTERVAL (investigation of NICE technologies for enabling risk-variable-adjusted-
length) dental recalls trial: a multicentre randomised controlled trial investigating the best dental recall
interval for optimum, cost-effective maintenance of oral health in dentate adults attending dental primary
care. BMC Oral Health 2018;18:135].
Objectives
The aim of this trial was to compare the effectiveness and cost–benefit of dental check-ups at different
recall intervals (fixed-period 6-month recall, risk-based recall or fixed-period 24-month recall) for
maintaining optimum oral health in dentate adults attending general dental practices.
The primary objectives were to compare the three recall strategies on:
l gingival bleeding on probing
l oral health-related quality of life
l value for money in terms of (1) cost per quality-adjusted life-year gained, (2) incremental net
(societal) benefit and (3) incremental net (dental health) benefits.
The secondary objectives were to compare the three recall strategies on:
l periodontal probing depths
l dental caries
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l calculus
l preventative and interventive dental treatment
l patient anxiety
l patient satisfaction with care
l oral health knowledge, attitudes and behaviours, and to explore dentists’ attitudes towards dental
recall intervals
l NHS and patient participant perspective costs
l determining the general population’s willingness to pay.
Methods
Design
The Investigation of NICE Technologies for Enabling Risk-Variable-Adjusted-Length (INTERVAL) trial
was a UK-wide, multicentre, parallel-group, randomised controlled trial with blinded outcome
assessment at 4-year follow-up.
To test the effect of dental recall interval, patient participants were randomised to one of three
recall intervals: a fixed-period 24-month recall interval, a risk-variable-adjusted-length recall interval
(risk-based recall) based on the National Institute for Health and Care Excellence guideline, and a
fixed-period 6-month recall interval.
A two-stratum trial design was proposed to overcome potential ethical considerations and dental clinician
and/or participant concerns. Participants were randomised to the fixed-period 24-month recall interval only
if the recruiting dentist considered them clinically suitable. Participants who were not considered suitable
for 24-month period recall were randomised to either a risk-based recall or a 6-month recall interval.
Setting
The trial sought to recruit general dental practitioners/practices from across the UK, representing
a cross-section of practitioners in terms of urban/rural areas, community-level sociodemographics,
and fluoridated or non-fluoridated communities.
Dentist participants
Inclusion criteria
l NHS provider for adult patients.
l Primary care provider: salaried service, corporate and independent operators.
l Willing to follow trial protocol.
Exclusion criteria
l Providing only private dental services to adults.
l Unwilling to follow trial protocol.
Patient participants
Inclusion criteria
Adult patients (≥ 18 years) who:
l were dentate
l had visited their dentist in the previous 2 years
l received their dental care in part or fully as an NHS patient, including dental examination.
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Exclusion criteria
l Patients with a medical condition indicating increased risk of bleeding.
l Immunocompromised patients.
Interventions
The trial interventions recall intervals were a fixed-period 24-month recall interval, a risk-variable-
adjusted-length recall interval based on the National Institute for Health and Care Excellence
guideline, and a fixed-period 6-month recall interval.
Patient participants allocated to the fixed-period 24-month recall interval and the fixed-period 6-month
recall interval groups were invited to attend their dentist at the scheduled time intervals for a routine
dental check-up. The content of this check-up remained as per current practice. A recognised definition of
a routine NHS dental check-up is clinical examination, advice, charting including monitoring of periodontal
status and report. Patient participants allocated to the risk-based recall interval group were allocated
recall appointments at time intervals determined by the evidence-based process outlined in the 2004
National Institute for Health and Care Excellence guideline on dental recall. The National Institute for
Health and Care Excellence guideline was developed using extensive consensus methods and the limited
evidence available. The recommendation was that the recall interval range for adults should vary from
3 to 24 months, depending on the likely risk of development or progression of dental disease.
Outcome measures
All primary and secondary outcomes were measured at the 4-year follow-up time point.
Primary outcomes
l Clinical: gingival bleeding on probing.
l Patient centred: oral health-related quality of life (Oral Health Impact Profile-14).
Secondary outcomes
Clinical:
l dental caries
l periodontal probing depth
l calculus
l preventative and interventive care.
Patient centred:
l dental anxiety
l oral health-related knowledge, attitudes and behaviours
l generic quality of life measured using the EuroQol-5 Dimensions, three-level version
l use of and reason for use of dental services
l satisfaction with care.
Economic outcomes
l NHS costs.
l Patient-incurred costs.
l General population preferences, willingness to pay calculated from a discrete choice experiment to
value service delivery and outcomes.
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l Incremental net benefits (willingness to pay minus costs) measured as societal net benefit
(willingness to pay for health and non-health aspects), and dental health net benefit (willingness
to pay for health outcomes, bleeding on brushing and caries experience only).
l Quality-adjusted life-years.
l Incremental cost per quality-adjusted life-year.
Service provider measures
l Dentist attitude towards dental recall intervals.
Clinical outcomes were assessed at 4 years post randomisation by trained outcome assessors who
were blinded to participant allocation. Patient-centred outcomes were measured at baseline and
annually via self-administered postal questionnaires over the 4-year follow-up period. Our sample size
calculations indicated that we needed to randomise 705 participants to stratum 1 (235 in each arm)
and 1030 to stratum 2 (515 in each arm). The primary analysis used an intention-to-treat framework
and all participants with available data remained in their allocated groups. Outcomes collected at year 4
were analysed using a generalised linear model with a random effect for dental practice; outcomes
collected at years 1, 2, 3 and 4 were analysed using a mixed-effects model with two random effects:
participant and practice. All analyses were adjusted for the protocol minimisation variables.
Economic evaluation
The economic analysis was conducted using different perspectives of benefits (quality-adjusted life-years,
willingness to pay for dental health outcomes, willingness to pay for dental recall and associated outcomes)
and costs [NHS (dental, sourced from the routine claims data), NHS (dental and other services, such as
primary and secondary medical care), and societal (including NHS and participant perspective costs)].
The preferred perspective depends on normative views of what benefits should be maximised with the
NHS dental budget and what costs should be minimised.
Routinely collected dental claims data were linked to trial data to determine the costs of NHS provided
dental care [from both an NHS and participant (including participant co-payments)] perspective.
Additional participant costs, including travel costs and the opportunity cost of time spent attending
dental appointments, were collected from participant self-reported questionnaires.
Quality-adjusted life-years were calculated based on participant responses to the EuroQol-5 Dimensions,
three-level version, valued using UK general population tariffs. A discrete choice experiment administered
to a nationally representative online sample of the UK general population was used to calculate willingness
to pay for health outcomes (bleeding on brushing and caries experience) and service delivery (frequency of
recall). The discrete choice experiment data were analysed using logistic regression to model preferences as
a function of the attributes. Missing costs and benefits data from the trial were imputed using multiple
imputation methods. All analyses were conducted following intention to treat.
The economic evaluation results were reported using three alternative perspectives on the scope of
benefits to be included in the evaluation. Framework 1 reported the results of a cost–utility analysis
as incremental cost per quality-adjusted life-year. Framework 2 used willingness-to-pay tariffs from
the discrete choice experiment, mapped to the trial interventions (value of recall frequency) plus health
outcomes (value of bleeding on brushing and caries experience) to calculate net (societal) benefit,
whereas framework 3 used willingness-to-pay tariffs mapped to health outcomes only to calculate net
(dental health) benefit. Within each evaluation framework, we considered a range of different scenario
analyses, including different perspectives of costs (costs to the NHS dental budget, costs to the wider
NHS budget and costs to both patient participants and the NHS), different methodological assumptions
(around discounting and mapping the discrete choice experiment results to the trial outcomes) and
regional-specific subgroup analyses.
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Uncertainty in the data was described using cost–benefit acceptability curves and scatterplots of
incremental costs and benefits, with the probability of each strategy being the optimal recall strategy
reported at a willingness to pay of £20,000 per quality-adjusted life-year (framework 1) and a benefit-
to-cost ratio = 1 (frameworks 2 and 3) for all scenario analyses considered.
Results
A total of 2372 participants were recruited, with 648 participants considered eligible to be randomised
to the 24-month recall arm and, therefore, randomised to one of the three intervention arms. A total
of 1724 participants were considered ineligible to be randomised to the 24-month recall arm and were,
therefore, randomised to the 6-month recall or risk-based recall arm.
There were no important differences or imbalances across randomised groups in each of the eligibility
strata. All participants were, in general, satisfied with the dental services received and had low dental
anxiety and a good knowledge about the frequency and duration of brushing; however, they were less
informed about what to do after brushing (i.e. spit but not rinse). Overall, participants in the ineligible
for 24-month recall stratum were older, self-reported to attend the dentist more regularly and had a
higher Oral Health Impact Profile-14 levels than those in the eligible stratum.
The primary clinical outcome, mean gingival bleeding on probing, was collected at the 4-year clinical
follow-up. Overall, 64% of participants attended their appointment and 71% of participants completed a
year 4 patient questionnaire, in the eligible for 24-month recall stratum. In the ineligible stratum, 70% of
participants attended the clinical appointment and 76% of participants replied to the year 4 patient
questionnaire. For the primary outcome, the adjusted difference between interventions was < 1% and
the confidence intervals excluded the possibility of a 7.5% difference between groups. There was no
evidence of a significant difference between the groups in any comparison: the 24-month recall group
versus the 6-month recall group had an adjusted mean difference of –0.91 (95% confidence interval
–5.02 to 3.20; p-value = 0.66); the risk-based group versus the 6-month recall group had an adjusted
difference of –0.98 (95% confidence interval –5.05 to 3.09; p-value = 0.64); the 24-month recall group
versus the risk-based group had an adjusted mean difference of 0.07 (95% confidence interval –3.99 to
4.12; p-value = 0.97). There was also no evidence of a significant difference between the recall arms for
any of the secondary clinical outcomes in any comparison in either eligibility stratum.
The primary patient-centred outcome, oral health-related quality of life, was measured at the 4-year
follow-up time point, as well as at baseline and annually throughout the follow-up period, through
patient questionnaires. There was no evidence of a difference across any comparison: the 24-month
recall group versus the 6-month recall group had an effect size of –0.24 (95% confidence interval
–1.55 to 1.07; p-value = 0.72); the risk-based group versus the 6-month recall group had an effect
size of –0.61 (95% confidence interval –1.93 to 0.71; p-value = 0.37); the 24-month recall group versus
the risk-based group had an effect size of 0.37 (95% confidence interval –0.95 to 1.69; p-value = 0.58).
Overall, there were no important differences between the groups across all secondary patient-reported
outcomes in either eligibility stratum.
The economic evaluation results are described under each analysis framework below. Scenario
analyses that affected the overall conclusions are emphasised.
l Framework 1 (maximising generic health benefit) used the results of the cost–utility analysis to
assess the most efficient strategy in terms of maximising generic health outcomes (i.e. EuroQol-5
Dimensions-based quality-adjusted life-years). There was substantial uncertainty surrounding the
optimal recall strategy across all analyses undertaken. This is due to concerns regarding the
quality-adjusted life-year’s sensitivity to capture any potential benefits of dental care interventions.
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The cost-effectiveness acceptability curves and scatterplots of the cost-effectiveness plane illustrate
the residual uncertainty, rendering it difficult to draw clear conclusions about the most efficient
use of resources using this metric; for example, in the combined analysis across both trial strata,
no strategy achieved a probability of cost-effectiveness > 70% at a threshold value of society’s
willingness to pay for a quality-adjusted life-year gain of £20,000. The probability of cost-
effectiveness was higher for the 24-month recall strategy in the analysis restricted to the eligible
for 24-month recall stratum because of the potential for cost savings from longer recall intervals.
l Framework 2 (maximising societal well-being): the discrete choice experiment provided important
information on the valuation of dental health outcomes. The general population was willing to
pay to avoid progressive levels of dental decay and bleeding gums. It also highly valued and
was willing to pay for more frequent dental recalls. Taking the broadest perspective of benefits,
including all components of value to the general population (incorporating both health and non-
health sources of utility), generates a high probability that 6-month recalls are net beneficial.
This finding is consistent across the full range of sensitivity analyses undertaken. This conclusion is
influenced by the high value that the general population attaches to the 6-month recall service
attribute in the discrete choice experiment.
l Framework 3 (maximising dental health benefits) evaluated the most efficient dental recall strategy
in terms of maximising dental health benefit (i.e. through the discrete choice experiment valuation
of bleeding and caries outcomes). For the stratum deemed eligible for 24-month recalls, differences
in costs to the total NHS dental budget (across the UK) are not statistically significantly different
across the randomised arms; however, substantial cost savings can be achieved from longer recall
intervals when considering the combined cost burden to both patients and the NHS. These savings
can be achieved without adversely affecting dental health outcomes. Twenty-four-month recall is
the most likely optimal strategy, for those eligible, with a probability of positive net dental health
benefit ranging between 65% and 99% across the full range of sensitivity analyses conducted.
For the trial population as a whole (including both the eligible and ineligible for 24-month recall
strata), there is substantial uncertainty regarding the most efficient strategy to maximise dental
health benefit. Risk-based recalls were more likely to generate positive net dental health benefit in
Scotland than in England, and when a wider perspective of the costing analysis was considered.
Conclusions
The INTERVAL trial involving regular adult NHS dental attenders has shown that a variable risk-based
recall interval is not detrimental to oral health and is acceptable to patients and dentists with the
potential for cost savings. Over a 4-year period, we found no difference in oral health for patient
participants allocated to a 6-month or a variable risk-based recall interval. Nor did we find a difference
between the recall intervals of 24 months, 6 months and risk based for the 30% of adults considered
suitable to be recalled at 24 months by their dentist. Economic evaluation results based on incremental
cost per quality-adjusted life-year were highly uncertain, perhaps because of a lack of sensitivity of
the EuroQol-5 Dimensions to capture variation in dental health outcomes. Taking a dental health-care
perspective of benefits, where dental health outcomes only are valued (bleeding on brushing and caries
experience), for those eligible for a 24-month recall, 24-month recalls generated the highest probability
of positive incremental net benefit. Taking a broader, societal perspective of benefits, and including the
value placed on more frequent recall services in the discrete choice experiment, 6-month recalls had
the highest probability of positive incremental net benefit.
Trial registration
This trial is registered as ISRCTN95933794.
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Chapter 1 Introduction
Introduction
The subsequent chapters of this monograph describe the INTERVAL (Investigation of NICE Technologies
for Enabling Risk-Variable-Adjusted-Length) Dental Recalls Trial, a National Institute for Health Research
(NIHR) Health Technology Assessment (HTA) programme-funded trial testing of the effectiveness and
cost–benefit of dental check-ups at different recall intervals. The trial protocol has been published.1
The reason for the trial
Background
Traditionally, patients have been encouraged to attend dental recall appointments at regular intervals of
6 months between appointments – irrespective of the individual’s risk of developing dental disease, the
principal function of the dental recall being prevention and early detection of oral disease, in particular
dental caries (tooth decay) and periodontal disease.2 The traditional clinical rationale, developed at times
of higher caries levels and progression rates, was the early detection of caries lesions while they were
small in order to restore them before lesion progression resulted in extensive destruction of tooth
tissue. This has evolved to a modern philosophy that seeks to detect small lesions at an early stage in
order to provide preventative interventions prior to lesion cavitation. The preventative advice provided
at recall examinations varies between practitioners and, indeed, between a practitioner’s individual
patients and may incorporate instruction on appropriate oral hygiene practices and dietary advice
for the prevention of dental disease, as well as advice aimed at modifying risk factors for oral disease
such as smoking cessation advice and alcohol-related health advice. The dental recall examination may,
therefore, be understood as having a dual function as a primary preventative (the prevention of oral
disease before it occurs) and a secondary preventative (limiting the progression and effect of oral
diseases at an early stage through early diagnosis) measure. The evolution of implementing the change
from surgical to preventative treatment philosophies has been, and continues to be, complex and slow.
The recommendation of a 6-month recall interval has become established practice in primary
dental care in many countries3–7 and has probably been a cornerstone of dental practice since it was
mentioned by Pierre Fauchard in 1746.8 There has been a longstanding international debate regarding
the clinical effectiveness and cost-effectiveness of different recall intervals for routine dental check-up
examinations,2,3,5,9–16 particularly in the light of changes in the epidemiology of dental diseases and
in the interests of careful resource management.9,17–19 This debate has been fuelled by conflicting
evidence from observational studies on the effects of regular attendance and by the subsequent
diverging interpretations of that conflicting evidence.20
Epidemiology and pathogenesis
Periodontal disease is an inflammatory disease of the soft and hard tooth-supporting tissues. Periodontal
diseases comprise gingivitis and periodontitis. Gingivitis is a reversible condition characterised by gingival
redness and oedema, and absence of periodontal attachment loss.21 The 2017 world workshop and
classification system gives clear definition of a gingivitis site and a gingivitis case (patient).21 A patient can be
defined as a ‘gingivitis case’ when bleeding on probing at > 30% of sites is evident at a minimum of 10% of
sites.21 Bleeding at between 10% and 30% of sites is defined as localised gingivitis and bleeding on probing
at > 30% of sites is generalised gingivitis. Gingival health is defined as bleeding on probing at < 10% of
sites. Gingivitis is a pre requisite for periodontitis and is also a risk indicator for dental caries progression.
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Periodontitis is the irreversible destruction of the tooth-supporting periodontal structures (periodontal
ligament, cementum and alveolar bone) due to inflammation.22 Periodontitis is characterised by
periodontal pocket formation and gingival recession. In addition, tooth mobility and migration may
occur as a result, as well as dentine hypersensitivity of the exposed root surface, root caries and,
ultimately, tooth loss.
Gingivitis and periodontitis are a continuum of the same inflammatory disease process,23 with evidence
that gingivitis is a risk factor for periodontitis,24 and that absence of gingival bleeding is a reliable
predictor for the maintenance of periodontal health.25 However, it is not currently possible to predict
progression from gingivitis to periodontitis at either the individual or the site-specific level. Accumulation
of microbial dental plaque is the primary aetiological factor for gingivitis and periodontitis, as well as
dental caries.26–28 Disease progression is also known to be affected by genetic factors (host defence
mechanism), calculus, smoking and systemic comorbidities, including type 2 diabetes.29–32
Despite the largely preventable nature of periodontal disease, it is considered the most common
disease of mankind,33 remains the major cause of poor oral health globally and is the primary cause of
tooth loss in older adults.22,34 Global estimates of gingivitis range from 50% to 90% of populations.35–37
Severe periodontitis is the sixth most prevalent human disease globally, with a prevalence of 11.2%,38
which appears to be rapidly increasing.33
Dental caries is a multifactorial chronic oral disease that affects most populations globally and is
considered the most important global oral health burden.39 Dental caries results from production of
organic acids by acidogenic bacteria within dental plaque (a biofilm formed on the tooth surface soon
after tooth cleaning). Dental caries is considered a consequence of an ecological shift in the balance of
the normally beneficial oral microbiota driven by a change in lifestyle and in the oral environment.40
Organic acids can cause mineral loss from the tooth surface by removing calcium and phosphate ions
from surface apatite crystals (demineralisation). In favourable conditions, a reversal of this process
is possible (remineralisation). The development of a carious lesion is a dynamic process that may
progress, halt or reverse. Progression of the carious lesion occurs where the demineralisation process
prevails over remineralisation. Carious lesions can range from early non-detectable mineral loss
restricted to enamel, through lesions that extend into dentine without any surface cavitations, to
cavitated lesions visible as holes in the teeth. Progression rates of carious lesions appear to be more
rapid in dentine than in enamel, with variable rates between individuals as well as between lesions
within an individual.41,42 Dental caries and its consequences are considered the most important burden
of oral health, affecting up to 100% of adults in most countries.43 It is not just a disease of children, but
appears to occur at a relatively constant rate throughout the life course.44
Where gingival recession has migrated apical to the amelocemental junction, the exposed root surface
of the tooth may be susceptible to root caries. Like coronal caries, the main aetiological factor for
the initiation and progression of root caries is the presence of a cariogenic biofilm and fermentable
carbohydrates. Owing to the lower level of mineralisation of dentine, a smaller decrease in pH will
induce demineralisation of the root surface.45 As with coronal caries, the formation of root caries is a
dynamic process of demineralisation and remineralisation, with progression of caries occurring where
the balance of factors favours demineralisation.46 Importantly, and unlike caries in enamel, coronal
dentine and root caries both involve not only demineralisation but also collagen degradation,47
resulting in a demineralisation process that is approximately twice as rapid on enamel.48
Root caries, like other forms of the disease, can be associated with pain, discomfort and tooth loss,49,50
which has the most significant impact on the oral health-related quality of life (OHRQoL) of the
elderly.51,52 Although a well-recognised disease, its prevalence is increasing as populations age and
retain more of their natural teeth into older life.47,53,54 There is a wide range in the reported global
prevalence of root caries for diverse populations ranging from 29% to 89%.55
INTRODUCTION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
2
Individuals and dental care professionals have different roles to play in the prevention and control
of periodontal diseases and dental caries. Consistent removal of the intraoral plaque biofilm by
means of personal tooth brushing and interdental cleaning is considered the foundation of successful
primary prevention of periodontal disease and dental caries.56,57 The dental care professionals’ role in
primary prevention involves assessment of an individual’s risk of developing oral disease and tailoring
preventative advice, including oral hygiene and dietary advice based on this risk assessment, although
the evidence relating to the beneficial effects of chairside provision of dental health education advice
is conflicting.58,59
In 2004, the National Institute for Health and Care Excellence (NICE) published a guideline entitled
Dental Recall: Recall Interval Between Routine Dental Examinations,60 following a remit received from the
Department of Health and Social Care and the Welsh Assembly Government. Within this guideline,
the role of the oral health review, or dental check-up, in providing primary prevention and secondary
prevention is highlighted. Subsequently, in 2011, the Scottish Dental Clinical Effectiveness Programme
(SDCEP) published their guidance on oral health assessment and review. The SDCEP guidance was
based on and was a tool to assist implementation of the NICE recommendations.61
Given that the global burden of oral disease is not shared evenly, the risk of developing oral disease
between patients is clearly variable. It has, therefore, been suggested that the preventative needs of
patients are also variable and that intervals between oral health reviews should be appropriate for the
needs of individual patients.
Dental check-ups at 6-month intervals have been customary in the general dental service (GDS) in the
UK since the inception of the NHS. Although a recall interval of 6 months is not explicitly recommended
by the NHS, this practice is implicitly recognised by NHS regulations that have remunerated dental
practitioners for providing a dental check-up at 6-month intervals for decades, and, since 2006, the
dental check-up has been free in Scotland. It has been argued that a 6-month dental recall policy is too
rigid and that recall intervals should match the individual needs of patients more closely – needs that
may change over time. Analysis of dental attendance patterns in NHS primary dental care using the
Dental Practice Board’s longitudinal data demonstrates an attendance pattern that is variable, with
many patients attending less frequently than every 6 months.59 Data from the Information Services
Division (ISD) in Scotland show that the vast majority of Scottish adults did not attend NHS primary
care dental services on an annual basis, with only 23% attending at least once per year in each of the
previous 6 years, and 21% not attending at all in the past 6 years.62
In addition, it has been consistently observed that caries experience is generally more extensive in
lower socioeconomic status groups,63 reinforcing the case for patient-specific recall intervals, based
on an assessment of the patient’s risk of oral disease.3,60,64 Evidence from the Dutch health system
suggests that there is an increase in general dentists moving away from recalling all patients at the
same interval in favour of applying an individualised recall interval, resulting in more frequent
screening for periodontal disease than with those dentists using a fixed-period recall protocol.65
One of the persistent arguments in favour of maintaining 6-month dental check-ups is that dentists
may miss the opportunity to diagnose oral cancer lesions at an early stage in patients who attend at
longer recall intervals. The incidence of oral cavity cancer in the UK is highest in Scotland, at 10.0 per
100,000 males,66 and has been relatively stable in Scotland since 2000 but rising in England and Wales.
However, it has been reported that 53.7% of patients diagnosed with oral cancer had not attended an
NHS primary care dentist in the 2 years preceding diagnosis,67 thus radically decreasing the opportunity
for early detection. From these data it is estimated that a dentist potentially encounters one case of oral
cancer every 10 years.67 Brocklehurst and Speight68 reviewed the pros and cons of a national screening
programme for mouth cancer, concluding that studies into mouth cancer screening have provided
evidence to satisfy only 5 of the 20 criteria required by the UK Screening Committee, with no evidence
of a test effective in the detection of oral lesions in the context of a screening programme,69 and that
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more research is needed to develop diagnostic tests more specific than conventional oral examination.68
The authors also report that screening programmes have not resulted in a demonstrable reduction
in mortality, apart from in high-risk groups, in which there is some evidence that screening may be
effective and cost-effective.68 Instead of asserting the need for shorter intervals between dental recall
appointments, these papers67–69 highlight the need for oral health services to develop strategies to reach
out to populations that do not attend primary care dental services regularly, instruct patients about
high-risk habits including alcohol and tobacco use, and better network with other primary care services.
Evidence base
The recommendations in the NICE guideline on dental recall60 are designed to aid dentists in assigning
individualised recall intervals to patients based on their risk of developing oral disease. The Guideline
Development Group produced a checklist for use by dentists when assessing risk, including specific risk
factors for consideration.60 The guideline recommends an adjustable recall interval for adults, ranging
from a minimum of 3 months to a maximum interval of 24 months between recall appointments for
patients who have repeatedly demonstrated an ability to maintain oral health. The guideline panel
recommended that the recall interval be regularly assessed, discussed and agreed based on each individual’s
oral health risk profile and amended accordingly. The Guideline Development Group considered a balance
of benefits and harms related to caries, periodontal disease and also oral mucosal lesions in making its
recommendations. The recommendations are, however, based on low-quality evidence and the clinical
experience of the Guideline Development Group. This lack of evidence has complicated the implementation
of this guideline for dentists and health service commissioners.
Although the concept of assigning risk-based recall intervals has gained increasing standing internationally,
the clinical effectiveness of this recall protocol is not supported by scientific evidence from clinical trials.
Furthermore, there remains significant variation in professional recommendations within and between
countries regarding the maximum time interval between dental check-ups that can reasonably be assigned
for patients at low risk of oral disease. This can be considered inevitable given that many guideline
recommendations regarding this issue have been informed primarily by professional consensus and are
subject to variation in interpretation.70
There is also a paucity of reliable scientific evidence to support the effectiveness of routine dental
checks of differing recall frequencies in adults. The scientific basis for the 6-month dental examination
was questioned more than 30 years ago.2 Since then, systematic reviews investigating this key question
have reported limited evidence of poor overall quality, which is insufficient to reach any conclusions
regarding the potential beneficial and harmful effects of varying recall intervals between dental check-
ups, and concluding that there is no evidence to support or refute the practice of encouraging patients
to attend for dental check-ups at 6-month intervals.71,72 The NICE guideline on dental recall reiterated
the need for research in this area to examine the effects of varying dental recall intervals on oral
health.59 The NICE guideline also concluded that the research base was severely lacking in terms of
determination of the optimal dental recall intervals on the basis of cost-effectiveness.60
There is, therefore, an urgent need to assess the relative effectiveness and cost-effectiveness of different
dental recall intervals in a robust, sufficiently powered randomised control trial (RCT) in primary dental care.
The questions addressed by the INTERVAL trial
Aim
The aim of this trial was to compare the effectiveness and cost–benefit of dental check-ups at different
recall intervals (fixed-period 6-month recall, risk-based recall or fixed-period 24-month recall) for
maintaining optimum oral health in dentate adults attending general dental practice.
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Objectives
The primary objectives were to compare the three recall strategies on:
l gingival bleeding on probing
l oral health-related quality of life
l value for money in terms of (1) cost per quality-adjusted life-year (QALY) gained, (2) incremental net
(societal) benefit and (3) incremental net (dental health) benefits.
The secondary objectives were to compare the three recall strategies on:
l periodontal probing depths
l dental caries
l calculus
l preventative and interventive dental treatment
l patient anxiety
l patient satisfaction with care
l oral health knowledge, attitudes and behaviours and to explore dentists’ attitudes towards dental
recall intervals.10
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Chapter 2 Trial design and methods
Study design
The trial was a UK-wide [England (London, Manchester, Birmingham, North East), Wales (Cardiff),
Northern Ireland (Belfast, County Down) and Scotland] multicentre, parallel-group, RCT with blinded
outcome assessment at 4-year follow-up.
The trial interventions were three recall intervals – a fixed-period 24-month recall interval, a
risk-variable adjusted-length recall interval (risk-based recall) based on the NICE guideline60 and a
fixed-period 6-month recall interval.
A two-stratum trial design was proposed to overcome potential ethical considerations and dental
clinician and/or participant concerns. Participants were randomised to the fixed-period 24-month recall
interval only if the recruiting dentist considered them clinically suitable.
Randomisation was organised within the two strata (Figure 1):
1. For those participants considered suitable for a fixed-period 24-month recall (stratum 1),
randomisation was to one of three groups:
i. Fixed-period 24-month recall versus risk-variable-adjusted-length recall (risk-based recall) versus
fixed-period 6-month recall.
2. For those participants not considered suitable for a fixed-period 24-month recall (stratum 2),
randomisation was to one of two groups:
i. Risk-variable-adjusted-length recall (risk-based recall) versus fixed-period 6-month recall.
An economic evaluation to determine the cost-effectiveness of different recall intervals and to
compare NHS and patient-incurred costs and benefits is included in Chapter 5.
Patients randomised Patients randomised
No
Stratum 2
Yes
Stratum 1
Patient eligible for 24-month recall interval
24-month
recall
Risk-based
recall
Risk-based
recall
6-month
recall
6-month
recall
FIGURE 1 Study design.
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Ethics approval and protocol amendments
Favourable ethical opinions were granted for the INTERVAL Dental Recalls Trial by the Fife and Forth
Valley Research Ethics Committee (feasibility study Research Ethics Committee reference number
09/S0501/1; main study Research Ethics Committee reference number 09/S0501/1).
The trial was registered with the International Standard Randomisation Controlled Trial Register
(ISRCTN), reference number 95933794.
Amendments to the protocol were made after recruitment of practices and participants, and on
conclusion of the feasibility study. These included an increase of more than one dentist per practice
able to participate in consenting, recruiting, randomising and establishing risk-based recall intervals
for participants in the risk-based arm and the assistance of dental postgraduate research networks to
identify and recruit potential dentists and identify and approach potential participants.
Additional amendments, notified to the funder, included an increase in the number of practices
recruited and increased numbers of participants per practice, extension of the recruitment period,
changes of Trial Steering Committee (TSC) and Data Monitoring Committee (DMC) members,
lengthening from 3 to 4 months plus or minus the 4-year anniversary of participant randomisation
for final year assessments, and adaptions to study administrative processes. All changes were in
accordance with approved contract variations.
Recruitment and consent of dental practices
The trial sought to recruit general dental practitioners/practices from across the UK (i.e. England, Wales,
Northern Ireland and Scotland), representing a cross-section of practitioners in terms of urban/rural
areas, community-level sociodemographics and fluoridated or non-fluoridated communities.
Dentists were recruited through local postgraduate dental research networks, by advertising
in professional dental publications and through presentations at dental conferences and dental
events. Trial information and recruitment evenings were organised in Birmingham and Cardiff and
across Scotland.
The Trial Office in Dundee (TOD) sent potential dentist participants a personalised invitation letter for
the dentist and their staff to attend a local information and recruitment session, at which the reasons
for and design of the trial and practice involvement were described. Dental professionals were given
the opportunity to discuss participation with the trial team. For dentists and teams that could not
attend, information packs about the trial were posted/e-mailed from the TOD.
Trial team members telephoned dental practices to follow up the notes of interest of involvement.
A site briefing/training session was arranged with the dentist, practice staff and TOD staff (see
Training of dentists). Following the site briefing, dentists who were interested in the trial were
asked to provide written consent to participate, a signed declaration agreeing to adhere to the trial
protocol and a completed clinician beliefs questionnaire (see the NIHR project web page for details:
www.journalslibrary.nihr.ac.uk/programmes/hta/063599/#/documentation; accessed October 2020).
Original signed and dated dentist consent forms and declarations were held securely as a part of the
trial site file at the TOD. Copies were made and returned to dentists.
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Inclusion/exclusion criteria: dental practices
The inclusion criteria were:
l NHS provider for adult patients
l primary care provider: salaried service, corporate and independent operators
l willingness to follow trial protocol.
The exclusion criteria were:
l providing only private dental services to adults
l unwilling to follow trial protocol.
Recruitment and consent of participants
Recruitment of patient participants was achieved through standard procedures and agreements for
primary care research in the four nations. In some areas of England, Wales and Northern Ireland,
regional Clinical Local Research Networks assisted dental practice staff to identify eligible patients
and facilitate an approach by including information about the trial in the appointment letter for their
routine dental examination. In Scotland, co-ordinators from the Scottish Primary Care Research
Network, when invited, provided a similar service. The appointment letter included an invitation to
participate, the patient information leaflet and the baseline patient and cost questionnaires (see the
project web page for copies of questionnaires: www.journalslibrary.nihr.ac.uk/programmes/hta/063599/
#/documentation).
In instances where the Clinical Local Research Networks and Scottish Primary Care Research Network
were not available at an agreeable time, or practices did not request or require assistance, practice
staff undertook the duties of identifying and contacting eligible patients and inviting them to
participate in the trial using the same paperwork.
At the routine appointment, discussion about the trial was held between the dentist and patient. If
agreeable, potential participants were screened for suitability prior to their routine dental examination.
Patients who contacted the practice to advise that they were not interested in taking part in the trial
were reassured that they would still receive a dental examination appointment with their dentist as
per practice policy.
There are a variety of patient recall appointment management strategies utilised within dental practices
across the UK. Some dental practices arrange routine examination appointments for their patients up
to 6 months or a year in advance. Some practices send letters, e-mail, telephone or text reminders to
their patients when their routine dental examinations are due, asking them to contact the dental practice
to make an appointment, whereas other practices pre-allocate the date and time of appointments and
ask patients to contact the practice if the appointment is not suitable. The INTERVAL Dental Recalls Trial
utilised a flexible and pragmatic participant recruitment strategy that aimed to be suitable for each
practice’s usual recall procedure.
Eligibility of those who expressed an interest in taking part was confirmed against the trial inclusion
and exclusion criteria. The dentist confirmed consent with those eligible and willing to participate
in the trial. A signed participant consent form was obtained in triplicate. The participant retained a
copy, the practice retained a copy in the patient’s notes in the site file, and the original copy was sent
to the TOD.
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Following consent, the dentist clinically examined the participant to establish suitability for randomisation
to the 24-month arm (see Randomisation). If participants had not completed the questionnaires provided
with the appointment letter, they were asked to complete the baseline questionnaire and cost questionnaire
in the waiting room of the dental practice before placing them in a sealed opaque envelope and returning
them to practice staff. Questionnaires were returned to the TOD by the dental practice in a sealed envelope.
The TOD staff did not have access to any participant data prior to the participants consenting to take
part in the trial.
Inclusion/exclusion criteria: participants
The inclusion criteria were adult patients (≥ 18 years of age) who:
l were dentate
l had visited their dentist in the previous 2 years
l received their dental care in part or fully as an NHS patient, including dental examination.
The exclusion criteria were:
l patients who had a medical condition indicating increased risk of bleeding
l immunocompromised patients.
Participants whose medical condition changed during the follow-up period were not prohibited from
continuing in the trial. Provision was made for dentists to record changes and rationale to the length of
the recall interval, on the patient attendance data (PAD) form, but such participants remained within
the allocated stratum.
Training of dentists
In England, Wales, Northern Ireland and Scotland, the process of training recruited dentists took the
same format.
Training in trial procedures
Trial staff visited the practice by arrangement for a 1- to 2-hour site briefing/training session at an
agreed and convenient time, attended by the participating dentist and practice staff. After a brief review
of the trial aim and objectives, trial procedures were described and discussed.
Recruited dentists were defined as local investigators within the dental practice, and were responsible
for recruiting, consenting and protecting the personal data of trial participants within the dental practice.
Local Investigators signed an agreement to conduct the trial in compliance with applicable legislation
including (1) the International Conference on Harmonisation Good Clinical Practice guideline73 and (2) the
Department of Health and Social Care’s Research Governance Framework for Health and Social Care
(April 2005)74 or the Scottish Executive Health Department’s Research Governance for Health and
Community Care (2nd edition 2006),75 whichever was relevant.
Dentists and practice staff were advised at the trial briefing/training and in monthly practice newsletters
that the International Conference on Harmonisation Good Clinical Practice guideline training was available
in their local area and that attendance at these sessions could be arranged through the TOD. The TOD also
signposted to the online NIHR Introduction to Good Clinical Practice e-learning (primary care) module.76
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Training in determining risk-based recall intervals
Following the site briefing/training session, each dentist was sent a link to an online training package.
The online training package presented risk-based recall interval determination according to the NICE
guideline,60 with written instruction, audio and video components, examples and test assessments. It
described a systematic approach dentists could follow to consider setting and review of individualised
patient recall intervals and to enable discussion and explanation between patient and dentist of the
risk-based recall interval. Dentists were instructed to complete this training before screening any
potential patient participants for the trial, and reminders via letter, e-mail, telephone and trial
newsletter requested that dentists complete it on an annual basis during follow-up.
On completion of the online training package, and before being awarded with a certificate of training
and 2 hours continuing professional development (CPD), dentists were required to complete an
evaluation form that asked users to measure to what extent they felt that the training programme
met the learning objectives, and how easy it was to access and understand. They were also asked to
suggest improvements regarding content, design, navigability and length.
Feedback from users was mixed; some found it difficult to access and to navigate, whereas others
found it user-friendly and were reassured that they could use the tool with patients. Some users found
the content appropriate, easy to understand and a good support for participating in the trial, whereas
others found some aspects to be basic to a practising dentist or felt that it could be shortened for the
experienced practitioner.
For additional reference on risk-based interval determination, practices in England, Wales and
Northern Ireland were provided with a link to the NICE guideline Dental Recall: Recall Interval Between
Routine Dental Examinations.60 Practices in Scotland were supplied with an electronic link and hard copy
of the SDCEP Oral Health Assessment and Review (OHAR) guidance.60,61 Both documents contained
templates for checklists to record variables identified as potential modifying factors (risk variables) that
influence the setting of recall intervals (see Trial interventions for more detail on risk-based templates).
Clinical outcome assessor training
The clinical outcome training was delivered by trial collaborators with expertise and experience of
training assessors in periodontal and caries measures. The clinical outcome assessors and scribes for
this trial were qualified, General Dental Council-registered dentists, dental hygienists/therapists and
dental nurses employed by the trial.
The emphasis of the training was consistency of the examination process and agreement of scoring
criteria. Following the didactic face-to-face and online training, the outcome assessors, with their
research nurse, examined 15 patient volunteers in a clinical setting similar to that of a dental practice.
The cohort of patient volunteers were similar in age and dental attendance behaviour to those recruited
to the trial. The clinical outcome assessments were conducted at Dundee Dental Hospital and School,
and each participant was examined by all outcome assessors.
The processes of clinical outcome assessment were agreed in advance, including the order of outcome
measure assessment, time allocation, sequence around the mouth and moisture control. The primary
clinical outcome of gingival bleeding on probing is a measure of gingival inflammation. It is described as
‘gingival inflammation/bleeding on probing’ in the study protocol;1 for clarity within this report it will be
described as gingival bleeding on probing, the definition and outcome measurement remaining the same as
outlined in the protocol. This clinical outcome does not allow for repeat assessment; therefore, neither
intra-assessor nor interassessor reliability measurements were possible. Training77 for the primary outcome
involved face-to-face discussion with the assessors and scribes about the assessment technique and
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scoring criteria. Prior to the assessment of the cohort of volunteer patients by the outcome assessment
teams, a slide presentation developed for training in commercial clinical trials was presented by a
periodontal clinical trial expert, and this was supplemented with group discussion about clinical
photographs and clinical cases. Periodontal training included positioning, angulation of instrument and
pressure of the University of North Carolina-15 (UNC15) periodontal probe, to ensure a standardised
approach by the outcome assessors. Periodontal probing depths were recorded at six sites on erupted
teeth using a probing force of approximately 25 g.
Training in caries assessment consisted of several components that have been developed and used
in other clinical trials and epidemiological studies. This included an online training programme for
the International Caries Detection and Assessment System (ICDAS), a half-day of slide presentations
and discussions of the ICDAS codes and protocol for the clinical examination. The assessor training
included both theoretical aspects and discussions regarding patient participants within the clinical trial
setting. Practical training included simulation of the assessment protocol on extracted carious teeth
representing carious lesions at all stages of lesion progression included in the ICDAS scale, as well as
clinical assessment of a cohort of volunteers similar to the trial population, who had been specifically
recruited for trial assessor training. All training in the use of ICDAS was completed under the
supervision of a trial collaborator experienced in the use of ICDAS in clinical research.
The caries detection elements of the ICDAS criteria are now well tested and are advocated for general
use as well as for use in the clinical trials and in dental epidemiology.78,79 The ICDAS criteria measure
both early stages of caries and more advanced stages of caries. For early caries, ICDAS measures the
surface changes and potential histological depth of carious lesions by relying on surface characteristics
related to the optical properties of sound and demineralised enamel prior to cavitation. Advanced
stages are recorded when cavitation is evident. The trial utilised a modified ICDAS as clinical data were
collected only on the caries experience. Restorations and non-carious tooth loss were not recorded.
The intensive face-to-face and online training was provided a month before the first trial outcome
assessment to provide sufficient time for additional training if required. The training was repeated
mid-way through the INTERVAL trial clinical outcome assessment period, to reinforce standardisation
in the process and clinical measures. Throughout the clinical outcome collection period, the assessment
team met regularly to confirm the outcome assessment processes and data collection methods to
achieve the highest level of standardisation possible.
Randomisation
Eligible and consenting patient participants were clinically examined by their dentist to determine
suitability for randomisation to the 24-month recall arm (yes/no). The decision that a patient was
eligible for a 24-month recall was based on routine clinical examination and risk assessment. Dentists
were instructed not to apply the detailed risk-based variable assessment unless randomised to the
risk-based arm in either stratum.
There were separate, identical algorithms in the trial design for the two strata. Eligible participants were
randomised in equal numbers within each of the two strata according to a minimisation algorithm including:
l dentist
l participant age (18–40 years/≥ 40 years)
l filled teeth (n ≤ 8/n > 8)
l absence of gingival bleeding on probing (yes/no)
l exempt from dental charges (yes/no).
Random allocation occurred via telephone, after the decision by the dentists about the patient’s
suitability for a 24-month recall. The trial utilised the automated central randomisation service at
TRIAL DESIGN AND METHODS
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the Centre for Healthcare Randomised Trials (CHaRT), University of Aberdeen, which had 24-hour
telephone access. The service prompted dental practice staff to enter and confirm details by entering
numbers (i.e. 1 = yes, 0 = no) on the telephone touch pad.
The dentist communicated the allocation outcome and confirmed trial details with the participant.
Participants randomised to a fixed-period recall interval, either 24 or 6 months, were managed
according to routine practice regarding the practice recall management system. For participants
randomised to receive a risk-based recall, further history taking, examination and assessments were
undertaken, if required, to determine the appropriate variable risk-based recall interval. This was
discussed and agreed with the patient participant prior to the recall interval being entered into the
routine practice management system (see NICE guideline60).
Owing to the nature of the interventions, it was not possible to blind participants and dentists to allocated
recall intervals. TOD staff received an e-mail notification when a successful randomisation had taken
place, providing practice and participant ID numbers, and trial arm allocation. Following randomisation,
dental practice staff were asked to send the original signed patient consent form, baseline patient
questionnaire and cost questionnaire, and screening/patient case report form (PCRF) to the TOD.
Trial interventions
The trial interventions recall intervals were a fixed-period 24-month recall interval, a risk-variable-
adjusted-length recall interval based on the NICE guideline60 and a fixed-period 6-month recall interval.
Fixed-period recall intervals (24 months, 6 months)
Patient participants allocated to the fixed-period 24-month recall interval and the fixed 6-month recall
interval groups attended their dentist at the scheduled time intervals for a routine dental check-up. The
content of this check-up remained as per current practice. A recognised definition of a routine NHS dental
check-up is clinical examination, advice, charting including monitoring of periodontal status and report.71
Risk-variable-adjusted-length recall interval (National Institute for Health and Care
Excellence guideline)
Patient participants allocated to the risk-based recall interval group attended their dentist at time
intervals determined by the evidence-based process outlined in the 2004 NICE guideline on dental
recall.60 The essential steps of the procedure and the risk factors collected at recall examinations are
outlined (from the guideline) in Figure 2.
The recommended steps in establishing the appropriate recall interval were:
1. Consider the age range – in the case of this trial, all patients were adults of ≥ 18 years.
2. Consider risk variables – identification of the pertinent risk and protective factors present for each
patient from both the checklist and a comprehensive oral health assessment, leading to the evaluation
of the impact of these factors in the context of the patient’s past levels of oral health and current
disease experience, and then consideration of a likely range of recall intervals.
3. Integrate prediction of recall need – use of all the information obtained by the dental team in order
to predict the potential level of threat to maintaining oral health and controlling disease for this
patient and, from this, judge the most appropriate next recall interval.
4. Discuss with patient – to explicitly discuss the recommended recall interval with the patient, explain
the influencing factors in setting the recall and record the agreed interval (or any reason given by a
patient in disagreement).
5. Review – at each check-up review (oral health review), the appropriateness of the preceding
interval is reviewed by the dentist and patient and the recall interval is reset according to the
experience from the last period along with any change in the risk and protective variables identified
at re-examination.
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Risk factor variables from
the NICE Dental Recall ‘Checklist’
Medical history 
Social history 
Dietary habits 
Exposure to fluoride 
Clinical evidence and dental history 
Recent and previous caries experience 
Recent and previous periodontal disease
experience  
Mucosal lesions 
3
months
3
months
3
months
3
months
3
months
3
months
12
months
12
months
12
months
24
months
24
months
24
months
Overview of how the interval between oral health reviews is set
If the patient is younger than
18 years
If the patient is 18 years or
older
discussion discussion
Step 1
Step 2
Step 3
Step 4
Step 5
>  Adjust the interval depending on
     the patient’s ability to maintain
     oral health between reviews
>  At next oral health review,
     consider whether the interview
     was appropriate
>  Record agreed interval or any
     reason for disagreement
>  Discuss recommended interval
     with the patient
>  Use clinical judgement to
     recommend interval to the
     next oral health interview
>  Integrate all diagnostic and
     prognostic information,
     considering advice from other
     members of the dental team
     where appropriate
>  Consider the patient’s age; this
     sets the range of recall intervals
>  Consider modifying factors
     (see checklist on page 2) in light
     of the patient’s medical, social
     and dental histories and findings
     of the clinical examination
reassessment reassessment
FIGURE 2 The NICE risk-based dental recall procedure and risk factors. Reproduced with permission. © NICE 2004 Dental Recall – Recall Interval Between Routine Dental Examinations.
Available from www.nice.org.uk/guidance/cg19/evidence/full-guideline-pdf-193348909.80 All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health
Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
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The frequency of recall interval appropriate for an individual patient depends on the likelihood that
specific diseases or conditions may develop or progress beyond the control of secondary prevention.
The selection of an appropriate recall interval for a patient is a multifaceted clinical decision that
involves judgement and cannot be decided mechanistically.
The NICE guideline60 was developed using extensive consensus methods and the limited evidence
available. The recommendation was that the recall interval range for adults should vary from 3 to
24 months according to risk.
The NICE guideline checklist60 was intended to be used as a guide to assist the dentist in setting an
appropriate recall interval. It is not an exhaustive list of all factors that may influence the choice of a
recall interval for a patient. There is insufficient evidence to assign a ‘weight’ to individual factors in
the checklist and dentists must use their clinical judgement to weigh the risk and protective factors
for each patient. The same checklist is in the SDCEP Oral Health Assessment and Review guidance61
and, therefore, for dentists across the UK guidance is consistent with the content of the trial training
material including the online resource.
It was anticipated that by taking a comprehensive history and carrying out a comprehensive oral health
assessment the dentist would be better informed to provide an accurate risk assessment and more
appropriate preventative and interventive treatment recommendations including advice.
It was envisaged that, once trained, the time taken to complete this process would be 20 minutes for
the first risk-setting visit and 15 minutes for subsequent recall examinations (oral health reviews).
Outcome measures
All primary and secondary outcome measures were measured at 4 years’ follow-up and are outlined below.
Primary outcomes
Clinical:
l gingival bleeding on probing.
Patient centred:
l OHRQoL [Oral Health Impact Profile-14 (OHIP-14)].81
Secondary outcomes
Clinical:
l dental caries
l periodontal probing depth
l calculus
l preventative and interventive care.
Patient centred:
l dental anxiety82
l oral health-related knowledge, attitudes and behaviours
l generic quality of life, measured using the EuroQol-5 Dimensions, three-level version (EQ-5D-3L)
l use of, and reason for use of, dental services
l satisfaction with care.
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Economic outcomes
l NHS costs.
l Patient-incurred costs.
l General population preferences, willingness to pay (WTP) calculated from a discrete choice
experiment (DCE) to value service delivery and outcomes.
l Incremental net benefits (INBs) (WTP minus costs), measured as societal net benefit (WTP for
health and non-health aspects) and dental health net benefit (WTP for health outcomes, bleeding on
brushing and caries experience only).
l Generic quality of life, measured using the EQ-5D-3L.
l QALYs.
l Incremental cost per QALY.
(See Chapter 3 for further details.)
Service provider measures
l Dentist attitude towards dental recall strategies.
Post hoc outcomes
l Self-reported bleeding.
Measurement of clinical outcomes
Clinical outcomes were assessed at 4 years post randomisation ± 4 months by trained outcome
assessors who were blinded to allocation. The blinding of the outcome assessors was achieved by
non-disclosure of the practice or patient to the allocated recall interval. The flexibility around the
4-year anniversary was to accommodate participant and practice factors influencing the convenience
of attending the outcome assessment visit. Each tooth was examined, except third molars, unless a
second molar was absent and the third molar tooth had drifted mesially to occupy the second molar
position. The periodontal examination was performed first and the sequence of assessment was
gingival bleeding on probing, periodontal probing depths and calculus. Teeth then were cleaned with
a manual toothbrush by the outcome assessor and an ICDAS caries examination was carried out.
More details on clinical data collection are outlined below.
Periodontal
Gingival bleeding on probing was measured according to the Gingival Index of Löe83 by running a colour-
coded UNC15 periodontal probe circumferentially around each tooth just within the gingival sulcus or
pocket. After 30 seconds, bleeding was recorded as being present or absent on the buccal and lingual
surfaces. The primary outcome was calculated by adding all the sites where bleeding was observed and
dividing it by the number of sites (twice the number of teeth) and was presented as a percentage.
Periodontal probing depth was measured using a colour-coded UNC15 periodontal probe. Clinical
probing depths were measured for all teeth at six sites per tooth (mesiobuccal, midbuccal, distobuccal,
mesiolingual/palatal, midlingual/palatal and distolingual/palatal). Clinical probing depth was calculated
as the mean of the six sites measured per tooth and is presented in millimetres.
Calculus was detected using a colour-coded UNC15 periodontal probe as being present or not.
Calculus was calculated by adding all the sites where calculus was observed and dividing it by the
number of teeth and presented as a percentage.
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Caries
We measured caries at the enamel and dentine threshold using ICDAS. After manual tooth brushing by
the outcome assessor, an examination of clean and wet/dry teeth (according to ICDAS procedure) was
performed. Examination was aided by a ball-ended explorer used to remove any remaining plaque and
debris and to check for surface contour, minor cavitation or sealants. All surfaces of all teeth were
examined and the status of each recorded in terms of caries detection. A score between 0 and 6 was
recorded for each surface.
Preventative and interventive care
Practice-reported data were collected throughout the 4-year trial including recall appointments on
the PAD forms completed by practice staff. The PAD form was used to collect data on intended recall
appointment dates, actual date of appointment, any rescheduling, length of time of appointment, any
further treatment required as an outcome of the recall and, if known, the reason why a participant had
not adhered to the recall interval. It also captured the expected date of the next recall appointment,
after taking into account any course of treatment that might be required.
NHS routine data reported details of the treatment provided under the NHS during the trial period
and was accessed through the routinely collected data in all participating regions in the UK, NHS
Business Services Authority (NHSBSA) England and Wales, Business Services Organisation (BSO)
Northern Ireland and ISD Scotland. Further details are provided in Chapter 3.
Measurement of patient-centred outcomes
Patient-centred outcomes were measured at 4 years and also collected annually, including at baseline,
through a self-administered questionnaire.
Annual questionnaires were mailed to participants from the TOD on the anniversary of their randomisation.
A Freepost envelope was included for ease of return. If the questionnaire had not been returned within
4 weeks, a reminder letter and another copy of the questionnaire were sent to the participants.
The full details of the calculations used to generate each patient-centred outcome are shown in
Appendix 1, Table 26. We used the relevant publication to inform the calculation of validated scores,
such as OHIP-14 and the dental anxiety scale.
Oral health-related quality of life
Quality of life was measured using OHIP-14.81 The OHIP-14 is a 14-question oral health-specific
patient-centred measure referring to symptoms in the past 12 months. The questions are scored from
0 (never) to 4 (very often) and summed to produce a score ranging from 0 to 56, with 56 being the
worst outcome.
Dental anxiety
Patient dental anxiety status was measured using recognised and validated psychological inventories
[Modified Dental Anxiety Scale (MDAS)].82,84 Five questions relating to different dental treatments and
situations were posed. The answers are scored on a scale from not anxious (rated as 1) to extremely
anxious (rated as 5). The range of the summed total of five items was 5–25.
Oral health knowledge, attitudes and behaviours
The questions for measuring patient-centred belief outcomes and beliefs [attitude and perceived
behavioural control (PBC)] outcomes were derived from social cognitive theory and the theory of
planned behaviour.85,86
Oral health knowledge outcome
Knowledge was measured using four questions related to oral health (frequency of brushing, duration
of brushing, frequency of flossing and frequency of interdental brush usage). The best value between
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flossing and interdental brush usage was used as a measure of interdental cleaning knowledge. Each
response varied from 0 to 3, with a score of 3 being the highest level of knowledge. The responses
were summed to produce a total score ranging from 0 to 9, with 9 being the best outcome.
Oral health beliefs (attitude and perceived behavioural control) outcomes
Oral health-related attitude was measured using a 7-point scale varying from 1 to 7 (strongly disagree
to strongly agree) and the higher the score, the better (i.e. the more positive) the attitude. The scale
comprised seven questions and the final score was the average of the individual item scores.
Perceived behaviour control was measured using a 7-point scale varying from 1 to 7 (strongly disagree
to strongly agree) with higher scores indicating more perceived behaviour control. The scale comprised
four questions and the final score was the average of the individual item scores.
Oral health behaviours
Patient-reported oral health behaviour outcomes were measured using four questions (frequency of
brushing, duration of brushing, frequency of flossing and frequency of interdental brush usage). Each
response ranged from 0 to 3, with a score of 3 being the best possible behaviour. The best value between
flossing and interdental brushes was used as a measure of interdental cleaning behaviour. The responses
for each question were summed to produce a total score ranging from 0 to 9, with 9 being the best outcome.
Use of and reason for use of dental services
A question within the annual patient questionnaire asked participants to record the number of times
they had attended the dental practice and the type of treatment received (NHS, private or combination),
and their payment cost of this treatment. Questions were also asked about frequency and treatment
data on non-scheduled attendance at services for dental problems (e.g. hospital accident and emergency,
hospital outpatients or general medical practitioners).
Satisfaction with care was a score averaging 12 items, each varying on a scale of 1 to 7 (strongly
disagree to strongly agree) and the higher the score, the more satisfied participants were with care.
The satisfaction measure was developed with dental patients in Scotland.
Service provider measures
Dentists were asked to complete a clinician belief questionnaire at baseline prior to the online risk-based
training and randomisation of participants.
The questionnaire collected data on the dentist’s professional history and profile, practice profile,
professional engagement and factors such as decision-making, confidence and workplace stress.
The majority of questions (n = 21) related to their attitude towards dental recall interval, ease of
its determination and the consequence for patients. A 7-item scale was developed from 1 (strongly
disagree) to 7 (strongly agree). Full details of the calculations used to generate dentist belief outcomes
are shown in Appendix 1, Table 27.
Post hoc outcome
Self-reported bleeding was included as a post hoc outcome and measured via patient questionnaire at
4 years post randomisation. It was measured by asking patients ‘Have you had bleeding from your
gums when brushing your teeth?’ The answer could vary from 0 (never) to 4 (very often).
Demographic characteristics
Participant demographic characteristics were collected at baseline and annually using a self-administered
postal questionnaire. The demographic characteristics included the most recent visit to the dental
practice, type of attender (regular/non-regular), type of toothbrush (manual/electric) and smoking status.
Participants also provided details on difficulty of travelling to the dental practice, which was scored from
1 to 7 on a Likert scale, where the higher the score, the easier participants found travelling to their dentist.
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Demographic characteristics are presented by year and randomised group, using either mean, standard
deviation (SD) or n (%) as appropriate.
Fidelity measures
Dental practice compliance with the protocol was monitored through face-to-face practice visits by a
member of the trial office team, regular telephone contact from the TOD to practices and an audit
of six participants per practice at the mid-point in the trial. The PAD forms were reviewed as part of
the audit and a judgement was made on whether or not they were compliant with the allocated recall
interval. Dentists were also reminded to complete the online risk-based variable training package
annually to reinforce the review needed for the participants randomised to a variable risk-based recall.
The audit of six participants (two participants from each of the three recall intervals or three each
from risk-based and 6 months if no participants had been allocated to 24 months) was conducted with
each practice to check if participants had been contacted to attend an appointment according to their
allocated treatment group. If ≥ 50% of these random six participants had not been contacted or invited
to attend, this triggered a telephone call to the practice to check the trial processes and, if required,
a visit to review protocol.
All practices received at least one face-to-face visit. This was to ensure practice compliance with the
protocol and confirm staff understanding of their role. It provided a valuable opportunity to answer
any queries the practice staff had and to build and maintain a rapport to ensure a smooth transition
into the follow-up phase of the trial. Practice staff were encouraged to flag INTERVAL participants in
their electronic system as an aide-mémoire to following up participants.
Regular telephone calls were made by TOD administration staff to designated main contacts in
practices during the course of follow-up to keep practice staff on board and on track, to provide an
opportunity to discuss queries and for TOD staff to seek updates on PAD forms where necessary.
Practices were encouraged to contact the TOD for guidance on any aspect of the trial.
An INTERVAL-branded site folder was prepared for each practice containing copies of their completed
screening log/PCRFs and participant consent forms, and a section in which to file copies of completed
PAD forms.
The TOD e-mailed and posted monthly newsletters to practices to remind dentists and staff of
procedures and processes for recruitment and training, and trial updates.
Number of check-ups received (routine data and patient attendance data forms)
The PAD forms were used to collect information on intended and actual appointment dates. The
information about the first intended appointment date per recall group was used to assess dentists’
intended compliance with the protocol.
Routine treatment data were obtained from the NHSBSA in England and ISD in Scotland for the time
period 2010 to 2018.62 The routine data provided information about the number of dental recalls
received throughout the trial by counting the number of claims for treatment made by dentists for
each participant.
Data collection
Baseline
Dentists were asked to complete the baseline clinician belief questionnaire after consenting to
participate in the trial.
DOI: 10.3310/hta24600 Health Technology Assessment 2020 Vol. 24 No. 60
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Clarkson et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
19
Patient-centred outcomes were collected at baseline using a self-administered questionnaire.
Questionnaires were returned to the TOD by the dental practice in a sealed envelope.
Ongoing
Recall appointment dates and times and further treatment information were collected by practices on
PAD forms. Routine NHS treatment data were obtained from national-level dental claims data held by
the ISD (Scotland), NHSBSA (England) and BSO (Northern Ireland).
Annual follow-up
Patient-centred outcomes were collected annually using self-administered postal questionnaires.
The annual follow-up questionnaire combined questions on patient-centred outcomes, OHRQoL
(OHIP-14), generic health (collected using the EQ-5D-3L), dental anxiety, oral health-related knowledge,
attitudes and behaviours, use of dental services and satisfaction with care.
Questions collecting descriptive measures were also included in this questionnaire. The annual patient
questionnaire also included questions for the health economic analysis, relating to patient-incurred
dental costs, and patient attendance at general NHS services (e.g. hospital accident and emergency)
for dental-related problems. Questionnaires were issued annually to participants at their home address
from the TOD with a covering letter and a Freepost envelope for return of the completed questionnaire.
Those participants who failed to return their questionnaire within 4 weeks were sent a reminder,
a further copy of the questionnaire and a Freepost envelope.
On the second anniversary of their recruitment to the trial, participants were sent a £15 gift voucher
for their participation in the trial.
Final/fourth-year follow-up
Dentists completed the end-of-trial clinician belief questionnaire after all clinical assessments had been
completed in their practice.
Patient-centred outcomes were collected at 4-year follow-up using the annual patient questionnaire.
To maximise return, the final questionnaire was sent to participants at least 6 weeks before the date of
their final year clinical assessment appointment, with a reminder sent 2 weeks before the appointment.
Participants who had not returned a questionnaire by the time of their follow-up assessment appointment
were asked to complete the questionnaire at that appointment prior to being assessed. A summary of
the data collection items and time point is presented in Figure 3.
Baseline Year 1 Year 2 Year 3 Year 4
Year 3
Annual patient
questionnaire
Year 1
Annual patient
questionnaire
Year 2
Annual patient
questionnaire
Year 4
Annual patient
questionnaire
Dentist ‘exit’
questionnaire
Baseline
patient
questionnaire
Patient costs
questionnaire
Baseline
Dentist
questionnaire
FIGURE 3 Data collection schedule summary.
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All participants were invited to attend a trial final-year clinical assessment appointment by their dental
practice either at the time of their routine check-up or as a separate appointment. A brief medical
history was undertaken about bleeding disorders or immunocompromised disorders. The assessor also
confirmed continuing consent with the participants. Gingival bleeding on probing scores, periodontal
probing depths, calculus and caries detection were measured by the assessors and recorded on a
clinical chart by the dental research nurse, who was a member of the trial team.
Participants who could not attend were contacted and given the option of attending at least one other
day or time. Patients who were no longer registered at the practice were offered the opportunity to
return to the practice (with practice permission) for an assessment examination, or at another INTERVAL
practice (if appropriate) or at a suitable satellite location.
All participants who attended the follow-up assessment received a letter of appreciation for their
participation in the trial, details of where the trial results would be published and a final £15 gift
voucher in recognition of their contribution. Letters and vouchers were subsequently posted, where
possible, to participants who did not attend a follow-up assessment.
Sample size
An exploratory trial in a similar population reported that 35% of gingival sites were bleeding on probing
(SD 25%).87 The Cochrane review of periodontal instrumentation (PI) suggested that 6-month PI versus
no PI reduces bleeding sites by 15%.88 The recall interval was expected to produce an effect lower
than this given that the majority of participants in all arms would still receive PI at some time during
follow-up. Assuming that either risk-based versus 24-month recall or 6-month versus 24-month recall
could reduce/increase the percentage of sites bleeding by 7.5%, the study with 235 participants in
each arm could detect such a difference with 90% power at 5% significance, and, likewise, detect a
difference of 0.3 of the SD of the OHIP-14 score or any other global measure of OHRQoL. For the
caries clinical outcome, assuming a SD of 3.5, the study with 235 participants per arm would detect a
shift in white spot lesions (from 3.3 to 4.2) at 80% power and 5% significance.79 We combined the two
strata, without introducing bias, to estimate this comparison. We anticipated smaller effect sizes for the
6-month versus risk-based recall comparison than 6-month versus 24-month recall given that many of
the participants in the risk-based group would be seen more frequently than 24 months. A study with
750 participants in each arm could detect a difference in bleeding scores of 4.5% with at least 90%
power and a 5% significance level,89 and likewise detect a difference of 0.17 of the SD of the OHIP-14
score. For the caries clinical outcome, assuming a SD of 3.5, a study with 750 participants per arm could
detect a 20% relative shift in white spot lesions from 3.3 to 3.9 at 90% power and 5% significance.79
Although there was no reason to be concerned about contamination effects in this trial or clustering
by dentist, the sample size was conservatively estimated such that if contamination occurred with
15% of the control participants or the intracluster correlation was 0.03, the study would still have
80% power to detect the hypothesised changes in the bleeding score. Our sample size calculations
indicated that we needed to randomise 705 participants to stratum 1 (235 in each arm) and 1030 to
stratum 2 (515 in each arm).
Contamination effects
There were no obvious mechanisms for contamination to occur in this trial. Our experience of
simultaneously conducting an educational cluster and patient randomised trial in dentistry suggested
that contamination occurred in at most 15% of participants (if any);89 therefore, fewer participants are
required to perform a patient randomised trial than a cluster randomised trial.90 There is no perceived
direct influence of skill on the patient outcomes and, even if that were hypothesised, the intracluster
correlation would be very low (< 0.03).
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The sample size has been conservatively estimated such that, if contamination occurred with 15% of
the control participants or the intracluster correlation was 0.03, the study would still have 80% power
to detect the hypothesised changes in the bleeding score.
Statistical analyses of outcomes
Baseline data were explored to better understand dentists’ decision-making process when allocating
participants to different strata (eligible to be randomised to 24-month recall vs. not eligible). The primary
analysis used an intention-to-treat framework and all participants with available data remained in their
allocated groups. The participant outcomes listed above were compared between 24-month, risk-based and
6-month recall groups (for the stratum eligible for a 24-month recall) and risk-based versus 6-month recall
(for the stratum ineligible for a 24-month recall). Outcomes collected at year 4 (clinical outcomes, behaviour,
knowledge and PBC scores) were analysed using a generalised linear model with a random effect for dental
practice. Outcomes collected at years 1, 2, 3 and 4 were analysed using a mixed-effects model with two
random effects: participant and practice. A time by treatment interaction term was included in the models.
The appropriate effect sizes and 95% confidence intervals were derived. All analyses were adjusted for the
protocol minimisation variables [age, dentist, filled teeth (≤ 8 or > 8) and absence of gingival bleeding on
probing]. Stata 15 (StataCorp LP, College Station, TX, USA) was used to undertake the analysis.
Missing data
Missing items in scales were dealt with as recommended in the literature by their authors, when
recommendations were available. Otherwise, a complete-case approach was used where, in the
presence of any missing items in a patient’s score, the score was considered missing. Continuous
missing data at baseline were imputed for modelling purposes as recommended in the literature,91 and
categorical missing data at baseline used the missing indicator method.92 The primary intention-to-treat
analysis was on observed data.
Sensitivity analysis
We explored differences between responders and non-responders to inform our missing data model.
As a sensitivity analysis, missing primary outcome data were imputed using a predictive mean matching
multiple imputation approach.92
Subgroup analysis
A pre-planned subgroup analysis explored the effect modification of age (< 45 years, 45–64 years,
≥ 65 years) and social class (exempt from payment and not exempt from payment) by including a
subgroup-by-treatment interaction term in the primary clinical outcome model described in Statistical
analyses of outcomes. Further pre-planned subgroup analyses included residence in a fluoridated area,
and dentist characteristics were included in the protocol; however, there were too few participants
(2%) in fluoridated areas to make a subgroup analysis meaningful. The dentist characteristics subgroup
analysis was an error in the protocol. A post hoc subgroup analysis by country was also included.
Trial oversight
The University of Dundee acted as the sponsor for the study. The trial was co-ordinated from the
TOD in the Dental Health Services Research Unit, Dundee, which provided day-to-day support for
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the dental practices and outcome assessors/research nurses. The TOD was responsible for issuing and
collecting trial documentation from practices and participants (including annual questionnaires and
reminders) and co-ordination of participant follow-up. The TOD was also responsible for the entry of
collected data into the database, including screening logs/PCRFs, PAD forms, baseline, costs and annual
patient questionnaires, baseline and follow-up dentist questionnaires and clinical data from outcome
assessments. Clinical data were entered by the dentally qualified assessment team.
CHaRT, in the Health Services Research Unit, University of Aberdeen, provided the database
applications and information technology programming for the trial, and hosted the randomisation
system, provided experienced trial management guidance, and took responsibility for all statistical
aspects of the trial (including interim reports to the TSC and the DMC).
Trial Operational Committee meetings were held weekly and attended by Co-Chief Investigators,
the Trial Manager and key TOD staff.
The Operational Management Committee met monthly, chaired by one of the Co-Chief Investigators,
and comprised co-investigators in TOD and CHaRT.
The Trial Management Committee (TMC) met approximately annually, chaired by the Co-Chief
Investigators, and comprised co-investigators, key members of the TOD and CHaRT and a
lay representative.
The TSC comprised an independent chairperson and two further independent members, plus a member
of the public acting as a lay patient representative. The TSC met approximately annually.
The DMC comprised an independent chairperson and two further independent members. The DMC
met approximately annually.
Patient and public involvement
Prior to the start of the trial, advice on the design and conduct of the study was sought from members
of the public partnership groups and from similar patient groups in other parts of the UK sourced
under guidance from INVOLVE (UK National Advisory group).
These independent public partnership groups comprise volunteers who work in partnership with NHS
Tayside and aim to provide a conduit for the views of people about their local services.
Patient advisors were a valuable resource at the outset of the trial and helped to ensure good conduct
and patient-friendly practice throughout the duration of the trial. Patient advisors were involved with
the trial design and provided invaluable feedback on trial recruitment and communication strategies.
Patient advisors also contributed to the content and layout of trial invitation, trial newsletters and the
design of patient participant questionnaires. This ensured that trial participants could understand and
easily complete these materials.
As quality of life was a primary outcome of the trial, patient advisors’ input to the proposed
questionnaire design was essential. Qualitative work with patients was carried out to ensure that the
outcome measures were patient centred.
Lay representatives on the TSC and TMC actively contributed to trial oversight, processes and procedures,
including helping to interpret the trial findings, preparation of the monograph and assisting with the
review of the Plain English summary.
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Chapter 3 Health economics methods
Introduction
In this chapter we report the methods used to conduct the within-trial health economic analysis
comparing different dental recall strategies as follows: eligible for 24-month recall – 24-month versus
risk-based versus 6-month recall; and ineligible for 24-month recall – risk-based versus 6-month recall.
All analyses are completed according to the intention to treat principle at 4 years’ follow-up. The health
economic analysis compares the costs and benefits of different dental care recall strategies. The results
are presented using different perspectives. Economic evaluations to inform UK health-care decision-
making, for example through NICE, typically take the form of cost–utility (i.e. cost per QALY) analyses,
reporting incremental cost-effectiveness ratios (ICERs). However, in the context of dentistry, there
are concerns that generic EQ-5D-3L-based QALYs lack the sensitivity to capture the processes and
outcomes of care that are of value to patients and decision-makers.93 Furthermore, it is argued that the
time dimension embedded in QALY calculations may underestimate the impact of acute health effects
such as painful caries.94,95
Similarly, from a cost point of view, dentistry is unique within health care as the majority of patients
pay a contribution towards their NHS care. It is, therefore, crucial to consider both the costs falling
directly on the NHS dental budget and the impact on patients in terms of co-charges for NHS care and
the opportunity cost of time and travel to dental care appointments when making recommendations
about the most efficient dental recall strategy.
For these reasons, it is necessary to consider different frameworks of evaluation that (a) are sensitive
to changes in important dental health outcomes such as bleeding or caries, (b) value outcomes that are
relevant to service users and (c) capture the full cost burden to both patients and the NHS of different
recall strategies. Providing results from a range of perspectives of benefits and cost is essential to
equip decision-makers with all the relevant information necessary to reach informed decisions about
the efficient allocation of scarce dental care resources.
In terms of the benefits, the scopes are WTP for dental recall interval and associated outcomes
[cost–benefit analysis, including all benefits (health and non-health) that are important to individuals],
QALYs and WTP for dental health outcomes (caries and self-reported bleeding gums). The preferred
analysis depends on what outcome a decision-maker wishes to maximise: social welfare, QALYs or
(WTP for) defined dental health (caries and bleeding). In terms of costs, the perspectives are NHS
dental budget, NHS total budget and societal perspective (NHS and participant).
Resource use and costs
Resource use and cost data are collected from an NHS and dental patient participant perspective.
NHS costs include provision of dental care services (obtained from data linkage to routinely collected
claims data) and costs of attending non-dental health professionals for dental problems (obtained
from participant questionnaires). Patient participant costs include co-payments for dental care,
purchase of dental care products, and the travel costs and the opportunity cost of time spent attending
dental appointments obtained from a combination of routinely collected data and participant
self-reported questionnaires.
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NHS dental costs
Resource use and costs associated with the use of NHS dental services are obtained through data
linkage for each randomised trial participant to national-level dental claims data held by the ISD
(Scotland), NHSBSA (England) and BSO (Northern Ireland). For the 13 participants recruited from
a single Welsh practice, resource use is obtained from practice note data extraction. The actual cost
to the NHS of providing treatments, the split of cost burden between the NHS and the patient, and
the level of granularity of data available for analysis is dependent on different remuneration systems
and contracting arrangements in place for payment of NHS dental care across different UK countries.
For example, dentists in Scotland and Northern Ireland are reimbursed on the basis of fee for service,
whereas in England contract payments are based on banded categories of treatment complexity.
This means that there is a greater granularity of data available for Scotland and Northern Ireland to
inform resource use and costing. There are also differences in patient co-charges for dental check-ups
ranging from £0.00 (Scotland) to £19.70 (England), which have implications for the interpretation of
NHS versus patient perspective costs across the regions. Tables 1 and 2 describe the NHS and patient
breakdown of treatment charges across the UK regions for fee-paying adults. All cost data are
reported in 2016/17 values based on the regional dental payment contracts. Regional specific
variation in the dental payment systems is discussed in the following paragraphs.
Use of NHS dental services: England and Wales (activity-based treatment bands)
In England, dental payment contracts are negotiated at either a national (GDS contracts) level or a
local (personal dental service contracts) level. GDS contracts are the most common across England,
accounting for approximately 85% of negotiated contracts, and are used to inform the costing analysis.98
Under GDS arrangements, each dental practice is contracted to provide a prespecified quantity of NHS
care, measured in a currency called units of dental activity (UDAs). All dental treatments are classified
into four treatment bands based on treatment complexity, with more complex treatment bands attracting
a greater number of UDAs.
TABLE 1 Treatment charges for dental care in England and Wales
England and Wales activity-based banding96,97
Band
Number
of UDAs
UDA unit
value
Band
treatment
value
England (2016/17
charges)a,b
Wales (2016/17
charges)a,b
Patient
charge
NHS
charge
Patient
charge
NHS
chargec
1 (e.g. check-up/X-ray/advice/PI) 1 £25 £25 £19.70 £5.30 £13.50 £6.20
2 (band 1 treatments + fillings,
extractions, root canal treatments)
3 £25 £75 £53.90 £21.10 £43.00 £10.90
3 (band 1 and 2 work + crowns,
dentures and bridges)
12 £25 £300 £233.70 £66.30 £185.00 £48.70
Urgent 1.2 £25 £30 £19.70 £10.30 £13.50 £6.20
UDA, unit of dental activity.
a In England and Wales, a number of services do not fall into any of the patient charge bands in their own right, but
are awarded UDAs when provided outwith other banded treatments. The number of UDAs for such treatments is as
follows: arrest of bleeding= 1.2 UDA, bridge repair = 1.2 UDA, denture repair = 1.2 UDA, issue of prescriptions = 0
UDA and removal of sutures = 1 UDA. These treatments incur £0 charge to the patient.
b Exceptions and exemptions apply to treatment across all regions where patients do not pay any of the cost
(e.g. receiving income support, < 18 years, in full-time education, pregnant or given birth in last 12 months,
receiving pension credit, universal credit, tax credit exemptions). Patient charges relate to 2016/17 values.
c Assumes that the value of a UDA in Wales is the same as in England (i.e. ≈ £25).
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The value of a UDA may vary across dental practices, depending on contract negotiations, population-
level general health and dental health in a catchment area and area deprivation. A value of £25 per
UDA is used for the analysis, based on the Steele report in 200999 and maintaining consistency with
NICE public health guidance on oral health promotion100 and the published Improving the Quality of
Dentistry (IQuaD) study.101 If patients are exempt from paying treatment charges, the NHS covers the
full value of treatment. It should be noted that, in England and Wales, dental check-ups without further
treatment requirement incur a band 1 charge.
Routine data downloads for England were taken on 4 May 2018. NHSBSA data are often entered, cleaned
and processed towards the end of the financial year, meaning that the quality of the data is probably
high for all claims starting prior to the end of March 2018. Some participants [n = 43/1031 (4.2%)]
were recruited to the trial after April 2014. Routine data for resource consumed by these participants
may be missing for the 3-month period from April to June 2018; however, this applies to a very small
proportion of participants over a very short time frame, so such missing data are unlikely to bias the
costing analysis. For the remainder of the linked participants in England, the routine data capture a
complete, and accurate, record of all primary NHS dental care received for the full 4-year duration of
follow-up in the trial.
Use of NHS dental services: Scotland and Northern Ireland
The remuneration systems are similar in Scotland and Northern Ireland. Dentists are paid on a fee-for-
service basis, with payment attached to over 300 different treatment codes. Payment contracts are
updated and refined on a regular basis. Costing data for this report are sourced from the statements of
dental remuneration in Scotland and Northern Ireland, with all treatment costs inflated to 2016/17 values
using an online tool.102 Dental check-ups are free of charge to the patient in Scotland. In Northern
Ireland, the patient pays a co-charge of £6.74 (2016/17 statements of dental remuneration), which is
approximately 80% of the total check-up value. For other items of service (e.g. scale and polish, fillings
and extractions), patients in Scotland and Northern Ireland pay approximately 80% of the item of
service value, unless they are exempt from payment charges. The payment mechanism in Scotland and
in Northern Ireland means that there is a high level of detail available to inform the costing analysis.
Routine data downloads were taken on 15 May 2018 (Scotland) and 29 August 2018 (Northern Ireland).
Communication with ISD and BSO indicates that the routine data are an accurate and complete
representation of all treatment and resource use up until 3 months prior to the data download. On this
basis, we are confident that the routine data are a complete representation of all primary dental care
contacts for 1157/1188 (97.4%) participants with known robustness of data quality for 990/1188 (83%)
TABLE 2 Treatment charges for dental care in Scotland and Northern Ireland
Scotland/Northern Irelanda
Treatment Patient charge (2016/17 charges) NHS charge (2016/17 charges)
Check-ups and case assessments Scotland: 0% of full cost Scotland: 100% of full cost
Northern Ireland: 80% of full cost Northern Ireland: 20% of full cost
Other treatments 80% of full cost 20% of full cost
Maximum charge per course of
treatment
Scotland: £384.00
Northern Ireland: unlimited
Unlimited
a Exceptions and exemptions apply to treatment across all regions where patients do not pay any of the cost (e.g.
receiving income support, < 18 years, in full-time education, pregnant or given birth in last 12 months, receiving
pension credit, universal credit, tax credit exemptions). Patient charges are based on regional and time-specific
statements of dental remuneration, inflated to 2016/17 values.
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participants for the full duration of follow-up; however, any biases are likely to be small in magnitude
because of the short period of time in which the data exist, but the quality cannot be guaranteed.
For Northern Ireland, all data are a complete and accurate reflection of the full record for all patients
over the 4-year follow-up.
Costing of NHS dental services
Costs to the NHS are calculated for each individual trial participant as the region-specific total treatment
value minus any patient charge contributions. For patients who are exempt from paying dental charges
(e.g. those on a low income), the full value is assigned to the NHS. Exemption status is, therefore, an
important determinant of NHS perspective costs, and the analysis tests for any differences in status
across the randomised groups.
The costing analysis excludes any treatment claims relating to or originating from examinations at
the baseline trial visit. To do this, all treatment claims with a start date prior to 3 months (specifically
90 days) post randomisation are excluded. This ensures that any treatment costs are driven by the
decision to randomise patients to different recall intervals and not driven by unrelated treatment need
identified on entry to the trial. In addition, all treatment claims with a start date occurring more than
4 years post randomisation are excluded. Some final outcome assessments may have occurred prior to
4 years post randomisation. The outcome assessment data were not routinely passed to the participant’s
dental practice, and it is not anticipated that having the assessment early had a significant impact on
costs. However, to ensure that the analysis does not create any bias by identifying treatment need
at the final outcome assessment, the proportion of respondents for whom this occurred is compared
across trial arms. If differences are identified, these are controlled for in the cost regression analyses.
Costs are reported from both an NHS and a societal perspective (NHS + patient participant). All costing
is reported in 2016/17 Great British pounds and costs occurring beyond the first year of follow-up are
discounted at a rate of 3.5% per annum.103,104
Costs of other NHS services during follow-up
Information about the use of other NHS services related to dental health was obtained from participant-
completed annual postal questionnaires. NHS resource use falling outside the dental budget included
secondary care visits (hospital inpatient admission, outpatient consultations, day case procedures,
and accident and emergency attendances) together with general practitioner (GP) appointments and
contact with out-of-hours services such as NHS 24 (Scotland), NHS Direct (England/Wales) or NIdirect
(Northern Ireland). The following approach was used to deal with instrument and item non-response as
well as inconsistent reporting on the participant-completed questionnaires:
l Where an instrument was not returned, data were treated as missing, and non-dental NHS costs
were imputed using multiple imputation.
l Where respondents ticked ‘No’ to an item of resource use, but entered a number of contacts, it was
assumed that no resource use was incurred.
l Where respondents stated that they attended hospital inpatient services for problems related to
their teeth but provided no further information, it was conservatively assumed that such responses
should be treated as day case admissions. National data show that the majority of hospital
admissions in the UK for dental problems are day-case procedures.104
l Where respondents stated that they attended secondary care, and provided information regarding
the reasons for attendance, these reasons were assessed for their link to dental care, and if clearly
not related to dental care, were excluded from analysis.
The reported rates of contact with secondary care (e.g. inpatient/outpatient) were compared with average
attendance rates obtained from ISD/Hospital Episode Statistics to determine their face validity.104 It would
be anticipated that, in a general dental population, as included in the trial, the rates of admission should
be similar to national-level data.
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Participant costs
Three sources of participant cost are included in the analysis: (a) participant co-charges for NHS dental
care, (b) direct out-of-pocket expenses for private dental care and (c) the opportunity cost of participant’s
(and any companion’s/carer’s) time spent attending dental appointments.
Co-payments for NHS dental care
Routine dental claims data were used to determine participant perspective charges for each treatment
provided to each trial participant. These were estimated based on treatment banding and exemption status.
In England, explicit recording of the patient charge is not necessarily required for NHS payment and this
may explain why, in some cases, the English data set indicates £0 co-payment despite the patient not
having any exemptions indicated, or the patient charges are missing. This is likely to be an administration
error and it is, therefore, assumed that the practice collected the appropriate patient charge.
Self-purchased dental care products
Participants reported whether or not and how frequently they used/replaced electric toothbrushes,
electric toothbrush heads and manual toothbrushes. The cost of a new electric toothbrush was
obtained from participant-reported data in each annual questionnaire. Costs of manual toothbrushes
and replacement heads for electric brushes were assumed to be the cheapest available prices for
commonly used toothbrush products using an online search of multiple retail stores conducted on
20 September 2018. The unit costs sourced are £8.48 [pack of four Oral-B electric heads (Procter &
Gamble, Cincinnati, OH, USA), sourced from Superdrug (Superdrug Stores plc, Croydon, UK) online]
and £2 [manual Colgate 360 (Colgate–Palmolive Company, New York, NY, USA), sourced from Boots
(Boots UK Limited, Beeston, UK)], adjusted back to 2016 values to account for inflation and to ensure
a common year of currency for all costs.
Private dental care costs
Participants reported the total cost of out-of-pocket spending on private dental care in each annual
questionnaire. Reported data are summed across each questionnaire to obtain the full cost of private
dental care over the trial time horizon and data are described descriptively as mean (SD) and median
(interquartile range) to demonstrate the impact of a small number of high-cost items (e.g. dental
implants) on the cost analysis.
Costs of time and travel
There is a direct cost to the participant for travelling to every dental appointment and an opportunity
cost of their time (and their companion’s/carer’s time, if accompanied) spent travelling when they
are away from their usual activities (e.g. work, leisure time and child care). Routine dental claims are
used to identify the number of attendances for NHS dental treatment. It is conservatively assumed
that each unique treatment’s start/acceptance date (rather than each item of service claimed in
Scotland/Northern Ireland) relates to a single dental visit. This approach probably underestimates
the true participant perspective costs if more than one visit was required for a course of treatment.
The unit time and travel cost to participants and companions of a return journey to the dental practice
is calculated using data provided by respondents in the baseline questionnaire, using a subset of
questions obtained from a standardised patient costs questionnaire.105 The cost of a visit is assumed
to remain constant at the individual level across the time horizon of the trial to avoid overburdening
respondents with multiple similar questions in each annual questionnaire. Unit costs of travel and the
opportunity cost of time commitment of travelling to and attending dental appointments are detailed
in Table 3. The total opportunity cost of time and travel is obtained by multiplying the number of
treatment courses by the unit opportunity cost of time and travel for each participant.
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Statistical analysis and reporting of cost data
Cost models are estimated using generalised linear models, specifying a log link function and gamma
family to account for a skewed distribution with a minimum of zero cost, and a long tail reflecting a
small proportion of participants with high costs. The chosen family (gamma) is based on the results
of a modified Park test, and the chosen link function is based on a combination of Akaike information
criterion (AIC) score and p-values from the Pearson correlation test, the Pregibon link test and the
modified Hosmer–Lemeshow test110,111 obtained using the glmdiag program for Stata. Costing models
are adjusted for the trial minimisation variables, region and baseline EQ-5D-3L score, and a random
effect for centre to control for practice-specific variation in treatment decisions. For the comparison
of treatment options across all trial participants, a fixed effect is included to account for randomised
stratum in the trial. The cost models are estimated using Stata’s meglm command. Recycled predictions
of the coefficient on randomised treatment determine the incremental costs compared with standard
care (currently 6-month recall). Two sets of results are reported. First, results are reported for all data
comparing risk-based recall with 6-month recall. Second, a three-way comparison is presented for
those participants randomised to the stratum of participants who are eligible for 24-month recall.
Costs associated with risk-based and 24-month recall are compared against each other, and with the
assumed standard care (i.e. 6-month recall).
Descriptive statistics for cost data (mean, SD, N) are reported for all resource use items from both
an NHS and a patient participant perspective based on complete-case data for information. NHS
perspective costs to the dental budget are relatively complete because of a high match rate across
the regions between the routine dental claims data and the recruited trial population. However,
participant perspective costs (based on questionnaire response data) are subject to significant missing data.
TABLE 3 Unit costs for the opportunity costs of time and travel
Activity Assumptions made Unit cost Reference
Paid work Median UK gross weekly wage:
£550; 39.1 hours per week
£14.07 Office for National Statistics; Annual Survey of Hours and
Earnings, 2017106
Transport Cost per milea £0.45 HM Revenue & Customs (approved mileage rate,
2016/17)107
Caring for a
relative or friend
Median gross weekly pay:
£341; 39.2 hours per weekb
£8.70 NHS Pay Review Body report 2016, page 17108
Leisure activities Value of non-working timec £7.79 Transport Analysis Guidance (TAG) Data Book, July 2017109
Child care Assumed as paid work £14.07 Office for National Statistics; Annual Survey of Hours and
Earnings, 2017106
Voluntary work Assumed as paid work £14.07 Office for National Statistics; Annual Survey of Hours and
Earnings, 2017106
Unemployed Value of non-working time £7.79 Transport Analysis Guidance (TAG) Data Book, July 2017109
Retired Value of non-working time £7.79 Transport Analysis Guidance (TAG) Data Book, July 2017109
Parking Participant’s individual costs Various Participant questionnaires
Housework Cost of housework in the NHS,
assumed annual salary £21,000
gross, 2012 values inflated to
2016/17
£10.56 NHS pay review body, 2016108
a Based on government-approved travel mileage reimbursement for use of own vehicles.
b Caring, leisure and other service occupations.
c Transport Analysis Guidance data report, based on values of non-working time (£ per hour, 2010 prices, inflated to
2016/17 values) based on the average of inflated prices for commuting and other time (£10.69 + £4.88)/2 = £7.79.
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For the statistical analysis of costs, the mechanism of data missingness was investigated using
logistical regression analysis, where the dependent binary variable (missing or not) was regressed on
sociodemographic characteristics (age, gender), minimisation variables, region, baseline EQ-5D-3L utility
score, and baseline measures of clinical outcome. Statistically significant explanatory variables were
assumed to indicate that data were missing at random as opposed to missing completely at random.
Best practice was applied, imputing data using multiple imputation of missing data following Stata’s MI
procedure.112 Missing cost data are imputed by component of cost (e.g. dental product costs) for each
questionnaire, using predictive mean matching (average of five closest values), accounting for the
repeated measures nature of the costs from the annual participant questionnaires. M = 5 imputed data
sets are used to ensure the stability of results, and the data sets were combined using Rubin’s rules to
obtain a single estimate of costs.113 All data imputation models account for randomised group and adjust
for explanatory variables as described above.
Benefits
Three different measures of benefit are included in the economic evaluation as alternative analyses.
The analyses differ in terms of the scope and definition of the benefits included. Benefits are considered as
(a) WTP for both dental recall frequency and associated dental health outcomes to inform a cost–benefit
analysis (CBA) that includes all perceived benefits, health and non-health, to the general population,
(b) QALYs to inform a cost–utility analysis (CUA) and (c) WTP for dental health outcomes, specifically
ICDAS and bleeding gums on brushing, where the utility of dental health outcomes is measured in
terms of WTP. The preferred analysis depends on what outcome a decision-maker wishes to maximise:
social welfare, QALYs or (WTP for) dental health outcomes. All benefits are valued using general
population preferences.
Willingness to pay: discrete choice experiment
Willingness to pay is calculated based on responses to an online DCE conducted with a nationally
representative sample of the UK population, with oversampling in Scotland to determine any subgroup
effects on preferences driven by different, regional-specific payment systems. A DCE is a survey designed
to elicit respondents’ preferences through the choices they make between different hypothetical goods
or services. In the context of this study, respondents make choices between different packages of dental
care that vary in terms of their recall frequency, health outcomes (bleeding gums when brushing and
caries experience over a 4-year period, as informed by ICDAS classification groups) and cost. Each
package comes at an annual cost over 4 years, reflecting the trial’s time horizon.
Discrete choice experiments assume that a treatment or service’s value depends on its component
attributes and the levels of those attributes. By including the price proxy within the DCE (i.e. the
annual cost of each dental package), we can obtain a monetary valuation for any given dental recall
package. These WTP estimates are used as a measure of benefit within the CBA, and can be used to
value all outcomes or a subset of those outcomes (e.g. health related only). The DCE received ethics
approval from the College Ethics Review Board at the University of Aberdeen (ref: 2015/12/1278).
The main considerations for the DCE design are as follows.
Discrete choice experiment selection of attributes and levels
The trial protocol sets the primary research question, and the DCE therefore seeks to value general
population preferences for different frequencies of dental recall (24 month, 12 month, 6 month, or risk
based). The selection of outcome attributes and levels was partially determined by the trial (e.g. valuing
avoidance of caries), but the selection of outcomes for valuation was also based on engagement with
key stakeholders (in formal and informal discussion), literature review and primary qualitative (focus
group) work with members of the general population to derive a set of attributes and levels meaningful
and important to respondents. It became clear from the focus group work that respondents would have
difficulty valuing and understanding the primary clinical trial outcome (gingival bleeding on probing).
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The DCE attribute for bleeding is, therefore, bleeding on brushing (this is mapped to a post hoc trial
outcome that asks respondents to report on the frequency of bleeding when they brush their teeth).
The final list of attributes and levels included in the DCE is provided in Table 4 and an example choice
set can be found in Figure 4.
Discrete choice experiment experimental design
A pivoted, segmented design was generated using Ngene™ experimental design software (ChoiceMetrics
Pty Ltd, Sydney, NSW, Australia) to select the combination of treatment descriptions, and to create
the choice sets, which minimised the design’s D-error. First, respondents were assigned to one of three
segments (good, moderate or poor dental health) based on their self-reported dental health as measured
using stated caries experience and bleeding frequency.
The opt-out scenario described the implications of choosing the ‘no dental check-up’ package (i.e. receiving
none of the services within the package and at no cost). Outcome attributes in the reference case were
tailored to each segment, reflecting a modest reduction in the outcome attributes if no dental package
was selected. The levels of the outcome attributes were then pivoted around these baseline (opt-out)
levels, to ensure that only realistic choice tasks were presented to respondents. The pivoting ensured
that respondents were not presented with situations in which their health could get worse by opting
into one of the dental packages.
The DCE has a single five-level attribute with three four-level attributes, resulting in 320 (51 × 43)
possible combinations and (320 × 319)/2 = 5040 unique choice sets. The resultant chosen main effects
D-optimal design consisted of 24 choices, split equally across three blocks of eight choices. Two further
choice tasks were added to test for consistency and dominance to each block of choices, meaning that
each respondent completed a total of 10 choice tasks. The responses to the internal validity choice tasks
were not included in the analysis models. The experimental design was based on vague priors, specifying
only the expected coefficient sign for outcome attributes and null priors for the recall frequency attribute.
Discrete choice experiment questionnaire development
There are three sections to the survey. Section 1 asks about respondents’ experiences of dental care,
current dental health, how often they attend their dental practice and by whom they are treated.
Responses to dental health questions are used to inform the pivoting of the design as described in
TABLE 4 Attributes and levels included in the DCE
Attributes Levels
You have a dental check-up Every 2 years
Every year
Every 6 months
It varies depending on your risk
In 4 years’ time, your gums will bleed Never
Hardly ever
Occasionally
Fairly often
Very often
Over the next 4 years, you will have No dental decay
Early dental decay
Moderate dental decay
Advanced dental decay
The annual cost to you £20 per year (total cost: £80 over 4 years)
£50 per year (total cost: £200 over 4 years)
£100 per year (total cost: £400 over 4 years)
£200 per year (total cost: £800 over 4 years)
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FIGURE 4 Example choice task. Note: the example choice set shown in Figure 4 is for a respondent categorised as having moderate dental health. If this hypothetical respondent chose
dental check-up package B, they would be willing to pay £200 per year for that package.
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Discrete choice experiment experimental design. Section 2 asks the respondents to complete the DCE,
and section 3 concludes the survey with a series of demographic and attitudinal questions that may
help explain choices. In addition, there are debriefing questions about ease of understanding, realism
and appropriateness of the choice task questions, as well as questions designed to understand respondents’
experiences of taking online surveys more generally. The questionnaire was designed using Qualtrics
(Qualtrics, Provo, UT, USA) online survey design platform.
Discrete choice experiment data collection
Data were collected using Qualtrics online panels. Data collection for the DCE was conducted in
parallel with the trial follow-up period and responses to the survey were provided between 7 July and
5 August 2016. The survey was nationally representative, with population census quotas sought for
age (among adult population), sex and region. We oversampled in Scotland (n = 183) to enable regional-
specific subgroup analysis split by contract type (UDA, England/Wales; fee for service, Scotland/Northern
Ireland). At the pilot stage, 30% of responses were sought from non-regular attenders (defined as not
having seen the dentist in the previous 2 years),114 but it was not possible to achieve this target and,
instead, a relaxed quote of 10% was sought for the main data collection phase. All responses were
anonymised and respondents could leave the survey at any time and did not need to provide a reason
for doing so. Those who completed the survey were reimbursed in a manner determined by the
survey panel.
Discrete choice experiment data analysis
The DCE data are analysed using best practice methods and followed random utility maximisation
theory.115 In brief, all data are analysed using a mixed logit model, specifically an error components logit
model, allowing for multiple choices per respondent. The observable, individual specific systematic
component of the utility function (Vnjt) for individual n, choosing dental check-up package j, in each
choice task t is specified as a linear additive function of the attributes and levels presented to the
respondents:
Vnjt = α + β1Recallannual + β2Recallsix−monthly + β3Recallrisk−based + +β4Bleedhardly− ever + β5Bleedoccasional
+ β6Bleedfairly often + β7Bleedvery often + β8Decayearly + β9Decaymoderate + β10Decayadvanced + β11Annual Cost,
(1)
where α is the alternative specific constant (ASC), included as a random (normally distributed)
parameter in the model. The ASC accounts for latent or unobserved utility associated with choosing
any package, regardless of the attribute levels, and β represents the marginal utilities associated with
the attributes and levels.
All categorical variables are effects coded where the β coefficients represent the effect of a unit
change in an attribute level (away from the grand mean) on utility. The advantage of effects coding
is that the reference level of an attribute is uncorrelated with the ASC. The reference categories for
the effects coded attributes are 24-month recall, never bleeding and having teeth that have no decay.
The utility of the reference category, relative to the grand mean of the attributes, is obtained as the
negative sum of the estimated coefficients for that attribute. The coefficient on cost indicates the
marginal change in utility for a £1 increase in annual cost. The error term is split into two, where
µn is the individual specific random effect and ϵj, the unobserved component of the error term,
is independent Type I extreme value distributed. The final model is estimated using the maximum
simulated likelihood method, with 200 Halton draws.
The marginal WTP of an attribute level is equal to the negative of the marginal rate of substitution
between that level and the cost attribute. For the purposes of result reporting, confidence intervals (CIs)
are based on the delta method, calculated using Stata’s nlcom command which computes point estimates
and CIs for potentially non-linear combinations of parameter estimates, implemented after running the
corresponding error components logit models.
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The models are re-estimated separately using interaction terms for several predetermined subgroups,
including (1) sex; (2) region, to determine if system of reimbursement, and patient co-charge (£0 in
Scotland) has an impact on preferences; (3) smoking status, to determine if current or previous smokers’
preferences differ from the overall group; (4) household income, to determine if lower ability to pay
(annual income < £20,800) has an impact on preferences; (5) experience of dental check-ups (attending
at least every 6 months); and (6) experience of dental decay, to determine if having experience of dental
decay has an impact on preferences for its avoidance. The impact of subgroups on main attribute-level
effects is assessed by the significance of interaction terms between subgroup identifier and attribute
level coefficient. Likelihood ratio tests are used to test the joint significance of the interaction terms.
Estimating benefits (willingness to pay) for each trial participant
Benefits in terms of WTP, are calculated for each trial participant by mapping the WTP tariffs obtained
from the DCE to the trial outcomes. Following an intention-to-treat principle, WTP values are attached
to the services provided (i.e. the number of check-ups received at a trial participant level, regardless of
randomised group). This means that the tariff for risk-based recall in the DCE was not directly assigned
to the trial interventions. This is in line with an intention-to-treat approach, but it is possible that
patients attach value directly to being allocated to a risk-based interval; therefore, sensitivity analysis
explores a per protocol approach to attaching DCE WTP values to trial interventions. For check-up
frequencies observed in the trial that extend beyond the valuation scope of the DCE (e.g. four check-
ups per year), a stepwise linear utility function is used to extrapolate the WTP tariffs predicted using
the DCE. WTP tariffs were assigned directly to the health outcome attributes observed in the trial
(i.e. self-reported bleeding on brushing and caries experience). Caries experience is defined as a composite
of treated caries assumed equal to the number of fillings provided over the follow-up phase in addition
to the untreated caries detected at the final outcome assessment. The marginal WTP tariffs attached
to each service and outcome are summed to obtain a total WTP measure of benefit. Two different
measures are presented: (A) total WTP calculated as the sum of marginal WTPs for mapped health
outcomes only (i.e. caries and bleeding), generating a dental health perspective of benefits, and (B) total
WTP calculated as A + the marginal WTP attached to service frequency, generating a broader and more
holistic measure of benefit for use in the CBA.
Quality-adjusted life-years
The EQ-5D-3L is used to capture generic health-related quality of life in the trial. Respondents
complete the EQ-5D-3L at baseline and in each annual follow-up questionnaire. Responses to the
EQ-5D-3L are then valued using UK general population tariffs, estimated using the time trade-off
method.116 The valuation generates a utility score for each EQ-5D-3L response on a scale of –0.564
(worst possible health state) to 1 (best possible health state). QALYs are then calculated using an area
under the curve approach with linear extrapolation between the annual data collection time points.
Any respondents who died over the course of the trial are assigned a zero utility score from the
follow-up time point after death to the end of the trial follow-up.
Statistical analysis of benefits data
The approach for the analysis of benefits data is similar for calculations of both WTP and QALYs.
All benefits, regardless of measurement approach, are discounted at a rate of 3.5% per annum in
line with NICE guidance.103 Total WTP and QALY data are both analysed using a generalised linear
regression model, adjusting for minimisation covariates, region and baseline EQ-5D-3L utility score,
and include a random effect for centre. For the comparison of all data in a single model, a fixed effect
for stratum is added. For each benefit measure, models are estimated using Stata’s meglm command
with a Gaussian family and identify link. The chosen family (Gaussian) is based on the results of a
modified Park test, and the chosen link function is based on a combination of AIC score, and p-values
from the Pearson correlation test, the Pregibon link test and the modified Hosmer–Lemeshow test.
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Missing data exist for benefits because participants may not have attended their final year clinical
assessment appointment or may not have returned questionnaires detailing experience of bleeding on
brushing. As with costs, the mechanism of missingness was explored using logistical regression models to
determine any predictors of missingness. Presence of significant explanatory variables was taken as an
indication that data were missing at random and could not be assumed missing completely at random,
and so multiple imputation would be required. Missing data are imputed using Stata’s MI procedure112,117
(by randomised group) using predictive mean matching (five closest values), and accounting for
minimisation variables and baseline EQ-5D-3L utility score. M = 5 imputed data sets are used and
results obtained from the combined data using Rubin’s rules.113
Economic evaluation
Cost–benefit analysis
The CBA compares the costs and benefits of alternative policies of dental recall against standard care
(currently 6-month scheduled recall). Both costs and benefits are measured in monetary terms and net
benefits can, therefore, be directly estimated (benefits minus cost). The INBs indicate whether moving
from standard care to an alternative policy increases or decreases overall societal welfare. The imputed
data sets are used to estimate net benefits and INBs. Net benefit is calculated for each participant in
the trial according to Equation 2:
Net benefit = total benefits− total costs. (2)
Cost–utility analysis: generic
This analysis is based on the cost of achieving changes in generic health profile, as measured using the
EQ-5D-3L, and uses QALYs as the measure of benefits. An incremental comparison of costs and QALYs
between each recall strategy is reported, and ICERs are calculated as the mean difference in costs
divided by the mean difference in QALYs. The ICER can then be compared with a threshold value of
WTP for a QALY gained, as is commonly considered by NICE. If the ICER is < £20,000 to £30,000 per
QALY gained, an intervention is typically considered to be an efficient use of resources. In cases where
there are additional costs but QALY losses, an intervention is said to be ‘dominated’ and is less likely to
provide good value for money.
Dental health-specific evaluation
Quality-adjusted life-years are unlikely to be sufficiently sensitive to capture changes in dental health;
therefore, an ‘alternative’ analysis is conducted using WTP for dental health outcomes (based on a
composite measure of caries experience as measured using ICDAS/fillings received and self-reported
bleeding gums on brushing) as the measure of benefit. INBs are estimated as described in the CBA.
Statistical analysis of costs and benefits together
For each analysis framework, data are analysed using multiple imputation of missing data, and regression
analyses as described in the preceding sections. The point estimate of INB, or incremental cost per
QALY gained, is obtained by dividing the treatment coefficient on costs by the treatment coefficient on
benefits regressions. This is done for each cost perspective (NHS dental perspective, NHS perspective
and societal perspective). The results should be considered in the light of the uncertainty surrounding
the point estimate. Uncertainty is illustrated using scatterplots of costs and benefits (WTP or QALYs)
on the cost-effectiveness (benefit) plane and cost-effectiveness (benefit) acceptability curves. The cost-
effectiveness acceptability curves (CEACs)/cost–benefit acceptability curves (CBACs) and scatterplots
are obtained using 1000 bootstraps of the corresponding analysis models, with imputation included
within each bootstrapped loop where required, following the guidance outlined in Brand 2019.118
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For the CBA, the CBACs illustrate the probability that INB is positive at various threshold values
of the benefit–cost ratio. A positive INB would be associated with a benefit–cost ratio > 1. The higher
the benefit–cost ratio, the more likely the intervention is to be cost-beneficial (i.e. an efficient use
of resources). For the CUA, CEACs illustrate the probability that each intervention is the optimal
(most efficient) strategy at increasing threshold values of society’s WTP for a QALY gained. These
analyses illustrate the impact of sampling uncertainty on the results, but it is also necessary to consider
uncertainty driven by key analysis assumptions. The range of deterministic and scenario analyses
carried out are described, with a justification for each, in Table 5.
TABLE 5 Scenario analyses considered
Topic Scenarios considered Justification for approach
Impact of costing perspective on results
Costing perspective Costs are considered from an NHS dental
care perspective, based on NHS payment
for dental care obtained from routine
claims data
To determine the direct impact of different
recall frequencies on the NHS dental budget
Costing perspective Costs are considered from both an NHS
dental care perspective and a broader
NHS health-care perspective including
costs falling outwith the dental budget
(e.g. hospital attendance, GP care and
out-of-hours service contacts)
To determine the impact of a narrow vs. wider
perspective of NHS-incurred costs on results
Costing perspective Costs are considered from an NHS dental
care, a broader NHS health-care perspective
and include all patient participant-incurred
costs (including costs directly associated with
attendance at NHS dental appointments and
all other private dental care)
To determine the impact of different
recall strategies on costs from both
the NHS perspective and the patient
perspective
To more fully understand the impact on
patients of attendance for dental visits
Costing perspective Costs are considered from both an NHS
dental care perspective and including
patient participant perspective costs
directly associated with attendance at
dental appointments
An even wider perspective of costs, including
all NHS and participant perspective costs
related to dentistry
Methodological issues
Reference analysis: multiple imputation, 3.5% discount rate for costs and benefits, WTP mapped to caries experience
(routine data) + untreated caries (trial outcome), ITT analysis, based on all UK regions combined
Discounting of costs
and benefits
Assume undiscounted costs and benefits Standard exploration of methodological
uncertainty
Imputation Complete cases
Mapping of WTP to
trial outcomes
Exploring the impact of mapping WTP for
caries avoidance to clinical trial outcome
(untreated caries) only
The clinical outcome assessment captures
untreated caries, but not caries experience
for participants when they obtained fillings
over the trial follow-up. Sensitivity analysis
(untreated caries only) may underestimate
value of caries experience, but may be more
robust given that it is unclear from routine
data if fillings are provided for caries
(or replacements/trauma)
continued
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TABLE 5 Scenario analyses considered (continued )
Topic Scenarios considered Justification for approach
ITT vs. per protocol
analysis
ITT analysis values the number of services
received in the CBA. The ‘per protocol’
analysis attaches WTP tariffs from the
DCE to randomised arms, regardless of
services delivered
Analysis conducted to explore the impact of
explicit valuation of risk-based recall on the
CBA results
UK vs. regional
analyses
Region-specific analyses for Scotland
and England
Regional-specific analyses conducted to
determine if the payment system for dentistry
(e.g. fee for service and free check-ups for
patients in Scotland) has an impact on cost-
effectiveness results. This analysis additionally
includes regional-specific subgroup WTP tariffs
from the DCE applied to trial participant
services and outcomes (by region)
ITT, intention to treat.
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Chapter 4 Trial results and clinical
effectiveness
Introduction
This chapter describes the study groups at trial entry, followed by a description of the interventions
received, the results at the annual follow-up points and a statistical analysis of the primary and
secondary outcomes. Randomised groups are presented separately dependent on eligibility stratum:
whether the patient participant was eligible or not to be randomised to a 24-month recall. If the
participant was eligible, three treatment options were available and are presented in this chapter (i.e.
risk-based recall, 24-month recall and 6-month recall). If the participant was not eligible to be recruited to
the 24-month recall stratum, two randomised groups are presented (risk-based recall and 6-month recall).
Recruitment to the study
Participants were recruited between July 2010 and July 2014. Data were closed to follow-up on
13 August 2018. The flow of participants for each INTERVAL eligibility stratum is shown separately
in Figure 5 (eligible to be randomised to 24-month recall) and Figure 6 (ineligible to be randomised
to 24-month recall), with information on primary outcome collection at the different follow-up time
points in the form of a Consolidated Standards of Reporting Trials (CONSORT) flow diagram.
Participants
Participants were recruited from 51 practices (see Appendix 1, Table 28). A total of 2372 participants were
recruited to the trial. Of the 648 participants recruited to the 24-month recall stratum, 217 were allocated
to risk-based recall, 216 to 24-month recall and 215 to 6-month recall. Of the 1724 participants
Randomised
(n = 648)
Risk-based recall
(n = 217)
24-monthly recall
(n = 216)
6-monthly recall
(n = 215)
Follow-up (year 1)
• Provided OHIP, n = 141
Follow-up (year 1)
• Provided OHIP, n = 152
Follow-up (year 2)
• Provided OHIP, n = 128
Follow-up (year 2)
• Provided OHIP, n = 143
Follow-up (year 3)
• Provided OHIP, n = 131
Follow-up (year 3)
• Provided OHIP, n = 129
Follow-up (year 1)
• Provided OHIP, n = 145
Follow-up (year 2)
• Provided OHIP, n = 137
Follow-up (year 3)
• Provided OHIP, n = 129
Follow-up (year 4)
• Provided OHIP, n = 145
• Provided bleeding measure, n = 142
Follow-up (year 4)
• Provided OHIP, n = 153
• Provided bleeding measure, n = 137
Follow-up (year 4)
• Provided OHIP, n = 52
• Provided bleeding measure, n = 134
FIGURE 5 The CONSORT flow diagram for participants eligible for the 24-month recall stratum.
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ineligible for 24-month recall stratum, 861 were allocated to risk-based recall and 863 were allocated to
6-month recall. In total, 1078 participants received a risk-based recall and 1078 received a 6-month
recall. Half of all participants (1188) were recruited from Scotland, 1031 were recruited from England
and Wales (43%) and 153 were recruited from Northern Ireland (7%).
Description of the groups at trial entry
Participant characteristics
Sociodemographic factors and dental characteristics
Participants and sociodemographic characteristics are shown in Table 6. The average age of participants
was 45 years (participants in the eligible for 24-month recall stratum were younger, on average by
around 4 years, than those ineligible for 24-month recall); the majority were women (around 55%)
and regular attenders, although there was a difference between the eligible for 24-month recall
stratum (around 74% self-reported having been to the dentist in the last year) and the ineligible
stratum (around 86% had been to the dentist in the last year). Approximately 15% of participants
self-identified as smokers in the last 12 months. Fifty-five per cent of the participants used manual
dental brushes. Participants found it easy to travel to the dentist (on average scoring 6 out of 7,
where 7 is the easiest to travel). Randomised groups were balanced on the sociodemographic factors
and dental characteristics collected.
Participants’ dental behaviour at baseline
Most participants (around 70%) brushed twice a day or more often and believed that this is what they
should do (around 86%). Around 56% of the participants reported taking 2 minutes or longer to brush.
Around one-quarter of the participants reported that they spit but do not rinse, and one-third reported
that they believed that is what they should do (Table 7).
Randomised
(n = 1724)
Risk-based recall
(n = 861)
6-monthly recall
(n = 863)
Follow-up (year 1)
• Provided OHIP, n = 617
Follow-up (year 2)
• Provided OHIP, n = 585
Follow-up (year 3)
• Provided OHIP, n = 551
Follow-up (year 4)
• Provided OHIP, n = 624
• Provided bleeding measure, n = 599
Follow-up (year 4)
• Provided OHIP, n = 630
• Provided bleeding measure, n = 597
Follow-up (year 1)
• Provided OHIP, n = 623
Follow-up (year 2)
• Provided OHIP, n = 599
Follow-up (year 3)
• Provided OHIP, n = 566
FIGURE 6 The CONSORT flow diagram for participants ineligible for the 24-month recall stratum.
TRIAL RESULTS AND CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
40
Patients’ reported outcomes
The baseline patient-reported outcomes summary is shown in Table 8. More details about individual
questions that produced the scales are given in Appendix 1, Table 26. OHIP-14 score, the patient-reported
primary outcome, was, on average, low, indicating good OHRQoL in both strata. OHIP-14 was around
4.5 in the eligible for 24-month recall stratum and 5.9 in the ineligible stratum, on a scale that goes
up to 56 for worst quality of life. Participants were, in general, satisfied with their dental services
TABLE 6 Participant characteristics at baseline by randomised group
Participant
characteristic
Eligible for 24-month recall Ineligible for 24-month recall
Risk based 24 month 6 month Risk based 6 month
Randomised, n (%) 217 (100.0) 216 (100.0) 215 (100.0) 861 (100.0) 863 (100.0)
Baseline questionnaire
returned, n (%)
181 (83.4) 186 (86.1) 187 (87.0) 810 (94.1) 803 (93.0)
Age (years), mean (SD), n 43.3 (15.1), 217 44.2 (15.2), 216 43.5 (14.5), 215 49.3 (14.1), 861 50.1 (15.3), 863
Gender, n (%)
Male 87 (40.1) 100 (46.3) 94 (43.7) 356 (41.3) 366 (42.4)
Female 128 (59.0) 115 (53.2) 121 (56.3) 498 (57.8) 491 (56.9)
Missing 2 (0.9) 1 (0.5) 0 (0.0) 7 (0.8) 6 (0.7)
Smoking status, n (%)
Smoked in the last
12 months
32 (14.7) 27 (12.5) 32 (14.9) 145 (16.8) 130 (15.1)
Missing 38 (17.5) 32 (14.8) 30 (14.0) 53 (6.2) 69 (8.0)
Time since previous visit to dentist, n (%)
< 1 year 165 (76.0) 157 (72.7) 165 (76.7) 737 (85.6) 741 (85.9)
1–2 years 13 (6.0) 24 (11.1) 16 (7.4) 62 (7.2) 51 (5.9)
> 2 years 1 (0.5) 4 (1.9) 4 (1.9) 4 (0.5) 0 (0.0)
Missing 38 (17.5) 31 (14.4) 30 (14.0) 58 (6.7) 71 (8.2)
Patient status, n (%)
NHS 152 (70.0) 154 (71.3) 155 (72.1) 695 (80.7) 677 (78.4)
Private 8 (3.7) 12 (5.6) 7 (3.3) 33 (3.8) 32 (3.7)
Combination 12 (5.5) 8 (3.7) 14 (6.5) 54 (6.3) 56 (6.5)
Missing 45 (20.7) 42 (19.4) 39 (18.1) 79 (9.2) 98 (11.4)
Type of toothbrush, n (%)
Manual 114 (52.5) 131 (60.6) 113 (52.6) 489 (56.8) 496 (57.5)
Electric 64 (29.5) 53 (24.5) 74 (34.4) 318 (36.9) 298 (34.5)
Missing 39 (18.0) 32 (14.8) 28 (13.0) 54 (6.3) 69 (8.0)
Regular attender:
self-report
158 (72.8) 163 (75.5) 168 (78.1) 740 (85.9) 735 (85.2)
Missing 39 (18.0) 31 (14.4) 28 (13.0) 60 (7.0) 71 (8.2)
Difficulty travelling to
dentist, mean (SD), n
6.4 (1.2), 179 6.5 (1.2), 186 6.4 (1.2), 186 6.4 (1.2), 805 6.3 (1.2), 791
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(giving, on average, a score of 5 out of 7 on the satisfaction scale, where 7 is maximum satisfaction with
the service). Their anxiety was on average around 10 points, on a scale ranging from 5 to 25, where 25
is the maximum anxiety.
Baseline overview
Overall, participants in the ineligible for 24-month recall stratum were older, self-reported to attend the
dentist more regularly and had higher OHIP-14 scores than those in the eligible stratum. Participants
were, in general, satisfied with the dental services received and had low dental anxiety and a good
knowledge about the frequency and duration of brushing; however, they were less informed about what
to do after brushing (i.e. spit, but not rinse). There were no important differences or imbalances across
randomised groups in each of the eligibility strata. Appendix 1, Tables 29–37, display all baseline tables
TABLE 7 Participants’ oral health-related behaviour at baseline by randomised group
Oral health-related behaviour
Eligible for 24-month recall Ineligible for 24-month recall
Risk based 24 month 6 month Risk based 6 month
Frequency of brushing, n (%)
Less than once per day 0 (0.0) 1 (0.5) 5 (2.3) 9 (1.0) 11 (1.3)
Once per day 33 (15.2) 42 (19.4) 42 (19.5) 151 (17.5) 116 (13.4)
Twice per day 123 (56.7) 128 (59.3) 132 (61.4) 560 (65.0) 587 (68.0)
More than twice per day 23 (10.6) 15 (6.9) 8 (3.7) 82 (9.5) 80 (9.3)
Missing 38 (17.5) 30 (13.9) 28 (13.0) 59 (6.9) 69 (8.0)
Duration of brushing, n (%)
< 1 minute 9 (4.1) 3 (1.4) 10 (4.7) 24 (2.8) 25 (2.9)
1 to 2 minutes 56 (25.8) 55 (25.5) 62 (28.8) 252 (29.3) 254 (29.4)
2 minutes 87 (40.1) 99 (45.8) 79 (36.7) 362 (42.0) 383 (44.4)
> 2 minutes 26 (12.0) 29 (13.4) 36 (16.7) 163 (18.9) 132 (15.3)
Missing 39 (18.0) 30 (13.9) 28 (13.0) 60 (7.0) 69 (8.0)
After brushing, n (%)
Rinse with water 78 (35.9) 100 (46.3) 97 (45.1) 432 (50.2) 435 (50.4)
Rinse with mouthwash 37 (17.1) 33 (15.3) 26 (12.1) 154 (17.9) 165 (19.1)
Spit not rinse 64 (29.5) 53 (24.5) 64 (29.8) 213 (24.7) 190 (22.0)
Missing 38 (17.5) 30 (13.9) 28 (13.0) 62 (7.2) 73 (8.5)
TABLE 8 Patient-reported outcomes at baseline by randomised group
Patient-reported outcome
Eligible for 24-month recall, mean (SD), n
Ineligible for 24-month
recalll, mean (SD), n
Risk based 24 month 6 month Risk based 6 month
Attitude (score from 1 to 7) 4.2 (0.8), 178 4.3 (0.9), 186 4.1 (0.7), 187 4.1 (0.9), 806 4.0 (0.9), 795
Satisfaction (score from 1 to 7) 5.2 (0.8), 147 5.2 (0.8), 153 5.2 (0.7), 158 5.3 (0.6), 703 5.3 (0.6), 701
OHIP-14 (score from 0 to 56) 4.5 (7.0), 175 4.7 (6.4), 183 4.4 (6.1), 182 5.8 (6.9), 778 6.1 (7.7), 778
Overall anxiety (score from 5 to 25) 10.4 (4.6), 176 10.7 (4.4), 186 10.5 (4.5), 185 10.2 (4.5), 801 10.1 (4.5), 798
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by country: Scotland, England and Northern Ireland. Average age is similar across countries, as is the
proportion of regular smokers. The percentage of regular attenders was higher in Scotland than in
England in the stratum eligible for the 24-month recall (85% vs. 70%). Around 80% of the participants in
Scotland reported that they were fully NHS; in England, around 72% of patients eligible for a 24-month
recall were fully NHS, as were 80% of patients in the ineligible for a 24-month recall stratum. In Northern
Ireland, around one-third of patients in the eligible for a 24-month recall stratum were fully NHS, as
were 65% of the ineligible patients. Patient-reported outcomes and behaviour and knowledge questions
produced similar results across countries, except for ‘What do you do after brushing?’ or ‘What should
you do after brushing?’ (i.e. spit, not rinse). In Scotland, around 35% of participants spit but do not
rinse and around 45% of participants know that this should be the case. In England, around 14% of
participants reported that they spit but do not rinse and around 16% of participants said that they
know that this should be the case. In Northern Ireland, around 16% of participants in the eligible for
24-month recall stratum spit but do not rinse or think that they should do that whereas in the ineligible
stratum this value is around 50% for both questions.
Trial follow-up
Description of the intervention
Using routine data from Scotland, England and Northern Ireland, the number of routine check-ups
reported during the trial is presented in Table 9. Participants eligible for 24-month recall, and who
had a clinical outcome assessment, had on average 3.7 check-ups in the risk-based group, 2.5 in the
24-month recall group and 5.1 in the 6-month recall group. Participants who were ineligible for the
24-month recall, and who had a clinical outcome assessment, had 5.0 check-ups on average during
the trial in the risk-based group and 5.4 check-ups in the 6-month group.
Once a participant had been randomised, dentists were asked to record the date of their first intended
appointment, which took account of any expected course of treatment. Participants in the eligible for
24-month recall stratum were assigned recall appointments that were intended to be at, on average,
13 months (risk-based recall), 24 months (24-month recall) and 7 months (6-month recall). Participants
in the ineligible for 24-month recall stratum were advised by clinicians to wait 9 months until their
first appointment if in the risk-based group and 8.5 months if in the 6-month recall group. Appendix 1,
Tables 38–40, presents the description of the intervention by country. Participants from England and
Northern Ireland had, on average, more check-ups than Scottish participants, but the discrepancy
between randomised groups was similar across countries.
TABLE 9 Description of the intervention (from participants with a clinical follow-up)
Intervention
Eligible for 24-month recall Ineligible for 24-month recall
Risk based
(n= 137)
24 month
(n= 128)
6 month
(n= 128)
Risk based
(n= 582)
6 month
(n= 578)
Check-ups received
0 1 (0.7) 8 (5.8) 0 (0.0) 1 (0.2) 0 (0.0)
1 15 (10.5) 50 (36.2) 7 (5.2) 14 (2.3) 7 (1.2)
2 27 (18.9) 22 (15.9) 9 (6.7) 44 (7.3) 30 (5.0)
3 or more 94 (65.7) 48 (34.8) 112 (83.0) 523 (86.3) 541 (89.9)
Missing 6 (4.2) 10 (7.2) 7 (5.2) 24 (4.0) 24 (4.0)
Number of check-ups,
mean (SD), n
3.7 (1.9), 137 2.5 (2.2), 128 5.1 (3.7), 128 5.0 (2.3), 582 5.4 (2.0), 578
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Overall, there was a clear difference in terms of number of check-ups received between the different
randomised groups in the eligible for 24-month recall stratum. The number of check-ups received
in the risk-based and 6-month recall was similar in the ineligible for 24-month recall stratum: there
was a higher number of check-ups in the risk-based group of the ineligible stratum than of the eligible
stratum. In terms of clinicians’ intentions at the beginning of the trial, there is a similar pattern on the
PAD forms: a clear separation in time between randomisation and first intended appointment between
randomised groups. However, participants ineligible for a 24-month recall had a similar interval
between randomisation and first intended appointment across the different groups.
Attendance at 4-year clinical examination and questionnaire returns
The primary clinical outcome was collected at the 4-year clinical follow-up. Overall, around 64%
and 71% of the participants attended their appointment and replied to the year 4 questionnaire,
respectively, in the eligible for 24-month recall stratum. In the ineligible stratum, 70% of participants
attended the clinical appointment and 76% replied to the year 4 questionnaire (Table 10). For most
participants (around 89% of the participants randomised), reasons for non-attendance were unknown.
When a reason was obtained from the practices, the most common reason for non-attendance was
inability to contact the patient (around 9%). This finding was similar across groups and in both strata.
The mean follow-up time was 122 months with a SD of 6.2 months. Approximately 71% of participants
in the eligible for 24-month recall stratum and 76% of participants in the ineligible for 24-month recall
stratum returned their year 4 questionnaire.
Participants’ characteristics at 4 years
Participants’ characteristics at 4 years are shown in Table 11. A lower percentage of participants
reported smoking in the last 12 months at year 4 than at baseline (12% vs. 15% approximately). The
majority of participants stated that they had been to dentist in the last year (around 90%); however,
there were important differences between groups. The group randomised to 24-month recall had
a lower percentage of participants that reported that they had attended in the last year (76%) and a
significantly higher percentage of participants reporting that the time since their previous visit was
between 1 and 2 years. Around the same percentage of participants across groups reported that
they used the NHS (70%) and used a manual toothbrush (50%). Most of the participants reported
to be regular attenders across the groups with similar percentages in the 6-month recall groups for
both strata and in the risk-based group in the ineligible stratum (around 90%). Around 84% of the
participants in the risk-based group eligible for a 24-month recall and in the 24-month recall stratum
reported the same. Participants, overall, found travelling to the dentist easy and with similar scores to
baseline (6 out of 7 on a Likert scale, where 7 is the easiest to travel). Participant characteristics at
years 1, 2 and 3 are presented in Appendix 1, Tables 41–43. Participant behaviour and knowledge
related to oral health at years 1, 2, 3 and 4 are presented in Appendix 1, Tables 44–47.
TABLE 10 Attendance rates
Time point
Eligible for 24-month recall, n (%) Ineligible for 24-month recall, n (%)
Risk based
(N= 217)
24 month
(N= 215)
6 month
(N= 216)
Risk based
(N= 861)
6 month
(N= 863)
Attended clinical
follow-up
143 (65.9) 138 (63.9) 135 (62.8) 606 (70.4) 602 (69.8)
Baseline 181 (83.4) 186 (86.1) 187 (87.0) 810 (94.1) 803 (93.0)
Year 1 145 (66.8) 155 (71.8) 152 (70.7) 638 (74.1) 640 (74.2)
Year 2 135 (62.2) 144 (66.7) 142 (66.0) 610 (70.8) 619 (71.7)
Year 3 134 (61.8) 131 (60.6) 134 (62.3) 571 (66.3) 584 (67.7)
Year 4 151 (69.6) 153 (70.8) 156 (72.6) 650 (75.5) 655 (75.9)
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Clinical outcomes
Table 12 summarises the clinical outcomes mean per stratum and per randomised group. On average,
participants had 34% of sites bleeding and 37% of surfaces with calculus across the randomised groups
in both the eligible and the ineligible stratum. The average number of teeth was around 24. Moderate
lesions were the most serious carious lesion found in about 65% of the participants. The ineligible stratum
had a slightly higher percentage of participants with extensive caries (14%) than the eligible stratum (18%).
Around 15–23% of participants had root caries. Around half of the participants presented generalised
gingivitis according to the 2017 World Workshop on the Classification of Periodontal and Peri-implant
Diseases.119 In Appendix 1, Table 48 presents the same clinical outcomes combining risk-based and 6-monthly
groups from the eligible and ineligible strata.
Statistical analyses
Primary clinical outcome (gingival bleeding)
The treatment effects for the primary clinical outcome and secondary outcomes can be found in Table 13.
Three treatment comparisons are presented for the eligible for 24-month recall stratum: 24-month recall
versus 6-month recall; risk-based recall versus 6-month recall and 24-month recall versus risk-based recall.
TABLE 11 Participant characteristics at year 4 by randomised group
Participant characteristic
Eligible for 24-month recall Ineligible for 24-month recall
Risk based 24 month 6 month Risk based 6 month
Number randomised 217 215 216 861 863
Replied to year 4 questionnaire 151 (100.0) 153 (100.0) 156 (100.0) 650 (100.0) 655 (100.0)
Smoked in the last 12 months 18 (11.9) 18 (11.8) 19 (12.2) 86 (13.2) 74 (11.3)
Missing 1 (0.7) 0 (0.0) 1 (0.6) 6 (0.9) 5 (0.8)
Time since previous visit to dentist
< 1 year 130 (86.1) 116 (75.8) 143 (91.7) 604 (92.9) 621 (94.8)
1–2 years 19 (12.6) 32 (20.9) 8 (5.1) 33 (5.1) 28 (4.3)
> 2 years 2 (1.3) 4 (2.6) 3 (1.9) 5 (0.8) 2 (0.3)
Missing 0 (0) 1 (0.7) 2 (1.3) 8 (1.2) 4 (0.6)
Patient status
NHS 104 (68.9) 94 (61.4) 105 (67.3) 460 (70.8) 469 (71.6)
Private 8 (5.3) 5 (3.3) 3 (1.9) 17 (2.6) 22 (3.4)
Combination 16 (10.6) 16 (10.5) 23 (14.7) 92 (14.2) 92 (14.0)
Missing 23 (15.2) 38 (24.8) 25 (16.0) 81 (12.5) 72 (11.0)
Type of toothbrush
Manual 72 (47.7) 86 (56.2) 82 (52.6) 328 (50.5) 339 (51.8)
Electric 73 (48.3) 54 (35.3) 69 (44.2) 275 (42.3) 274 (41.8)
Both 6 (4.0) 13 (8.5) 4 (2.6) 42 (6.5) 36 (5.5)
Missing 0 (0.0) 0 (0.0) 1 (0.6) 5 (0.8) 6 (0.9)
Regular attender: self-report 128 (84.8) 127 (83.0) 142 (91.0) 612 (94.2) 614 (93.7)
Missing 0 (0.0) 1 (0.7) 1 (0.6) 7 (1.1) 5 (0.8)
Difficulty travelling to dentist,
mean (SD), n
6.2 (1.4), 151 6.4 (1.1), 151 6.3 (1.2), 154 6.3 (1.3), 644 6.3 (1.3), 646
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TABLE 12 Clinical measures at 4 years by eligibility stratum and randomised group
Clinical outcomes
Eligible for 24-month recall Ineligible for 24-month recall
Risk based 24 month 6 month Risk based 6 month
Attended clinical follow-up, n 143 138 135 606 602
Primary clinical outcome, mean (SD), n
Gingival bleeding: mean
percentage of sites bleeding
35.6 (19.1), 142 34.4 (20.1), 137 35.6 (21.7), 134 33.4 (22.2), 599 32.8 (22.1), 597
Secondary clinical outcomes, mean (SD), n
Calculus: mean proportion of
surfaces with calculus
34.1 (26.0), 142 38.2 (28.3), 138 37.4 (24.9), 133 37.3 (27.8), 604 38.0 (27.8), 600
Mean pocket depth (mm) 2.2 (0.5), 142 2.1 (0.3), 137 2.1 (0.4), 133 2.2 (0.4), 594 2.2 (0.4), 594
Number of teeth 24.2 (4.8), 143 24.0 (4.5), 138 24.8 (4.0), 135 23.9 (4.6), 606 23.3 (5.2), 602
Most advanced carious lesion per person, n (%)
Sound surfaces (ICDAS 0) 1 (0.7) 1 (0.7) 0 (0.0) 3 (0.5) 8 (1.3)
Initial lesions (ICDAS 1–2) 22 (15.4) 28 (20.3) 33 (24.4) 100 (16.5) 107 (17.8)
Moderate lesions (ICDAS 3–4) 98 (68.5) 87 (63.0) 87 (64.4) 393 (64.9) 376 (2.5)
Extensive caries or treatment
needed (ICDAS 5–6)
20 (14.0) 22 (15.9) 13 (9.6) 110 (18.2) 107 (17.8)
Missing 2 (1.4) 0 (0.0) 2 (1.5) 0 (0.0) 4 (0.7)
Mean number of surfaces with caries, mean (SD), n
Any caries 15.5 (9.8), 143 14.1 (7.9), 138 14.7 (8.4), 135 14.7 (8.9), 606 14.7 (9.2), 602
Initial lesions 12.4 (8.8), 143 11.7 (7.4), 138 12.4 (7.5), 135 11.2 (7.5), 606 11.3 (7.8), 602
Moderate lesions 2.8 (2.5), 143 2.1 (1.9), 138 2.2 (2.2), 135 3.1 (3.1), 606 3.0 (3.0), 602
Extensive caries or treatment
needed
0.30 (0.9), 143 0.28 (0.85), 138 0.16 (0.60), 135 0.43 (1.5), 606 0.36 (1.3), 602
Root caries, n (%)
Yes 26 (18.2) 21 (15.2) 17 (12.6) 121 (20.0) 137 (22.8)
No 99 (69.2) 101 (73.2) 99 (73.3) 417 (68.8) 390 (64.8)
Missing 18 (12.6) 16 (11.6) 19 (14.1) 68 (11.2) 75 (12.5)
Gingivitis severity,a n (%)
No gingivitis (< 10% sites
bleeding)
10 (7.0) 14 (10.1) 18 (13.3) 100 (16.5) 96 (15.9)
Localised gingivitis (10–30% sites
bleeding)
58 (40.9) 50 (36.5) 42 (31.3) 183 (30.2) 201 (33.4)
Generalised gingivitis (more than
30% sites bleeding)
74 (52.1) 73 (53.3) 74 (55.2) 316 (52.1) 300 (49.8)
Missing 1 (0.7) 1 (0.7) 1 (0.7) 7 (1.2) 5 (0.8)
a Gingivitis severity classified using the 2017 World Workshop on the Classification of Periodontal and
Peri-implant Diseases and Conditions.119
Values are mean (SD), n, unless indicated otherwise.
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For the primary outcome, the adjusted difference between interventions was < 1% and the CIs excluded
the possibility of a 7.5% difference between groups. There was no evidence of a significant difference
between the groups in any comparison: the 24-month group versus 6-month group had an adjusted
mean difference of –0.91 (95% CI –5.02 to 3.20; p-value = 0.66); the risk-based versus 6-month recall
had an adjusted difference of –0.98 (95% CI –5.05 to 3.09; p-value = 0.64); and the 24-month versus
risk-based recall had an adjusted mean difference of 0.07 (95% CI –3.99 to 4.12; p-value = 0.97).
For the overall sample (combining eligible and ineligible strata), one comparison is presented for each
outcome: risk-based recall versus 6-month recall. The adjusted mean difference between the groups
was 0.78 (95% CI –1.17 to 2.72; p-value = 0.43).
TABLE 13 Treatment effects for clinical outcomes
Outcome Comparison Effect size (95% CI); p-value
Eligible for 24-month recall stratum
Primary clinical outcome
Gingival bleeding: mean percentage of sites bleeding 24 month vs. 6 month –0.91 (–5.02 to 3.20); 0.66
Risk based vs. 6 month –0.98 (–5.05 to 3.09); 0.64
24 month vs. risk based 0.07 (–3.99 to 4.12); 0.97
Secondary clinical outcomes
Calculus: mean proportion of surfaces with calculus 24 month vs. 6 month 0.19 (–5.46 to 5.83); 0.95
Risk based vs. 6 month –2.92 (–8.52 to 2.67); 0.31
24 month vs. risk based 3.11 (–2.45 to 8.67); 0.27
Mean pocket depth (mm) 24 month vs. 6 month –0.03 (–0.12 to 0.06); 0.51
Risk based vs. 6 month 0.07 (–0.02 to 0.15); 0.14
24 month vs. risk based –0.10 (–0.18 to –0.01); 0.03
Most serious level of caries found per person Risk based vs. 6 month 1.58 (0.96 to 2.62); 0.07
24 month vs. 6 month 1.38 (0.83 to 2.29); 0.22
24 month vs. risk based 0.87 (0.53 to 1.44); 0.59
Root caries 24 month vs. risk based 0.86 (0.40 to 1.83); 0.70
Risk based vs. 6 month 1.69 (0.75 to 3.78); 0.20
24 month vs. 6 month 1.45 (0.64 to 3.32); 0.37
Overall sample (eligible and ineligible for 24-month recall stratum)
Primary clinical outcome
Gingival bleeding: mean percentage of sites bleeding Risk based vs. 6 month 0.78 (–1.17 to 2.72); 0.43
Secondary clinical outcomes
Calculus: mean proportion of surfaces with calculus Risk based vs. 6 month –1.30 (–3.68 to 1.08); 0.29
Mean pocket depth (mm) Risk based vs. 6 month 0.03 (–0.01 to 0.07); 0.14
Most serious level of caries found per person Risk based vs. 6 month 1.18 (0.96 to 1.46); 0.12
Root caries Risk based vs. 6 month 0.86 (0.64 to 1.14); 0.29
Notes
Effect size represents mean difference for continuous outcomes and odds ratio for categorical or binary outcomes
(most serious level of caries found per person; root caries). The odds ratio interpretation is for a one unit increase in
the outcome (e.g. most serious level of caries), the odds for cases in a group that is > x vs. ≤ x are the proportional
odds times larger. For example, when comparing risk-based recall with 6-month recall for the overall sample (both
strata), the proportional odds ratio is 1.18. That means that the odds of having extensive caries vs. having the
combined initial and medium lesions are 1.18 times higher in the risk-based group than in the 6-month recall group.
The models are adjusted for protocol minimisation variables and have a random effect for centre.
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Sensitivity analysis
We used multiple imputation for the primary clinical outcome (gingival bleeding). The treatment effects
for the eligible for 24-month recall stratum were as follows: 6-month recall versus risk-based recall
–0.05 (95% CI –4.9 to 4.8, p = 0.98); 24-month recall versus risk-based recall –1.34 (95% CI –5.8 to 3.1,
p = 0.55); 24-month recall versus 6-month recall –1.3 (95% CI –6.5 to 3.9, p = 0.62). For the ineligible
for 24-month recall stratum, the treatment effects were as follows: 6-month recall versus risk-based
recall 0.57 (95% CI –1.5 to 2.6, p = 0.58). The sensitivity analyses did not change the interpretation
of the results.
Secondary clinical outcomes
The remaining treatment effects for secondary clinical outcomes are also presented in Table 13. There
was no evidence of a significant difference between the groups in any comparison in either eligibility
stratum. The clinical outcomes are presented by country in Appendix 1, Tables 49–51.
Patient-reported outcomes at 4 years
Table 14 shows the patient-reported outcomes at 4 years. Participants in the eligible for 24-month
recall group had lower OHIP-14 scores than ineligible participants, as observed at baseline. Participants
remained positive about dental services, with a high level of satisfaction on average (around 5 out of 7,
where 7 represents the maximum satisfaction with the service). Anxiety levels remained similar, and
on average around 10 out of 25 on the MDAS, ranging from 5 to 25 (maximum anxiety). Outcomes
measured only at 4 years included PBC, attitude, oral health behaviour and knowledge. The first two
ranged from 1 to 7 (where 7 means maximum PBC and most positive attitude); participants had, on
average, a score of 4.8 for PBC and 4.2 for attitude.
Patient-reported outcomes means and standard errors per year and per stratum are presented in
Figures 7–10. Overall, the scores remained unchanged during the trial and are similar across groups.
Patient-reported outcomes by year and stratum are presented in Appendix 1, Tables 54–56.
TABLE 14 Patient-reported outcomes at 4 years
Patient-reported outcome
Eligible for 24-month recall Ineligible for 24-month recall
Risk based 24 month 6 month Risk based 6 month
Primary patient-reported outcome, mean (SD), n
OHIP-14 (score 0–56) 4.1 (5.7), 145 4.8 (6.4), 153 4.8 (6.2), 152 5.5 (6.8), 624 5.8 (8.3), 630
Secondary patient-reported outcomes, mean (SD), n
Satisfaction (score 1–7) 5.2 (0.7), 151 5.0 (0.7), 153 5.1 (0.7), 155 5.3 (0.6), 647 5.2 (0.6), 654
Dental anxiety (score 5–25; MDAS) 10.5 (4.5), 150 10.9 (4.7), 153 11.0 (4.8), 155 10.3 (4.5), 645 10.5 (4.7), 649
Perceived behaviour control
(score 1–7)
4.8 (1.4), 149 4.6 (1.4), 153 4.5 (1.5), 155 4.7 (1.5), 647 4.7 (1.4), 654
Attitude (score 1–7) 4.3 (0.9), 151 4.3 (0.9), 153 4.1 (0.8), 155 4.1 (0.9), 647 4.1 (0.8), 654
Behaviour (score 1–9) 5.2 (1.8), 151 4.9 (1.7), 153 5.3 (1.6), 155 5.5 (1.7), 648 5.4 (1.7), 654
Knowledge (score 1–9) 6.5 (1.5), 150 6.6 (1.3), 153 6.8 (1.2), 155 6.6 (1.4), 648 6.7 (1.4), 651
Self-reported bleeding (score 1–5) 2.0 (1.0), 148 2.0 (0.9), 151 2.2 (1.0), 154 2.1 (1.0), 590 2.1 (1.0), 603
EQ-5D-3L utility (score –0.594 to 1) 0.893 (0.208),
145
0.884 (0.209),
151
0.856 (0.268),
157
0.866 (0.230),
637
0.867 (0.237),
645
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FIGURE 7 Primary participant reported outcome: OHRQoL (OHIP-14; mean and standard error) by randomised allocation and risk stratum. (a) Eligible for 24-month recall; and
(b) ineligible for 24-month recall.
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FIGURE 8 Anxiety (mean and standard error) by randomised allocation and risk stratum. (a) Eligible for 24-month recall; and (b) ineligible for 24-month recall.
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FIGURE 9 Attitude scale (mean and standard error) by randomised allocation and risk stratum. (a) Eligible for 24-month recall; and (b) ineligible for 24-month recall.
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FIGURE 10 Satisfaction scale (mean and standard error) by randomised allocation and risk stratum. (a) Eligible for 24-month recall; and (b) ineligible for 24-month recall.
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Statistical analyses of patient-reported outcomes
Table 15 presents the treatment effects for the patient-reported outcomes. There was no evidence
of a difference across comparisons for oral health impacts (OHIP-14), the patient-reported primary
outcome, with adjusted treatment differences smaller than one-quarter of a SD. Overall, there were no
important differences between the groups across all the patient-reported outcomes and in the eligible
for 24-month recall stratum and overall samples (eligible and ineligible strata).
TABLE 15 Treatment effects for patient-reported outcomes
Outcome/status Comparator Effect size (95% CI); p-value
Eligible for 24-month recall stratum
Primary patient-reported outcome
OHIP-14 Risk based vs. 6 month –0.61 (–1.93 to 0.71); 0.37
24 month vs. 6 month –0.24 (–1.55 to 1.07); 0.72
24 month vs. risk based 0.37 (–0.95 to 1.69); 0.58
Secondary patient-reported outcomes
Anxiety Risk based vs. 6 month –0.31 (–1.22 to 0.61); 0.51
24 month vs. 6 month 0.02 (–0.90 to 0.93); 0.97
24 month vs. risk based 0.32 (–0.60 to 1.24); 0.49
Attitude Risk based vs. 6 month 0.15 (–0.03 to 0.32); 0.11
24 month vs. 6 month 0.17 (–0.01 to 0.35); 0.06
24 month vs. risk based 0.02 (–0.15 to 0.20); 0.79
Behaviour Risk based vs. 6 month 0.01 (–0.02 to 0.04); 0.53
24 month vs. 6 month 0.00 (–0.03 to 0.03); 0.89
24 month vs. risk based –0.01 (–0.04 to 0.02); 0.62
Knowledge Risk based vs. 6 month –0.03 (–0.06 to 0.01); 0.10
24 month vs. 6 month –0.01 (–0.05 to 0.02); 0.42
24 month vs. risk based 0.01 (–0.02 to 0.05); 0.41
PBC Risk based vs. 6 month 0.30 (–0.02 to 0.61); 0.06
24 month vs. 6 month 0.09 (–0.22 to 0.40); 0.59
24 month vs. risk based –0.21 (–0.52 to 0.10); 0.19
Satisfaction Risk based vs. 6 month 0.05 (–0.10 to 0.20); 0.51
24 month vs. 6 month –0.11 (–0.26 to 0.04); 0.16
24 month vs. risk based –0.16 (–0.31 to –0.01); 0.04
Self-reported bleeding Risk based vs. 6 month –0.16 (–0.37 to 0.06); 0.15
24 month vs. 6 month –0.22 (–0.43 to –0.01); 0.04
24 month vs. risk based –0.06 (–0.28 to 0.15); 0.57
EQ-5D-3L Risk based vs. 6 month 0.032 (–0.013 to 0.076); 0.165
24 month vs. 6 month 0.024 (–0.021 to 0.069); 0.290
24 month vs. risk based –0.008 (–0.053 to 0.037); 0.741
continued
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Subgroup analyses
Bleeding on probing outcome
Figures 11 and 12 show the means and 99% CIs for the differences in bleeding at 4 years in the subgroups
for recall frequency and strata, respectively. There was no evidence of treatment heterogeneity by
age category or by payment for treatment at the 1% level (see Appendix 1, Table 52). There was also
no evidence of treatment heterogeneity for country in the overall sample (eligible for 24-month recall
stratum and ineligible for 24-month recall stratum); however, in the eligible for a 24-month recall stratum,
participants in England who were randomised to a 6-month recall showed a significant improvement
compared with those randomised to a risk-based recall (mean difference 4.98, 95% CI 1.14 to 8.83;
p < 0.001).
Caries outcome (post hoc subgroup analyses)
Figures 13 and 14 show the odds ratios and 99% CIs for caries at 4 years, comparing by recall frequency
and by stratum. For this purpose, caries were grouped into two categories: sound surfaces/initial lesions
(n = 303) versus moderate or serious lesions (n= 1313). There was no evidence of treatment heterogeneity
by age category, country or payment for treatment at the 1% level; in the overall sample in England,
patients randomised to 6-month recall were less likely to have serious carious lesions than those
randomised to risk-based recall (odds ratio 1.66, 95% CI 0.98 to 2.81; p = 0.01). Interaction coefficients
are shown in Appendix 1, Table 53.
Service providers’ measures
Baseline
Table 16 provides dentists’ and practices’ characteristics at baseline, for dentists who replied to
both the baseline questionnaire and the follow-up questionnaire (out of the 68 responders, 49 replied
to both questionnaires, 16 to the baseline questionnaire only and three to the follow-up questionnaire
only). Most practices had one dentist responding. About 55% of the respondents were male, had a
TABLE 15 Treatment effects for patient-reported outcomes (continued )
Outcome/status Comparator Effect size (95% CI); p-value
Overall sample (eligible and ineligible for 24-month recall)
Primary patient-reported outcome
OHIP-14 Risk based vs. 6 month –0.35 (–1.02 to 0.32); 0.30
Secondary patient-reported outcomes
Anxiety Risk based vs. 6 month –0.11 (–0.52 to 0.29); 0.59
Attitude Risk based vs. 6 month 0.04 (–0.04 to 0.11); 0.38
Behaviour Risk based vs. 6 month 0.00 (–0.01 to 0.02); 0.52
Knowledge Risk based vs. 6 month –0.01 (–0.03 to 0.00); 0.15
PBC Risk based vs. 6 month 0.06 (–0.08 to 0.20); 0.38
Satisfaction Risk based vs. 6 month 0.03 (–0.03 to 0.09); 0.31
Self-reported bleeding Risk based vs. 6 month –0.02 (–0.12 to 0.08); 0.72
EQ-5D-3L Risk based vs. 6 month 0.008 (–0.012 to 0.029); 0.432
Notes
Effect size represents mean difference. The models are adjusted for protocol minimisation variables and have a random
effect for centre. For all variables except behaviour, knowledge, PBC and self-reported bleeding, the mixed-effects
model also has a random effect for participant and an interaction time*treatment effect. The effect size presented
corresponds to the treatment effect at 4 years.
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Overall
Age
< 45 years
45–64 years
≥ 65 years
Country
Scotland
England
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Pays for treatment
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No
Favours 24-month recall
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347
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No effect
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FIGURE 11 Subgroup results for recall allocation in the eligible for 24-month recall stratum for bleeding on probing: difference between arms by subgroup.
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Mean difference
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No effect
Overall effect
Age
Favours RB recall Favours 6-month recall
< 45 years
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n p-value
0.65
0.04
< 0.001
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FIGURE 12 Subgroup results for recall allocation in the overall sample (eligible and ineligible strata) for bleeding on probing: difference between arms by subgroup. RB, risk-based.
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Overall
Odds ratio
99% CI
No effect
Overall effect
No
Yes
Pays for treatment
Northern Ireland
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Country
Age
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45–64 years
≥ 65 years
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FIGURE 13 Subgroup results for recall allocation in the eligible for 24-month recall stratum for caries: odds ratio by subgroup (CIs with cap have been truncated to fit the plot).
RB, risk based.
Overall
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650
1506 0.32
Scotland
England
Northern Ireland
Odds ratio
99% CI
No effect
Overall effect
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
0.04
0.01
0.69
0.63
p-valuen
870
975
311
1071
962
123
< 45 years
45–64 years
≥ 65 years
FIGURE 14 Subgroup results for recall allocation in the overall sample (eligible and ineligible strata) for caries: odds ratio by subgroup. RB, risk based.
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6
median of 16 years being qualified as a dentist and 69% were principal dentists or practice owners.
The median practice list size was 5000 with considerable variability. Most of the dentists considered
their practices to be non-rural (86%). There was a median of three other dentists working in the
practice and five nurses. Most of the practices had a mixture of NHS and private patients (65%).
Follow-up
Table 17 presents dentists’ beliefs at baseline and at follow-up, and their change from baseline.
Dentists’ attitudes regarding a 24-month recall improved, as did their attitude regarding a 6-month
recall. Overall, their general attitude about the patients’ ability to assess risk and perceived ability to
assess risk decreased from baseline. However, dentists who deemed at least one patient eligible for
the 24-month recall (n = 40) increased slightly in their perceived ability to judge risk, whereas those
who did not consider any patient eligible for a 24-month recall (n = 6) decreased their perceived ability.
Appendix 1, Table 57, presents more details about dentists’ beliefs by whether or not the dentist
deemed at least one of their patients eligible for a 24-month recall.
TABLE 16 Dentists’/practices’ characteristics at baseline
Characteristic
Median (percentile 25 –
percentile 75), count or n (%)
Number of dentist respondents 49
Gender
Male 27 (55.1)
Female 21 (42.9)
Missing 1 (2.0)
How long have you been qualified as a dentist? 16.0 (10.0–23.0), 49
Within this practice are you
Principal/practice owner 34 (69.4)
Associate 10 (20.4)
Other 5 (10.2)
What is your approximate total practice list size? 5000.0 (2400.0–8000.0), 41
Do you consider your practice to be rural/remote?
Yes 5 (10.2)
No 42 (85.7)
Missing 2 (4.1)
How many other members of the dental team in the practice are dentists? 3.0 (2.0–4.0), 46
How many other members of the dental team in the practice are nurses? 5.0 (3.0–6.0), 46
How many other members of the dental team in the practice are hygienists? 1.0 (0.0–1.0), 25
Is your practice
NHS patients only 16 (32.7)
Mixture of NHS and private 32 (65.3)
Missing 1 (2.0)
Before this study, how did you usually set your patient recall appointments?
Routinely, every 6 months 29 (59.2)
Other 15 (30.6)
Missing 5 (10.2)
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TABLE 17 Dentists’ beliefs at baseline and follow-up and change from baseline
Dentists’ beliefs
Baseline, mean
(SD), n
Follow-up, mean
(SD), n
Change from baseline
(follow-up–baseline),
mean (SD), n
Attitude regarding a 24-month recall 3.8 (1.2), 46 4.4 (1.2), 48 0.6 (1.1), 45
Attitude regarding a 6-month recall 3.7 (1.0), 46 4.0 (1.2), 48 0.2 (0.9), 45
General attitude to the patient‘s ability to
maintain self-care
4.6 (1.1), 46 4.0 (1.1), 48 –0.6 (1.4), 45
Perceived ability to assess risk 4.1 (0.9), 46 4.1 (1.1), 48 –0.1 (1.2), 45
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Chapter 5 Health economics results
Introduction
This chapter reports the results of the within-trial health economic analysis (4-year follow-up).
Descriptive statistics for resource use, costs and outcomes (QALYs, WTP) are presented separately
by randomised stratum as follows: [eligible for 24-month recall (24 month; risk based; 6 month)
and ineligible for 24-month recall (risk based; 6 month)] using complete-case data. The chapter then
reports the findings of the online general population DCE. The economic evaluation results, combining
incremental costs and benefits, are then reported under the three different evaluation frameworks
(see Chapter 3) based on multiple imputation of missing data. A range of alternative scenario analyses
are provided to investigate the impact of different costing perspectives and methodological issues on
the results.
Resource use and costs
Resource use and costs are reported for NHS dental care, NHS other care and participants. This
section details descriptive statistics from complete-case data. The reader is referred to Appendix 2,
Table 59, for descriptive statistics based on multiple imputation of missing data.
Costs of NHS dental services
NHS dental care costs are based on routinely collected dental claims in the four different UK regions.
Data were successfully linked for n = 1121/1188 (94%), n = 932/1031 (90%), n = 143/153 (93%) and
collected from practice notes for 13/13 (100%) participants in Scotland, England, Northern Ireland and
Wales, respectively. Given the high linkage rate, missing dental claims data were not considered to
have an important impact on cost. Overall, n = 552/2209 (25%) participants with dental claims data
were exempt from payment of dental charges for the majority of treatment claims. The proportion of
participants exempt from charges was evenly balanced across the randomised groups. For the ineligible
for 24-month recall stratum, 186/861 (22%) and 161/863 (19%) were exempt in the risk-based and
6-month recall groups, respectively. For the stratum where participants were eligible for 24-month
recall, 74/217 (34%), 57/215 (27%) and 74/216 (34%) were exempt from charges in the risk-based,
6-month and 24-month recall groups, respectively. There are no statistically significant differences in
the proportions exempt across groups, providing reassurance that any treatment effects on NHS costs
are not biased by eligibility for fully funded NHS care. Table 18 reports details of treatment claims and
costs to the dental budgets of the respective regions.
Resource use data are reported separately for check-ups, fillings and extractions (for the UK as a
whole and at a regional level). Participants ineligible for 24-month recall incurred greater resource use
than the eligible stratum. The average number of check-ups for respondents in the risk-based group
was closer to the 6-month group in the ineligible stratum, but approximately mid-way between the
6-month and 24-month group in the eligible stratum. This indicates the likelihood of greater need for
more frequent checks in the risk-based group in the ineligible stratum. A similar pattern of greater
treatment consumption in the ineligible than the eligible stratum is also observed for other treatments
such as fillings and extractions, and appears consistent across the regions.
Other NHS resource use and costs (descriptive data)
Table 18 also indicates the resource use and costs associated with care for dental health problems
provided by services other than dental practices (e.g. GP consultations, inpatient admissions,
outpatient consultations and accident and emergency admissions). Emergency dental consultations
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TABLE 18 NHS-provided dental care
Category
Ineligible Eligible
Risk based 6 month Risk based 6 month 24 month
Resource use Cost Resource use Cost Resource use Cost Resource use Cost Resource use Cost
Mean SD n Mean SD n Mean SD n Mean SD n Mean SD n Mean SD n Mean SD n Mean SD n Mean SD n Mean SD n
UK-wide data: total NHS dental costs
Check-ups 4.53 2.48 800 – – – 4.84 2.23 804 – – – 3.44 2.14 201 – – – 4.32 3.42 201 – – – 2.38 2.19 203 – – –
Fillings 1.63 1.95 800 – – – 1.48 1.90 804 – – – 1.21 1.93 201 – – – 1.29 1.71 201 – – – 1.14 1.69 203 – – –
Extractions 0.22 0.54 800 – – – 0.20 0.54 804 – – – 0.07 0.26 201 – – – 0.21 0.70 201 – – – 0.17 0.47 203 – – –
Dental budget
costs
– – – £130 £188 800 – – – £113 £149 804 – – – £97 £174 201 – – – £96 £214 201 – – – £80 £146 203
UK-wide data: other NHS resource use
GP consultations 0.76 1.76 371 £29 £66 371 0.80 1.58 393 £30 £60 393 0.94 1.51 69 £36 £57 69 0.73 1.36 80 £27 £51 80 0.81 1.99 77 £30 £75 77
Inpatient
admissions
1.61 12.51 432 £7 £67 425 1.10 10.33 455 £9 £78 450 0.01 0.11 85 £8 £74 85 1.04 10.05 97 £14 £97 96 2.98 16.97 100 £7 £71 97
Outpatient
consultations
0.03 0.29 374 £5 £42 374 0.08 0.52 400 £12 £77 400 0.01 0.12 69 £2 £18 69 0.05 0.22 82 £7 £30 82 0.03 0.16 78 £3 £22 78
Accident and
emergency
attendances
0.01 0.10 376 £1 £13 376 0.01 0.07 399 £1 £10 399 0.00 0.00 68 £0 £0 68 0.01 0.11 82 £1 £13 82 0.00 0.00 78 £0 £0 78
Total (other NHS
resource use)
£34 £96 331 £46 £116 355 £49 £106 55 £50 £112 69 £24 £49 66
Total NHS costs
(dental+ other)
£136 £164 323 £147 £209 347 £114 £130 54 £131 £169 69 £90 £143 66
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0
Category
Ineligible Eligible
Risk based 6 month Risk based 6 month 24 month
Resource use Cost Resource use Cost Resource use Cost Resource use Cost Resource use Cost
Mean SD n Mean SD n Mean SD n Mean SD n Mean SD n Mean SD n Mean SD n Mean SD n Mean SD n Mean SD n
NHS dental costs: Scotland
Diagnosis 4.75 2.31 393 £34 £16 393 5.22 2.16 400 £38 £14 400 3.79 2.38 107 £27 £17 107 4.87 2.19 111 £36 £15 111 3.10 2.84 110 £21 £20 110
Check-ups
(1A 1B 1C)
3.59 1.69 393 – – – 4.09 1.59 400 – – – 2.82 1.78 107 – – – 3.88 1.62 111 – – – 2.10 2.05 110 – – –
Periodontal 3.06 2.56 393 £15 £26 393 3.10 2.52 400 £14 £20 400 2.47 2.85 107 £15 £26 107 2.80 2.38 111 £14 £24 111 1.64 2.11 110 £10 £22 110
Conservative 2.08 2.57 393 £20 £44 393 2.20 2.98 400 £20 £59 400 1.71 2.66 107 £28 £69 107 1.86 2.25 111 £22 £67 111 1.64 2.72 110 £21 £71 110
Fillings (14A,
14C1, 14C2)
1.47 1.92 393 – – – 1.58 2.18 400 – – – 1.25 2.15 107 – – – 1.35 1.64 111 – – – 1.20 1.77 110 – – –
Surgical 0.45 1.09 393 £2 £7 393 0.39 1.03 400 £1 £4 400 0.16 0.53 107 £0 £2 107 0.32 0.87 111 £1 £7 111 0.45 1.07 110 £2 £6 110
Extractions
(21/22)
0.22 0.52 393 – – – 0.19 0.49 400 – – – 0.07 0.26 107 – – – 0.14 0.40 111 – – – 0.22 0.51 110 – – –
Prosthesis 0.25 0.79 393 £7 £29 393 0.26 0.85 400 £5 £24 400 0.34 1.25 107 £8 £40 107 0.11 0.51 111 £3 £22 111 0.13 0.47 110 £4 £20 110
Orthodontic 0.00 0.00 393 £0 £0 393 0.00 0.05 400 £0 £1 400 0.00 0.00 107 £0 £0 107 0.00 0.00 111 £0 £0 111 0.00 0.00 110 £0 £0 110
Other 1.09 2.52 393 £1 £5 393 0.81 1.69 400 £1 £4 400 1.65 4.15 107 £2 £7 107 1.07 2.37 111 £1 £4 111 1.06 2.42 110 £2 £6 110
Total Scotland £79 £85 393 £79 £79 400 £80 £130 107 £77 £98 111 £59 £114 110
NHS dental costs: Northern Ireland
Diagnosis 6.33 2.60 30 £17 £19 30 7.33 2.63 30 £19 £14 30 4.54 2.94 28 £13 £15 28 4.96 3.00 26 £16 £19 26 3.79 2.78 29 £16 £17 29
Check-ups
(101/111)
5.07 1.80 30 – – – 5.83 2.00 30 – – – 3.46 2.15 28 – – – 3.92 2.62 26 – – – 2.93 2.03 29 – – –
Periodontal 3.33 2.54 30 £15 £20 30 4.80 2.30 30 £23 £19 30 2.21 2.23 28 £12 £20 28 2.23 2.07 26 £14 £20 26 2.34 2.04 29 £20 £25 29
Conservative 3.10 3.57 30 £53 £129 30 2.93 4.31 30 £43 £85 30 2.29 3.02 28 £32 £61 28 2.42 2.93 26 £28 £46 26 2.48 3.18 29 £35 £70 29
Fillings
(1401–04;
1421; 1426)
2.20 2.31 30 – – – 1.57 2.11 30 – – – 1.57 1.83 28 – – – 1.69 1.95 26 – – – 1.76 2.01 29 – – –
continued
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TABLE 18 NHS-provided dental care (continued )
Category
Ineligible Eligible
Risk based 6 month Risk based 6 month 24 month
Resource use Cost Resource use Cost Resource use Cost Resource use Cost Resource use Cost
Mean SD n Mean SD n Mean SD n Mean SD n Mean SD n Mean SD n Mean SD n Mean SD n Mean SD n Mean SD n
Surgical 0.53 1.17 30 £5 £23 30 0.40 0.77 30 £2 £5 30 0.14 0.45 28 £1 £3 28 0.35 0.75 26 £3 £11 26 0.10 0.41 29 £2 £9 29
Extractions
(2101)
0.20 0.48 30 – – – 0.13 0.35 30 – – – 0.04 0.19 28 – – – 0.15 0.37 26 – – – 0.03 0.19 29 – – –
Prosthesis 0.20 0.76 30 £5 £16 30 0.17 0.53 30 £4 £14 30 0.00 0.00 28 £0 £0 28 0.00 0.00 26 £0 £0 26 0.41 1.38 29 £10 £30 29
Orthodontic 0.00 0.00 30 £0 £0 30 0.00 0.00 30 £0 £0 30 0.00 0.00 28 £0 £0 28 0.00 0.00 26 £0 £0 26 0.00 0.00 29 £0 £0 29
Other 0.20 0.48 30 £1 £3 30 0.83 1.09 30 £2 £4 30 0.32 0.98 28 £1 £2 28 0.27 0.60 26 £1 £2 26 0.21 0.49 29 £1 £2 29
Total Northern
Ireland
– – – £96 £186 30 – – – £94 £117 30 – – – £58 £83 28 – – – £62 £88 26 – – – £85 £120 29
NHS dental costs: England/Wales
Band 1 3.37 2.39 377 £29 £28 377 3.87 2.57 374 £30 £33 374 3.17 1.98 66 £25 £24 66 3.86 3.01 64 £30 £38 64 1.56 1.45 64 £14 £20 64
Check-up 5.46 2.83 377 – – – 5.56 2.54 374 – – – 4.44 2.32 66 – – – 5.23 5.34 64 – – – 2.61 2.45 64 – – –
Band 2 1.95 2.04 377 £76 £106 377 1.52 1.58 374 £52 £75 374 1.20 1.60 66 £55 £98 66 1.30 2.29 64 £54 £146 64 1.05 1.88 64 £56 £132 64
Fillings 1.75 1.94 377 – – – 1.37 1.53 374 – – – 1.00 1.56 66 – – – 1.02 1.72 64 – – – 0.75 1.27 64 – – –
Extractions 0.23 0.58 377 – – – 0.23 0.59 374 – – – 0.09 0.29 66 – – – 0.34 1.10 64 – – – 0.14 0.47 64 – – –
Band 3 0.40 0.78 377 £68 £172 377 0.37 0.76 374 £56 £143 374 0.26 0.69 66 £49 £173 66 0.22 0.55 64 £45 £143 64 0.17 0.42 64 £32 £88 64
Band: urgent 0.46 0.92 377 £13 £26 377 0.40 0.82 374 £11 £23 374 0.36 0.74 66 £10 £21 66 0.42 1.97 64 £12 £56 64 0.41 1.05 64 £12 £30 64
Band: free 0.02 0.32 377 £1 £9 377 0.03 0.22 374 £1 £6 374 0.00 0.00 66 £0 £0 66 0.02 0.13 64 £0 £4 64 0.00 0.00 64 £0 £0 64
Band: other 0.01 0.12 377 £0 £1 377 0.01 0.07 374 £0 £0 374 0.00 0.00 66 £0 £0 66 0.02 0.13 64 £0 £0 64 0.02 0.13 64 £0 £0 64
Total England
and Wales
– – – £187 £243 377 – – – £151 £194 374 – – – £140 £244 66 – – – £141 £350 64 – – – £114 £195 64
Black text indicates broad treatment categories. Light blue text indicates specific treatments within those categories. For example, the number of conservative treatments that were fillings.
Specific treatment codes from the respective statements of dental remuneration in Scotland and Northern Ireland are provided in brackets.
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(with community dental practices) are included in the dental budget and, therefore, will have been picked
up through the routine data linkage. There are no obvious differences in the use of non-dental NHS
services for dental problems across the randomised groups; however, it should be noted that complete
data regarding use of non-dental NHS services for dental problems are available for only 37% of
participants (n = 876/2372). A total of 385 (16%) randomised participants (between 15% and 20%
across the groups) returned no questionnaires, and so have provided no resource use data regarding
the use of non-dental services for dental problems. Missing data for the costs associated with the use
of other (non-dental) NHS services appear to be evenly distributed across the randomised groups, and
additional logistical regression analyses do not indicate that the probability of missingness is significantly
predicted by any patient characteristics or dental health outcomes. An assumption of missing completely
at random is therefore plausible; however, given the high proportion of missing data, multiple imputation
is undertaken to complete the data set and improve the precision of the results.
Participant costs (descriptive statistics)
Table 19 reports participant cost data, specifically payment of dental co-charges, consumer out-of-
pocket expenditure on dental care (electric toothbrushes, heads and other private treatment) and the
opportunity cost of time and travel incurred while attending dental appointments.
It was possible to ascertain opportunity costs of time and travel, and co-charges for NHS dental care
for 90% (2128/2372) of participants following the assumptions detailed in Chapter 3. However, data
completion was poor for annual questionnaires asking about private care costs, and purchase of dental
products such as electric and manual toothbrushes. As a result, total complete-case participant costs
across all items and questionnaires were calculable for only 8% (182/2372) of the sample. Missing
participant cost data do not appear to be driven by randomised group or patient characteristics;
however, multiple imputation is still required to complete the data set, given the significant proportions
of missing data.
Benefits
Benefits are assessed in this study using a DCE with the general population to obtain WTP tariffs to map
to clinical trial outcomes (see Chapter 3) and services received and in terms of EQ-5D-3L-based QALYs.
Quality-adjusted life-years
Table 20 details descriptive statistics for the EQ-5D-3L and calculated QALYs from the trial. Across
all time points, full EQ-5D-3L profile response data were available for only 35% (836/2372) of the
randomised trial population. However, there were only 151 (6%) members of the trial population
missing all EQ-5D-3L time points (including baseline). Missing data were evenly distributed across the
randomised groups. Additional regression analysis found no evidence that missingness was determined
by any participant characteristics or dental health outcomes. QALY data were, therefore, assumed to
be missing at random.
Respondents were generally in good health, with greater than 3.5 undiscounted QALYs gained over
4-year time horizon across the randomised arms and strata.
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TABLE 19 Participant costs
Category
Ineligible Eligible
Risk based 6 month Risk based 6 month 24 month
Cost Cost Cost Cost Cost
Mean SD n Mean SD n Mean SD n Mean SD n Mean SD n
Costs directly associated with attendance for NHS dental care
Participant co-charges £108 £129 800 £115 £128 804 £71 £101 201 £77 £85 201 £51 £82 203
Scotland £84 £101 393 £89 £97 400 £57 £90 107 £65 £73 111 £51 £85 110
England/Wales £131 £151 377 £140 £148 374 £87 £103 66 £99 £98 64 £49 £73 64
Northern Ireland £117 £104 30 £138 £142 30 £86 £129 28 £77 £89 26 £60 £91 29
Opportunity cost of time and travel £98 £50 775 £99 £44 787 £76 £51 191 £88 £65 191 £59 £43 184
Scotland £92 £47 383 £95 £45 396 £71 £57 103 £84 £41 109 £60 £44 99
England/Wales £104 £52 362 £102 £42 362 £83 £41 63 £96 £100 59 £56 £42 57
Northern Ireland £107 £53 30 £122 £48 29 £79 £51 25 £81 £42 23 £61 £41 28
Total costs (co-charges plus opportunity costs)
of attending NHS dental care
£209 £159 775 £216 £154 787 £150 £128 191 £169 £125 191 £116 £111 184
Other participant-incurred costs
Private dental care £109 £842 388 £99 £828 403 £23 £77 71 £13 £54 79 £95 £745 81
Electric toothbrushes £39 £56 204 £41 £54 204 £38 £50 35 £40 £74 45 £24 £31 38
Brush heads £16 £11 217 £15 £11 228 £18 £10 39 £15 £11 44 £13 £11 44
Manual brushes £19 £10 283 £20 £10 297 £20 £10 47 £22 £10 56 £22 £10 64
Total (all participant costs) £430 £581 76 £420 £724 70 £278 £104 12 £232 £167 16 £188 £213 8
Total cost of attending NHS appointments £343 £261 775 £332 £224 787 £252 £237 191 £269 £291 191 £204 £212 184
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TABLE 20 EQ-5D-3L-based QALYs
Timepoint
Ineligible for 24-month recall Eligible for 24-month recall
Risk based 6 month Risk based 6 month 24 month
Mean SD n Mean SD n Mean SD n Mean SD n Mean SD n
Undiscounted QALYs
Baseline 0.898 0.208 602 0.903 0.196 590 0.931 0.135 134 0.891 0.235 140 0.927 0.172 140
1 year 0.882 0.207 613 0.889 0.204 620 0.902 0.187 140 0.872 0.224 148 0.920 0.174 149
2 years 0.874 0.217 597 0.881 0.226 603 0.887 0.225 133 0.887 0.201 143 0.891 0.195 142
3 years 0.878 0.217 561 0.872 0.226 574 0.889 0.235 129 0.863 0.264 137 0.907 0.174 124
4 years 0.866 0.230 637 0.867 0.237 645 0.893 0.208 145 0.856 0.268 157 0.884 0.209 151
QALY 3.523 0.715 310 3.491 0.801 319 3.507 0.761 65 3.483 0.906 71 3.522 0.781 71
Discounted QALYs
Baseline 0.898 0.208 602 0.903 0.196 590 0.931 0.135 134 0.891 0.235 140 0.927 0.172 140
1 year 0.882 0.207 613 0.889 0.204 620 0.902 0.187 140 0.872 0.224 148 0.920 0.174 149
2 years 0.845 0.210 597 0.851 0.219 603 0.857 0.217 133 0.857 0.195 143 0.861 0.189 142
3 years 0.820 0.202 561 0.814 0.211 574 0.830 0.220 129 0.806 0.246 137 0.847 0.162 124
4 years 0.781 0.207 637 0.782 0.213 645 0.805 0.188 145 0.772 0.242 157 0.797 0.188 151
QALY 3.392 0.688 310 3.363 0.769 319 3.378 0.728 65 3.355 0.871 71 3.392 0.751 71
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Discrete choice experiment results
Sample characteristics
The online DCE was completed by 597 respondents sampled from the general population. The median
survey completion time was 16.03 minutes (interquartile range 11.85–21.98 minutes; minimum
3.95 minutes, maximum 1640.10 minutes). Table 21 compares the sociodemographic characteristics
and dental health experiences of the sample with the same characteristics in the general population.
The sample was generally a good representation of the UK general population and satisfactorily
matched the sought quotas for the survey. There is, however, over-representation of respondents from
Scotland relative to the general population. These respondents were purposely oversampled to enable
subgroup analysis of preferences across the UK regions and, in particular, to detect any impact of free
check-ups in Scotland on preferences; therefore, it is less appropriate to compare the survey sample
against the general population on regional distribution. Respondents were generally more regular
attenders than the general population, and it is possible that the decision to participate in the survey
was driven by this in part. Despite multiple invitations to the survey panel seeking at least 10% of our
sample with their last attendance > 2 years ago, this was not achievable, and only 4% of the sample
had their last dental check-up more than 2 years prior to completing the DCE.
TABLE 21 Characteristics of the DCE sample
Characteristic General populationa
DCE sample,
n (%)b (N= 597)
Sociodemographic characteristics
Age (years), mean (SD)a,c ≈47 49.54 (16.60)
Sexa,c Male 49% 292 (49)
Female 51% 305 (51)
Country of residencec England 84% 392 (66)
Scotland 8% 183 (31)
Wales 5% 13 (2)
Northern Ireland 3% 9 (2)
Smoker statusd Yes 18% 128 (21)
No 59% 355 (59)
Previous 23% 114 (19)
Annual gross incomee Low 54% 248 (42)
Medium 37% 189 (32)
High 8% 92 (15)
Refused to answer N/A 62 (10)
Left blank N/A 6 (1)
Educational attainmentc SVQ (level 1/2) 29% 210 (35)
SVQ (level 3) 12% 83 (14)
Degree 27% 151 (15)
Professional 6% 64 (11)
Apprentice 4% 12 (2)
None 22% 77 (13)
Employmentc Employed 61% 328 (55)
Unemployed 4% 27 (5)
Retired 14% 143 (24)
Student 9% 13 (2)
Other 11% 86 (14)
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TABLE 21 Characteristics of the DCE sample (continued )
Characteristic General populationa
DCE sample,
n (%)b (N= 597)
Self-reported dental healthf Very poor 1% 11 (2)
Poor 6% 45 (8)
Fair 21% 201 (34)
Good 47% 260 (44)
Very good 24% 80 (13)
Self-reported general healthc Very poor 1% 11 (2)
Poor 4% 44 (7)
Fair 13% 175 (29)
Good 34% 268 (45)
Very good 47% 99 (17)
Dental health categoryg Good N/A 340 (57)
Moderate 221 (37)
Poor 36 (6)
Experiences of dental care
Registered with dental practice Yes NRh 576 (96)
No 17 (3)
Do not know 4 (1)
Usual method of payment for dental carei Co-charge/mix 45% 276 (46)
NHS 23% 110 (18)
Out of pocket 131 (22)
Treatment plan 62 (10)
Insurance 6 (1)
Any private treatment 27% 199 (33)
Never 2% 2 (0)
Other 3% 10 (2)
Time since last check-upi < 6 months 450 (75)
6–12 months 106 (18)
< 1 year 69% 556 (93)
1–2 years 10% 20 (3)
2–5 years 8% 8 (1)
> 5 years 12% 9 (2)
Never 1% 4 (1)
N/A, not applicable; NR, not reported; SVQ, Scottish Vocational Qualification.
a Data reported for a subset of the general population aged ≥ 16 years, n= 39,432,606 (Office for National Statistics120).
b Percentages are rounded to the nearest whole number so may not always add to 100%.
c Data source is 2011 census for England and Wales (Office for National Statistics120).
d Smoking status sourced from Office for National Statistics.121
e Income categories are low, < £20,800; medium, £20,800–41,600; and high, > £41,600. UK population data reflect
average income of a single person household, as survey asked about individual (not household) income. The source is
the UK family resources survey (UK DWP, 2017).122 To enable comparison with general population, item non-response
is excluded from the sample percentage calculations.
f Data sourced from the UK adult dental health survey (Steele and O’Sullivan114).
g Dental health categories reflect allocation to segments in the experimental design. See Chapter 3, Discrete choice
experiment experimental design, for further details. No equivalent general population data exist.
h No data available at a population level.
i Source of data is the UK adult dental health survey (Steele and O’Sullivan114).
The entries in italic relate to subtotals. For example, Any private treatment is the sum of entries for out of pocket,
treatment plan and insurance.
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Respondents are generally in good dental health, with only 6% of the sample assigned to the poorest
segment of dental health in the DCE design. The smaller sample in this segment means that the DCE
has less power to detect significant preferences for the worst levels of dental health outcomes
(bleeding very often and advanced decay).
Preferences for dental care
The results of the error components model describing preferences estimated from the effects coded DCE
and calculated WTP tariffs for mapping to the trial interventions and outcomes are reported in Table 22.
TABLE 22 The DCE model results and WTP
Attribute level
Preference coefficient WTP
Coefficient SD Coefficient 95% CI
ASC 1.484*** 1.675*** £252.67 £210.65 to £294.69
24-month recalla,b –0.423*** –£71.95b –£86.33 to –£57.57
Annual recallb –0.015 –£2.61b –£15.10 to £9.88
6-month recallb 0.348*** £59.32b £46.35 to £72.29
Risk-based recallb,c 0.089** £15.24c £2.91 to £27.57
Bleed nevera 0.208*** £35.37 £16.36 to £54.37
Bleed hardly ever 0.099** £16.82 £1.05 to £32.58
Bleed occasionally 0.089** £15.23 £1.55 to £28.91
Bleed fairly often –0.127** –£21.70 –£40.60 to –£2.79
Bleed very often –0.268*** –£45.71 –£79.85 to –£11.58
Decay nonea 0.565*** £96.21 £77.57 to £114.84
Decay early 0.058* £9.91 –£1.91 to £21.74
Decay moderate –0.241*** –£41.02 –£53.08 to –£28.95
Decay advanced –0.382*** –£65.11 –£83.70 to –£46.51
Annual cost –0.006***
Number of observations 14,328
Number of respondents 597
Log-likelihood (null) –4578
Log-likelihood (model) –3856
AIC 7739
BIC 7837
AIC/N 0.54
BIC/N 0.55
*p < 0.1, **p < 0.05, ***p < 0.01.
BIC, Bayesian information criterion; N in AIC/N and BIC/N refers to the number of observations.
a Indicates reference level. It should be noted that DCE results and WTP values are based on effects coded data, and
so all coefficients for any given attribute are relative to the grand mean for the attribute, hence the reason for
example that annual recall is not significant.
b Values presented for 2-yearly, annual and 6-month recall from the DCE are mapped to trial outcome count data
for two, four and eight check-ups (from routine data), respectively. Intervening values, not directly predicted by the
DCE are obtained by stepwise linear prediction up to 8 check-ups, and logarithmic extrapolation function beyond 8.
The resultant functions used to map WTP to trial outcomes are as follows [where y =WTP and x= number of
check-ups]: (a) if x≤ 4; y = 34.671x – 141.29; (b) if 5 > x≤ 8; y = 15.481x – 64.531; if x > 8; y = 94.689ln(x) – 136.35.
c As the analysis is primarily based on intention to treat and number of check-ups received (rather than randomised
allocation), it was not possible to map the WTP for risk-based recall directly to the trial outcomes. The information
is, however, still relevant as it provides an indication of the general population’s preference for this service as
described in the DCE.
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The ASC is both positive and statistically significant. This indicates that the general population prefers
any dental check-up package to none. The SD of the constant is also significant, suggesting that there
is significant preference heterogeneity among the sample for this parameter. This indicates that the
strength of preference for opting into a dental check-up package varies across the sample. Overall,
57% (339/597) of respondents always opted in, compared with only 6% (35/597) who always opted
out. Preferences for dental recall frequency, decay, bleeding on brushing, and cost are as expected.
Respondents prefer to have more frequent recalls, prefer to avoid dental decay, prefer no bleeding
gums and prefer cheaper dental care packages. The WTP estimates appear to have good face validity,
and findings are in line with those expected after completion of the preparatory qualitative work.
Additionally, the WTP tariffs obtained for bleeding gums closely match those obtained in a previously
conducted DCE for the IQuaD study,101 indicating a high level of benefit transferability.
The WTP tariffs can be interpreted as follows: the estimated tariffs are the general population’s WTP
for each attribute level (e.g. 6-month recall) controlling for variation in all other attributes included in
the DCE. In terms of understanding the impact of the WTP results for mapping to the trial outcomes,
the difference in WTP across levels within an attribute represent the general population’s value for
moving from one state of the world to another. Consider dental decay: the DCE results show that the
general population is willing to pay, on average, £161.32 per year, over a 4-year period, to avoid
moving from a state of no dental decay (WTP tariff: +£96.21) to a state of advanced dental decay
(WTP tariff: –£65.11).
Discrete choice experiment subgroup analyses
Subgroup analyses are conducted by using interaction effects to examine the impact of subgroup
membership (gender, region, smoking status, employment status, income, experienced check-up
frequency and experience of dental decay) on preferences. In general, subgroup membership influences
overall preference patterns (as indicated by significant likelihood ratio tests). Many of the interaction
effects are expected and serve to verify the face validity of the analysis results. For example, those
who are in employment and have higher incomes are less sensitive to changes in the cost attribute.
Those with experience of dental decay have stronger preferences to keep their teeth decay free and
avoid more advanced levels of decay. Those who regularly attend the dentist every 6 months are more
likely to prefer 6-month recalls, and are more likely to accept more expensive dental care packages.
Smoking status and region do not appear to have any meaningful impact on preferences for any of
the individual attribute levels; however, female participants in the sample placed less emphasis on
differences in dental decay than the sample as a whole. Full details of subgroup analysis results are
provided in Appendix 2, Table 58.
Total monetary measures of benefit (discrete choice experiment results mapped to
trial outcomes)
The WTP tariffs obtained from the DCE analysis are mapped to the corresponding services received in
the trial and observed trial outcomes, to enable a CBA to be completed. Total benefits (complete-case
data) across randomised arms and strata are reported in Table 23. The impact of plausible alternative
assumptions for mapping DCE results to trial outcomes (as described in Chapter 3) is highlighted in
light blue.
Including WTP for health benefit (caries experience + bleeding on brushing) only in the definition of
total benefits (see Table 23, WTP for health outcomes, analysis number 8) shows little evidence of
difference across groups in either stratum. This is based on attaching WTP to avoid caries to both
fillings received and untreated caries as measured at the final trial outcome assessment appointment.
Amending the definition of caries applied for the mapping of WTP to trial outcomes (i.e. including or
excluding fillings from the measurement of caries experience) impacts on mean WTP, but does not
substantially alter conclusions across the randomised arms in either stratum.
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TABLE 23 Total monetary benefits (WTP) combining DCE and trial interventions and outcomes
Number Description
Eligible Ineligible
Risk based 6 month 24 month Risk based 6 month
Mean SD n Mean SD n Mean SD n Mean SD n Mean SD n
WTP tariffs mapped to individual trial outcomes (including sensitivity analyses)a
1. Constant £948 £0 217 £948 £0 215 £948 £0 216 £948 £0 861 £948 £0 863
Recall
2. Recall ITT –£122 £198 201 –£56 £206 201 –£236 £211 203 –£30 £195 800 £1 £175 804
3. SA1 recall PPb £54 £0 217 £211 £0 215 –£256 £0 216 £54 £0 861 £211 £0 863
4. Bleeding on brushing £71 £57 147 £61 £55 154 £71 £47 151 £67 £54 589 £67 £58 601
Caries
5. Untreated caries + fillings assume moderatec,d –£140 £66 186 –£131 £65 178 –£138 £73 175 –£149 £56 767 –£144 £66 757
6. SA2 untreated caries onlye –£127 £87 141 –£110 £87 133 –£120 £95 138 –£130 £88 607 –£123 £99 599
7. SA3 untreated+ fillings assume extensived,f –£186 £82 186 –£186 £87 178 –£189 £89 175 –£203 £68 767 –£198 £79 757
WTP for health outcomes
8. (4 + 5) Health (bleeding on brushing + untreated
caries + fillings assume moderate)
–£71 £84 140 –£65 £86 142 –£68 £91 137 –£83 £81 561 –£78 £86 568
9. (4 + 6) Health (bleeding on brushing + untreated
caries only)
–£58 £100 126 –£45 £99 128 –£53 £106 126 –£62 £104 517 –£57 £108 517
10. (4 + 7) Health (bleeding on brushing + untreated
caries + fillings assume extensive)
–£109 £98 140 –£114 £103 142 –£113 £106 137 –£131 £90 561 –£127 £95 568
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Number Description
Eligible Ineligible
Risk based 6 month 24 month Risk based 6 month
Mean SD n Mean SD n Mean SD n Mean SD n Mean SD n
WTP overall
11. (1 + 2 + 4+ 5) Total WTP ITT (bleeding + untreated
caries + fillings assume moderate)
£780 £207 137 £871 £207 140 £659 £219 135 £870 £181 550 £902 £186 553
12. (1 + 2 + 4+ 6) Total WTP ITT (bleeding on brushing + untreated
caries only)
£794 £212 125 £901 £213 126 £661 £224 124 £893 £190 506 £929 £194 504
13. (1 + 2 + 4+ 7) Total WTP ITT (bleeding on brushing + untreated
caries + fillings assume extensive)
£742 £207 137 £822 £209 140 £614 £207 135 £822 £175 550 £854 £186 553
ITT, intention to treat; PP, per protocol; SA, scenario analysis
a All WTP tariffs are discounted at an annual rate of 3.5% in line with current NICE guidance for the methods of technology appraisal.103
b This is a per protocol attachment of WTP to trial arms, assuming that participants remain in their allocated recall group and are valuing the offer of a service, rather than the
service received and for which the patient attended.
c Assumes that if a filling was reported, that at least one of those fillings was for treatment of a moderate carious lesion (this is a more conservative assumption that assumes
dentists are more likely to treat less severe carious lesions that might not, for example, include patients experiencing pain). To obtain a measure of caries experience, the most
severe level of caries [i.e. filled (assuming moderate) or untreated] was used to assign the WTP tariff.
d Combined measures of untreated caries and fillings (assumed to reflect treatment of caries) is our preferred measure as it better reflects the impact on patient’s experience of
health states (not necessarily captured in a single follow-up visit) and is more congruent with the way in which the DCE question was framed. However, not all fillings will be for
carious lesions and this may introduce a bias if fillings not for caries (e.g. replacement fillings) are more likely in one randomised group than another. The magnitude of any bias is
likely to be small because the literature shows that only a small proportion of fillings provided are replacements.123
e Untreated caries are based on the clinical follow-up examination only and ignore those who have not returned for an examination, for whom a large number of data are available
from the routine records.
f Assumes that, if a filling was reported, that at least one of those fillings was for extensive caries. To obtain a measure of caries experience, the most severe level of caries [i.e. filled
(assuming extensive) or untreated] was used to assign the WTP tariff.
Light blue text refers to the impact of scenario analyses around the base-case approach on results.
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However, substantial cross-group differences are observed when expanding the valuation space to
include WTP for the service received (and all the perceived benefits associated with more frequent
check-ups). Applying the high valuation of more frequent check-ups to the number of check-ups
received in the trial generates substantial differences in WTP across the randomised arms from this
wider, societal perspective.
Economic evaluation results
This section combines costs and benefits data, using multiple imputation of missing data, under three
evaluation frameworks: (1) cost per QALY gained, (2) INB (intervention receipt + dental health benefits)
and (3) INB (dental health outcomes: bleeding gums and caries experience).
Economic evaluation results for risk-based versus 6-month recall (whole trial population)
Table 24 reports the results and Figures 15–17 illustrate the joint uncertainty in costs and benefits for
the comparison of risk-based versus 6-month recall using the data set pooled across strata. The figures
illustrate joint uncertainty in costs and benefits using scatterplots of the cost-effectiveness (benefit)
plane and cost-effectiveness (benefit) acceptability curves for each analysis framework. The preferred
recall strategy is highlighted in each of the analyses in Table 24 for ease of reading.
For the comparison of risk-based versus 6-month recall, there was no evidence of a difference in total
costs to the dental budget, QALYs gained or dental health outcomes. On the balance of probabilities,
6-month recall has a greater chance of being the most efficient strategy when considering costs from
only a dental health budget perspective. There is substantial uncertainty in this conclusion for the
CUA and cost per monetary valuation of dental outcomes, with a much higher chance of net benefit
associated with 6-month recall when adopting a societal approach to benefit valuation in the CBA.
The results for the CUA and CBA remain robust to the range of deterministic sensitivity analyses
undertaken. The results of the incremental cost per unit of (monetary) health benefit (i.e. framework 3)
are generally robust, with two exceptions:
1. Including participant costs of attending dental appointments (i.e. the opportunity cost of time and
travel, and the co-charge payments incurred) reduces the cost-effectiveness case for 6-monthly
recalls. In this scenario, there is no evidence to suggest that 6-month recall is an efficient use of
resources when society is only willing to pay for health benefits; however, broadening the costing
perspective does not change the findings from the CBA that 6-monthly recalls have the greatest
probability of maximising societal net benefit.
2. The most efficient recall strategy when measuring benefits in terms of WTP for dental health
(bleeding and caries) outcomes is sensitive to the UK region analysed. Considering data from
Scotland (fee for service) only suggests a substantially higher chance that risk-based recall is
associated with positive net (dental health) benefits, whereas in England (treatment banding),
6-month recall is the most likely net beneficial strategy. There are two reasons for these divergent
region-specific results. First, in England there are more band 2 treatments (specifically fillings)
provided in the risk-based group (ineligible stratum only), generating higher costs relative to
6-month recall than in Scotland. Second, the larger number of fillings is also counted on the
benefits side (as a negative) in the WTP calculation in England; therefore, the combined effect of
these drivers is a substantial difference in the probability of each strategy being an efficient use of
resources across the regions (simultaneously accounting for the joint uncertainty in both costs and
dental health benefits).
Economic evaluation results for risk-based versus 6-month versus 24-month recall
(stratum eligible for 24-month recall)
Table 25 and Figures 18–20 report the corresponding findings from the three-way comparison of
risk-based versus 6-month versus 24-month recall for those deemed eligible for 24-month recall.
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TABLE 24 Economic evaluation results (risk based vs. 6 months)
Analysis
Incremental cost:
mean difference, risk
based vs. 6 month
(95% CI)
Framework 1: CUA Framework 2: CBA
Framework 3: WTP (dental
outcomes)
Probability of being the most efficient recall
strategy
Incremental QALY:
mean difference,
risk based vs.
6 month (95% CI)
ICER
(£/QALY)
Incremental benefits:
mean difference, risk
based vs. 6 month
(95% CI) INB
Incremental
benefits: mean
difference, risk
based vs. 6 month
(95% CI) INB
Recall
strategy
CUA (@
£20,000
per QALY)
CBA (@
benefit/
cost= 1)
WTP (dental
outcomes)
(@ benefit/
cost=1)
Costing perspective:
NHS dental
+£1.82
(–£6.66 to +£10.30)
–0.006
(–0.042 to +0.031)
Dominated –£39.39
(–£58.40 to –£20.38)
–£41.21 –£4.05
(–£11.76 to +£3.66)
–£5.87 Risk based 30% 0% 17%
6 month 70% 100% 83%
Costing perspective:
NHS all
–£1.32
(–£19.22 to +£16.58)
–0.006
(–0.042 to +0.031)
£220 –£39.39
(–£58.40 to –£20.38)
–£38.07 –£4.05
(–£11.76 to +£3.66)
–£2.73 Risk based 31% 0% 34%
6 month 69% 100% 66%
Costing perspective:
NHS+ participant-
incurred costs
–£13.02
(–£68.09 to +£42.05)
–0.006
(–0.042 to +0.031)
£2170 –£39.39
(–£58.40 to –£20.38)
–£26.37 –£4.05
(–£11.76 to +£3.66)
+£8.97 Risk based 32% 22% 69%
6 month 68% 78% 31%
Costing perspective:
direct costs to NHS and
participants of attending
NHS dental care
–£2.87
(–£20.31 to +£14.57)
–0.006
(–0.042 to +0.031)
£478 –£39.39
(–£58.40 to –£20.38)
–£36.52 –£4.05
(–£11.76 to +£3.66)
–£1.18 Risk based 30% 0% 51%
6 month 70% 100% 49%
Map WTP for caries
outcome to untreated
caries only
+£1.82
(–£6.66 to +£10.30)
–0.006
(–0.042 to +0.031)
Dominated –£41.79
(–£61.10 to –£22.49)
–£43.61 –£6.45
(–£17.07 to +£4.17)
–£8.27 Risk based 30% 0% 12%
6 month 70% 100% 88%
WTP mapped to trial
outcomes using per
protocol analysis
+£1.82
(–£6.66 to +£10.30)
–0.006
(–0.042 to +0.031)
Dominated –£171.66
(–£159.92 to –£183.41)
–£176.48 –£6.45
(–£17.07 to +£4.17)
–£8.27 Risk based 30% 0% 17%
6 month 70% 100% 83%
Scotland only –£3.57
(–£12.61 to +£5.48)
–0.008
(–0.057 to +0.041)
£446 –£65.54
(–£99.29 to –£31.78)
–£61.97 +£6.52
(–£10.72 to +£23.77)
+£10.09 Risk based 37% 0% 91%
6 month 63% 100% 9%
England only +£11.42
(–£3.91 to +£26.74)
–0.003
(–0.058 to +0.052)
Dominated –£23.18
(–£48.03 to +£1.67)
–£34.60 –£13.21
(–£23.95 to –£2.46)
–£24.63 Risk based 35% 0% 1%
6 month 65% 100% 99%
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TABLE 24 Economic evaluation results (risk based vs. 6 months) (continued )
Analysis
Incremental cost:
mean difference, risk
based vs. 6 month
(95% CI)
Framework 1: CUA Framework 2: CBA
Framework 3: WTP (dental
outcomes)
Probability of being the most efficient recall
strategy
Incremental QALY:
mean difference,
risk based vs.
6 month (95% CI)
ICER
(£/QALY)
Incremental benefits:
mean difference, risk
based vs. 6 month
(95% CI) INB
Incremental
benefits: mean
difference, risk
based vs. 6 month
(95% CI) INB
Recall
strategy
CUA (@
£20,000
per QALY)
CBA (@
benefit/
cost= 1)
WTP (dental
outcomes)
(@ benefit/
cost=1)
Undiscounted costs and
benefits
+£1.74
(–£7.23 to +£10.70)
–0.007
(–0.064 to +0.050)
Dominated –£11.83
(–£17.12 to –£6.54)
–£13.57 –£1.15
(–3.58 to +£1.28)
–£2.89 Risk based 31% 0% 25%
6 month 69% 100% 75%
Complete-case analysisa CUA: –£1.48
(–£13.01 to +£10.05)
CBA: –£7.00
(–£20.90 to +£6.89)
WTP (dental): –£7.00
(–£20.90 to +£6.89)
–0.022
(–0.067 to + 0.020)
£67.27 –£53.43
(–£83.25 to –£23.61)
–£46.00 –£4.42
(–£14.19 to +£5.35)
+£2.58 Risk based 25% 0% 62%
6 month 75% 100% 38%
a For the complete-case analysis, number of observations was as follows: CUA (n= 742); CBA (n= 961); WTP dental health framework (n= 961).
Note that the estimates of incremental costs and benefits are obtained from mixed-effects regression using MI estimate. Ratios are calculated parametrically and the probability of cost–benefit is obtained
through bootstrapped loops of the chosen multiple imputation model (n= 2000 repetitions with m= 5 imputed data sets). All analyses are reported on the multiply imputed data set unless otherwise stated.
All models are based on the combined trial sample randomised to 6 month or risk based, with adjustment for stratum. Purple shaded text indicates the most efficient strategy for each comparison in each
analysis framework.
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For the analysis of trial data for those eligible for the 24-month recall, the 24-month interval is the
least costly interval overall, and is significantly less costly than 6-month recall. For the CUA and WTP
for dental outcomes frameworks, there is a 59% and a 86% probability that 24-month recall is the
most efficient strategy when considering costs to the dental budget, driven by the potential for cost-
savings without adversely affecting health outcomes (generic or dental). However, as DCE respondents
highly value more frequent check-ups, the wider societal measure of benefit (CBA) remains favourable
to 6-month recall.
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FIGURE 15 Risk-based vs. 6-month recall (CUA): (a) scatterplot of incremental costs and incremental QALYs; and (b) CEAC.
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In the eligible stratum, analysis frameworks focused on generic health (CUA) and dental health
(WTP for dental outcomes) and both indicate that 24-month recall is the most likely recall strategy to
deliver an efficient use of resources. The conclusion remains robust to the range of scenario analyses
undertaken; however, broadening the scope of benefit valuation to include society’s WTP for services
received, the optimal treatment decision would remain 6-month recalls. For the CBA, sensitivity
analyses remain robust to this conclusion.
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FIGURE 16 Risk-based vs. 6-month recall (CBA): (a) scatterplot of incremental costs and incremental benefits (WTP);
and (b) CBAC. NB, net benefit.
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In summary, for those eligible for longer recall intervals, 24-month recall is, on average, the least costly
interval for both the NHS and patients, and delivers significant cost savings when combining all costs
of attending dental appointments (NHS and patient incurred). These cost savings are achieved with
no meaningful differences in generic or dental health outcomes. From these perspectives, 24-month
recall is the most likely strategy to generate positive net benefit; however, the general population
places a significant value on more frequent dental checks, despite their additional cost and lack of
clinical benefit. Taking a more holistic view of benefits, 6-month recall generates the greatest net
benefits despite the potential for additional patient and NHS costs.
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FIGURE 17 Risk-based vs. 6-month recall (WTP for dental health outcomes): (a) scatterplot of incremental costs and
incremental benefits (WTP); and (b) CBAC. NB, net benefit.
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TABLE 25 Economic evaluation results (participants eligible for 24-month recall)
Analysis Comparison
Incremental cost,
mean difference
(95% CI)
Framework 1: CUA Framework 2: CBA
Framework 3: WTP (dental
outcomes)
Probability of being the most efficient recall
strategya
Incremental QALY,
mean difference
(95% CI) ICER
Incremental benefits,
mean difference
(95% CI) INB
Incremental benefits,
mean difference
(95% CI) INB
Recall
strategy
CUA P
(C/E) @
£20,000
CBA P
(C/B) @
BCR= 1
WTP (dental
health)
P (C/B) @
BCR= 1a
Costing perspective:
NHS dental
24 month vs.
risk based
–£6.46
(–£18.03 to +£5.11)
+0.007
(–0.102 to +0.117)
Dominant –£109.22
(–£151.34 to –£67.09)
–£102.76 +£0.57
(–£18.28 to +£19.43)
£7.03 Risk based 16% 0% 12%
24 month vs.
6 month
–£12.32
(–£30.94 to +£6.29)
+0.021
(–0.052 to +0.095)
Dominant –£172.43
(–£241.82 to –£103.04)
–£160.11 –£1.22
(–£20.62 to +£18.18)
£11.10 6 month 25% 100% 3%
Risk based vs.
6 month
–£5.86
(–£21.85 to +£10.12)
+0.014
(–0.082 to +0.110)
Dominant –£63.21
(–£110.24 to –£16.18)
–£57.35 –£1.80
(–£19.72 to +£16.13)
£4.06 24 month 59% 0% 86%
Costing perspective:
NHS all
24 month vs.
risk based
–£3.61
(–£40.11 to +£32.89)
+0.007
(–0.102 to +0.117)
Dominant –£109.22
(–£151.34 to –£67.09)
–£105.61 +£0.57
(–£18.28 to +£19.43)
£4.18 Risk based 17% 0% 20%
24 month vs.
6 month
–£9.33
(–£50.44 to +£31.77)
+0.021
(–0.052 to +0.095)
Dominant –£172.43
(–£241.82 to –£103.04)
–£163.10 –£1.22
(–£20.62 to +£18.18)
£8.11 6 month 25% 100% 10%
Risk based vs.
6 month
–£5.73
(–£43.81 to +£32.35)
+0.014
(–0.082 to +0.110)
Dominant –£63.21
(–£110.24 to –£16.18)
–£57.48 –£1.80
(–£19.72 to +£16.13)
£3.93 24 month 59% 0% 70%
Costing perspective:
NHS+ participant–
incurred costs
24 month vs.
risk based
–£37.92
(–£178.37 to +£102.53)
+0.007
(–0.102 to +0.117)
Dominant –£109.22
(–£151.34 to –£67.09)
–£71.30 +£0.57
(–£18.28 to +£19.43)
£38.49 Risk based 17% 6% 26%
24 month vs.
6 month
–£25.22
(–£126.33 to +£75.89)
+0.021
(–0.052 to +0.095)
Dominant –£172.43
(–£241.82 to –£103.04)
–£147.21 –£1.22
(–£20.62 to +£18.18)
£24.00 6 month 25% 94% 9%
Risk based vs.
6 month
+£12.70
(–£120.90 to +£146.31)
+0.014
(–0.082 to +0.110)
£907 –£63.21
(–£110.24 to –£16.18)
–£75.91 –£1.80
(–£19.72 to +£16.13)
–£14.50 24 month 59% 0% 65%
Costing perspective:
direct costs to NHS
and participants of
attending NHS
dental care
24 month vs.
risk based
–£41.84
(–£64.87 to –£18.82)
+0.007
(–0.102 to +0.117)
Dominant –£109.22
(–£151.34 to –£67.09)
–£67.38 +£0.57
(–£18.28 to +£19.43)
£42.41 Risk based 16% 1% 1%
24 month vs.
6 month
–£57.82
(–£106.55 to –£9.09)
+0.021
(–0.052 to +0.095)
Dominant –£172.43
(–£241.82 to –£103.04)
–£114.61 –£1.22
(–£20.62 to +£18.18)
£56.60 6 month 23% 99% 0%
Risk based vs.
6 month
–£15.98
(–£58.60 to +£26.64)
+0.014
(–0.082 to +0.110)
Dominant –£63.21
(–£110.24 to –£16.18)
–£47.23 –£1.80
(–£19.72 to +£16.13)
£14.18 24 month 62% 0% 99%
Map WTP for caries
outcome to
untreated caries only
24 month vs.
risk based
–£6.46
(–£18.03 to +£5.11)
+0.007
(–0.102 to +0.117)
Dominant –£108.03
(–£153.00 to –£63.07)
–£101.57 +£1.76
(–£23.33 to +£26.84)
£8.22 Risk based 17% 0% 8%
24 month vs.
6 month
–£12.32
(–£30.94 to +£6.29)
+0.021
(–0.052 to +0.095)
Dominant –£174.98
(–£248.18 to –£101.78)
–£162.66 –£3.78
(–£27.71 to +£20.16)
£8.54 6 month 26% 100% 5%
Risk based vs.
6 month
–£5.86
(–£21.85 to +£10.12)
+0.014
(–0.082 to +0.110)
Dominant –£66.95
(–£118.77 to –£15.13)
–£61.09 –£5.53
(–£32.39 to +£21.23)
£0.33 24 month 57% 0% 88%
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Analysis Comparison
Incremental cost,
mean difference
(95% CI)
Framework 1: CUA Framework 2: CBA
Framework 3: WTP (dental
outcomes)
Probability of being the most efficient recall
strategya
Incremental QALY,
mean difference
(95% CI) ICER
Incremental benefits,
mean difference
(95% CI) INB
Incremental benefits,
mean difference
(95% CI) INB
Recall
strategy
CUA P
(C/E) @
£20,000
CBA P
(C/B) @
BCR= 1
WTP (dental
health)
P (C/B) @
BCR= 1a
WTP mapped to trial
outcomes using per
protocol analysis
24 month vs.
risk based
–£6.46
(–£18.03 to +£5.11)
+0.007
(–0.102 to +0.117)
Dominant –£304.53
(–£345.87 to –£263.20)
–£298.07 +£0.57
(–£18.28 to +£19.43)
£7.03 Risk based 16% 0% 12%
24 month vs.
6 month
–£12.32
(–£30.94 to +£6.29)
+0.021
(–0.052 to +0.095)
Dominant –£468.59(–£511.45 to
–£425.72)
–£456.27 –£1.22
(–£20.62 to +£18.18)
£11.10 6 month 25% 100% 3%
Risk based vs.
6 month
–£5.86
(–£21.85 to +£10.12)
+0.014
(–0.082 to +0.110)
Dominant –£164.06
(–£196.36 to –£131.76)
–£158.20 –£1.80
(–£19.72 to +£16.13)
£4.06 24 month 59% 0% 86%
Scotland only 24 month vs.
risk based
–£9.98
(–£17.44 to –£2.51)
+0.000
(–0.163 to +0.163)
Dominant –£126.67
(–£184.99 to –£68.35)
–£116.69 –£11.92
(–£55.69 to +£31.86)
–£1.94 Risk based 34% 0% 30%
24 month vs.
6 month
–£16.27
(–34.02 to +£1.48)
–0.000
(–0.095 to +0.095)
£162,700 –£229.56
(–£332.09 to –£127.03)
–£213.29 +£6.34
(–£33.22 to +£45.89)
£22.61 6 month 43% 100% 0%
Risk based vs.
6 month
–£6.30
(–£25.79 to +£13.20)
–0.001
(–0.154 to +0.153)
£6,300 –£102.89
(–£196.35 to –£9.44)
–£96.59 +£18.26
(–£24.47 to +£60.98)
£24.56 24 month 23% 0% 70%
England only 24 month vs.
risk based
–£9.62
(–£40.96 to +£21.72)
+0.048
(–0.098 to +0.194)
–£131.30
(–£190.82 to –£71.79)
–£121.68 +£12.51
(–£15.94 to +£40.95)
£22.13 Risk based 5% 22% 10%
24 month vs.
6 month
–£15.67
(–£47.99 to +£16.64)
+0.063
(–0.064 to +0.190)
Dominant –£170.20
(–£269.40 to –£70.99)
–£154.53 –£4.14
(–£36.90 to +£28.63)
£11.53 6 month 10% 78% 14%
Risk based vs.
6 month
–£6.05
(–£31.95 to +£19.85)
+0.015
(–0.156 to +0.187)
Dominant –£38.89
(–£111.66 to +£33.88)
–£32.84 –£16.64
(–£48.90 to +£15.62)
–£10.59 24 month 86% 0% 76%
Undiscounted costs
and benefits
24 month vs.
risk based
–£6.43
(–£18.23 to +£5.38)
+0.023
(–0.071 to +0.118)
Dominant –£31.38
(–£43.57 to –£19.19)
–£24.95 +£0.91
(–£3.81 to +£5.62)
+£7.34 Risk based 17% 16% 15%
24 month vs.
6 month
–£13.97
(–£33.15 to +£5.20)
+0.002
(–0.089 to +0.094)
Dominant –£48.81
(–£68.23 to –£29.40)
–£34.84 +£1.21
(–£4.53 to +£6.95)
+£15.18 6 month 29% 84% 2%
Risk based vs.
6 month
–£7.55
(–£24.51 to £9.42)
–0.021
(–0.109 to +0.067)
£359.52 –£17.43
(–£30.76 to –£4.10)
–£9.88 +£0.30
(–£5.19 to +£5.79)
+£7.85 24 month 54% 0% 83%
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TABLE 25 Economic evaluation results (participants eligible for 24-month recall) (continued )
Analysis Comparison
Incremental cost,
mean difference
(95% CI)
Framework 1: CUA Framework 2: CBA
Framework 3: WTP (dental
outcomes)
Probability of being the most efficient recall
strategya
Incremental QALY,
mean difference
(95% CI) ICER
Incremental benefits,
mean difference
(95% CI) INB
Incremental benefits,
mean difference
(95% CI) INB
Recall
strategy
CUA P
(C/E) @
£20,000
CBA P
(C/B) @
BCR= 1
WTP (dental
health)
P (C/B) @
BCR= 1a
Complete–case
analysis
b
24 month vs.
risk based
CUA:–£10.58
(–£31.51 to +£10.35)
CBA: –£15.23
(–£36.23 to +£5.77)
WTP (dental):–£15.23
(–£36.23 to +£5.77)
+0.036
(–0.101 to +0.173)
Dominant –£111.63
(–£171.69 to –£51.56)
–£96.40 +£4.95
(–£19.78 to +£29.67)
+£20.18 Risk based 6% 0% 11%
24 month vs.
6 month
CUA: –£14.49
(–£36.47 to +£7.50)
CBA: –£26.45
(–£59.45 to +£6.54)
WTP (dental): –£26.45
(–£59.45 to +£6.54)
–0.048
(–0.152 to +0.056)
£301.88 –£218.40
(–£305.18 to –£131.62)
–£191.95 –£3.02
(–£30.36 to +£24.32)
+£23.43 6 month 76% 100% 8%
Risk based vs.
6 month
CUA: –£3.91
(–£25.54 to +£17.73)
CBA: –£11.22
(–£45.81 to + 23.36)
WTP (dental): –£26.45
(–£59.45 to +£6.54)
–0.084
(–0.210 to +0.042)
£46.45 –£106.77
(–£173.03 to –£40.52)
–£95.55 –£7.97
(–£31.22 to +£15.28)
+£18.48 24 month 17% 0% 81%
a Percentages are rounded to the nearest whole number for presentation in the table, and may, therefore, occasionally sum to 0.99 or 1.01.
b For the complete-case analysis, number of observations was as follows: CUA (n= 202), CBA (n=285), WTP dental health framework (n= 285).
BCR, benefit–cost ratio; P (C/B), probability of positive net benefit at a BCR = 1; P (C/E), probability of cost-effectiveness.
Notes
Estimates of incremental costs and benefits are obtained from mixed-effects regression using MI estimate. Ratios are calculated parametrically and the probability of cost–benefit is obtained through bootstrapped loops of the chosen
multiple imputation model (n=2000 repetitions with M=5 imputed data sets). All analyses are reported on the multiply imputed data set unless otherwise stated. Purple shaded text indicates the most efficient strategy for each
comparison in each analysis framework.
In this case, the ICER is reported for an intervention in the south-west quadrant of the cost-effectiveness plane; therefore, a lower value of the ICER indicates that the cost savings achieved for the risk-based intervention are not sufficient
to justify a QALY loss. In such scenarios, lower ICERs indicate that an intervention is less cost-effective than its comparator.
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FIGURE 18 Eligible for 24-month recall: (a) scatterplot of incremental costs and incremental QALYs; and (b) CEAC,
for risk-based vs. 6-month recall (CUA).
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FIGURE 19 Eligible for 24-month recall: (a) scatterplot of incremental costs and incremental benefits (WTP); and
(b) CBAC, for risk-based vs. 6-month recall (CBA). NB, net benefit.
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FIGURE 20 Eligible for 24-month recall: (a) scatterplot of incremental costs and incremental benefits (WTP); and
(b) CBAC, for risk-based vs. 6-month recall (WTP for dental health outcomes). NB, net benefit.
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Chapter 6 Discussion and conclusions
The INTERVAL trial involving regular adult NHS dental attenders has shown that a variable risk-basedrecall interval is not detrimental to oral health and is acceptable to patients and dentists with the
potential for cost savings. Over a 4-year period, we found no difference in oral health between patient
participants allocated to a 6-month or a variable risk-based interval. Nor did we find a difference between
the intervals of 24-month, 6-month and risk-based recall for the 30% of adults considered suitable to be
recalled at 24 months by their dentist. However, people greatly value and are willing to pay for frequent
dental check-ups.
To our knowledge, this is the first national, multicentre, pragmatic RCT in a primary care setting
to evaluate the clinical and patient-centred outcomes as well as the cost–benefit of different recall
intervals. The INTERVAL trial investigated the implementation of a risk-variable approach to recall
as recommended in the NICE guideline on dental recall.60 The guideline takes account of the effect
of dental checks on people’s well-being, general health and preventative habits; caries incidence and
avoiding restorations; periodontal health and avoiding tooth loss; and avoiding pain and anxiety. It aims
to improve or maintain patients’ quality of life and reduce morbidity associated with oral and dental
disease. This guideline was initially published in 2004 and most recently reviewed in 2018, confirming
that there was no emerging evidence to change the recommendations. Challenges to assumed routines
of dental practice, such as the 6-month dental recall and the benefit of regular scale and polish, were
voiced as early as 1970.2,124 The mantra of a 6-month recall has been in existence for decades, and trying
to establish the scientific basis for a 6-month or a variable risk-based recall interval was the reason for
this trial. Assessment of the cost-effectiveness of different recall intervals was also considered important
given the associated patient and NHS costs. Contemporary health care supports a patient-centred,
appropriate, preventative and compassionate approach, and a dental recall visit is the opportunity for
oral disease to be diagnosed early and for preventative advice and therapy to be provided. The aim
of this RCT in primary care dental practice was to provide evidence for the benefit or harm of dental
check-ups at different recall intervals on maintaining oral health.
The primary clinical outcome, gingival bleeding on probing, is a measure of gingivitis, a recognised
precursor of periodontitis, caused by plaque retention, and is reversible with effective plaque removal.
This outcome was chosen because it is an indicator of general oral health status, measurable and
responsive to changes in oral self-care behaviour leading to either an improvement or a deterioration.
At follow-up, on average, 35% of sites were bleeding on probing, which is similar to values reported in
other studies, including the IQuaD study.21,119 The prevalence of gingivitis confirmed that the trial
interventions had the opportunity to have an impact on maintaining oral health, and that we could
detect a beneficial or harmful effect. The intervention in INTERVAL was a check-up or recall appointment,
which would include oral assessment, disease diagnosis and preventative/oral self-care advice, therefore,
with the potential to have an impact on maintaining oral health. Around half of the participants had
generalised gingivitis, as defined by the 2017 World Workshop on the Classification of Periodontal and
Peri-implant Diseases and Conditions (> 30% sites bleeding) and only around 10% had clinical gingival
health. Our findings challenge the usefulness of the new classification, since it does not seem to be
sensitive enough to distinguish diseased from non-diseased individuals in a healthy sample.
At the 4-year follow-up, for adults allocated by their dentist to the 24-month eligible stratum (therefore,
at low risk and suitable for a dental recall of 24 months), there was no evidence of a clinically meaningful
or statistically significant difference in gingival bleeding on probing between those randomised to a
recall interval of 24 months, risk based or 6 months (24-month vs. 6-month recall –0.91, 95% CI –5.02
to 3.20, p = 0.66; risk-based vs. 6-month recall –0.98, 95% CI –5.05 to 3.09, p = 0.64; 24-month vs.
risk-based recall 0.07, –3.99 to 4.12, p = 0.97). Similarly, there was no evidence of a difference between
the overall group of participants randomised to a variable risk-based or 6-month recall (0.78 95% CI
–1.17 to 2.72; p = 0.43).
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We are confident in the finding of no clinical benefit of 6-month recall over a variable risk-based interval,
including for those assessed by the dentist as being eligible because of low risk for a 24-month recall,
because the adjusted mean bleeding difference between interventions was < 1% and the 95% CIs were
small enough to exclude the prespecified clinically important difference in bleeding of 7.5% and 4.5%.
INTERVAL did not find a difference in patient-reported generic or oral health-related quality of life
between any group, and the participants were satisfied being allocated to a recall interval based on risk.
No evidence of a difference was found in any of the secondary clinical outcomes measured between the
three recall intervals for those eligible for 24-month recall or the overall 6-month and risk-based recall
groups. The clinical secondary outcomes were periodontal probing depth, caries on coronal surfaces
measured at three levels (i.e. initial, moderate and extensive) and the presence of root surface caries,
calculus, dental treatment. Patient-centred outcomes included patient anxiety, patient satisfaction with
care and patient oral health knowledge, attitudes and behaviours. The range of outcomes measured in
INTERVAL was comprehensive, encompassing the important and relevant clinical and patient-centred
outcomes. The absence of evidence of a difference between the three recall strategies, therefore,
indicates that a variable risk-based recall interval can be supported as it is not detrimental to oral health.
All participants were assessed by their dentists at trial entry to determine whether or not they were
suitable for a 24-month recall, and the 30% of participants considered to be eligible were randomised
to a 24-month, risk-based or 6-month recall interval. All other participants were randomised to be
recalled at a variable interval determined by risk or at 6 months. Dental practices were asked to recall
their participants in keeping with their randomised allocation; however, this could be changed if the
dentist considered it necessary or if requested by the patient participant because of concerns about
their oral health. The pragmatic nature of the trial meant that scheduling of dental appointments
and, therefore, the interval between them varied, as they do in routine dental practice because of
either practice factors or patient factors. Prior to and since the publication of the NICE dental recall
guidelines,60 common practice is to provide a scale and polish or PI at the same time as a dental
recall visit. The instruction to participants was not to alter the frequency of this treatment and not to
delay in making an appointment if they needed to see the dentist. However, towards the end of the
trial follow-up period, dentists were instructed to provide any planned scale and polish following the
collection of clinical outcomes by blinded assessors.
At the start of INTERVAL, dentists’ attitudes towards a risk-based approach to recall interval varied.
Prior to randomising, all participant dentists were provided with training in the process of the NICE
allocation of a variable recall interval. In addition to face-to-face training, it included an interactive
online resource that dentists were asked to review as required and repeat annually. The online training
included clinical scenarios to demonstrate the range of factors that should be assessed and considered
prior to deciding the risk-based recall interval. It was designed to embed the process by taking the
clinician through the stages of consideration of modifying factors of risk, integrating this with clinical
information and making a clinical judgement of a suitable recall interval, discussing this with the patient
and reviewing the interval at subsequent check-ups. The online training was designed to be compliant
with CPD requirements and, after completion, a form could be printed to record verifiable CPD.
Oral health-related quality of life was assessed using the validated OHIP-14 measure, which has been
widely used as a measure of OHRQoL. Participants deemed eligible to be allocated to a 24-month
recall had, on average, a better OHRQoL score than those deemed ineligible. Participants deemed
ineligible were also more likely to identify themselves as regular attenders. This suggests that dentists
reliably assessed patients’ risks and had done so already, which is in line with their confidence to assess
patients’ risks. Similarly, dentists reported that they intended to schedule appointments every 12 months
for participants allocated to the risk-based arm in the eligible for 24-month recall stratum, and every
9 months in the ineligible for 24-month recall stratum. National routine data suggest that, in the NHS,
the most frequent interval between check-up visits is 9 months, and this reflects the experience of the
participants randomised to 6-month visits.
DISCUSSION AND CONCLUSIONS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
86
At 4 years, there was a clear separation in the number of check-ups received by the 30% of participants
in the 24-month recall stratum: those randomised to the 24-month recall interval had half the number
of check-ups of those in the 6-month interval group, and those allocated to a risk-based interval
experienced a frequency between the two (24 month= 2.4, 6 month= 4.3 and risk based= 3.4 check-ups).
There was a twofold difference in the number of check-up visits between groups of participants who were
considered eligible for a 24-month recall. For participants randomised to a risk-based interval who had
been considered suitable for a 24-month recall, the decision made by the dentist when applying the risk
assessment framework was to allocate an interval of around 12 months. This was closer to the actual
recall attendance of the 6-month group than those randomised to be seen at 24-month intervals.
For the 70% of INTERVAL participants who at baseline were considered not eligible for a 24-month
recall interval, compared with those who were eligible, both the 6-month and risk-based groups were
seen more frequently than the corresponding groups. Having the eligible for 24-month recall stratum
allowed us to demonstrate the ability of dentists to assess risk as evidenced by the different number
of check-ups for the risk-based groups between strata. At baseline the mean OHRQoL (OHIP-14)
score was higher in the ineligible group, indicating that the dentists reliably judged these patients to be
at higher risk when scheduling check-ups more frequently. The difference in the number of check-ups
during the 4 years was small, 0.3 from routine claims data. National routine data suggest that, in the
NHS, the most frequent interval between check-up visits is 9 months, and this reflects the experience
of the participants randomised to 6-month visits. From the practice data and the monitoring of allocated
recall interval, dentists intended to schedule appointments according to group; however, as INTERVAL
was a pragmatic trial, the patient participants were able to amend visit dates in accordance with their
need for a convenient appointment time.
The economic analysis was conducted using different perspectives of benefits (QALYs, WTP for dental
health outcomes, WTP for dental recall and associated outcomes) and costs (NHS dental, sourced from
the routine claims data; NHS dental and other services, such as primary and secondary medical care;
and societal, including NHS and participant perspective costs). The preferred perspective depends on
normative views of what benefits should be maximised with the NHS dental budget and what costs
should be minimised.
The comparison of risk-based recall with 6-month recall is based on data across both trial strata, to
which patients who are ineligible for 24-month recall contribute the majority of data. Using evaluation
frameworks that maximise generic or dental health, there is substantial uncertainty regarding the most
efficient recall strategy. In general, 6-month recall has a higher probability of cost-effectiveness, but
the certainty around this conclusion tends to decrease as a wider perspective of participant-incurred
costs is included. The results are sensitive to country-level subgroups, with risk-based recall having a
higher probability of cost-effectiveness in a Scottish setting. As the general population places a high
value on 6-month recall, expanding the valuation space to include all societal benefits (i.e. WTP for
different recall intervals) leads to a high probability that 6-month recall has the greatest net benefits
in a societal CBA framework. This conclusion is robust to sensitivity analyses undertaken.
Only participants who were deemed eligible for 24-month recall were randomised to the three-way
comparison of 6-month versus risk-based versus 24-month recall, and so were more likely to be deemed
at low risk of dental problems. The 24-month recall strategy is the least costly strategy to the NHS
and generates significant cost savings compared with both 6-month and risk-based recall when also
considering the opportunity cost of time and travel, and patient co-charges associated with attending
the dental practice more regularly. When adopting either a generic or a dental health maximisation
perspective, 24-month recall is likely to be the most efficient strategy; however, when taking a broader
perspective of benefits, and incorporating the general population’s valuation of recall intervals, these
cost savings are offset by the perceived benefit of more frequent recall. In all cases where a wider
perspective of benefits is included in the CBA, 6-month recall remains the strategy with the greatest
likelihood of positive net benefits and this conclusion is robust to sensitivity analyses undertaken.
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In summary, the recall strategy generating the greatest value for money is dependent on eligibility for
24-month recall and the decision-maker’s views on the scope of costs and benefits that should be
valued in the economic evaluation.
Framework 1 (maximising generic health benefit) used the results of the CUA to assess the most
cost-effective strategy in terms of maximising generic health outcomes (i.e. EQ-5D-3L-based QALYs).
There was substantial uncertainty surrounding the optimal recall strategy across all analyses undertaken.
This is a result of concerns regarding the QALY’s sensitivity to capture any potential benefits of dental
care interventions. The CEACs and scatterplots of the cost-effectiveness plane illustrate the residual
uncertainty, rendering it difficult to draw clear cost-effectiveness conclusions using this metric;
for example, in the combined analysis across both trial strata, no strategy achieved a probability
of cost-effectiveness > 70% at a threshold value of society’s WTP for a QALY gain of £20,000.
The probability of cost-effectiveness was higher for the 24-month recall strategy in the analysis
restricted to the eligible for 24-month recall stratum because of the potential for cost savings from
longer recall intervals.
Framework 2 (maximising societal well-being), taking the broadest perspective of benefits, including all
components of value to the general population (incorporating both health and non-health sources of utility),
generates a high probability that 6-month recalls are net beneficial. This finding is consistent across the full
range of sensitivity analyses undertaken. This conclusion is influenced by the high value that the general
population attaches to the 6-month recall service attribute in the DCE.
The DCE provided important information on the valuation of dental health outcomes; however, it is
unclear why the general population places such a high value on service provision, controlling for health
outcomes. The high WTP values attached to more frequent dental recall services was the main driver
of results favouring 6-month recall in the wider-perspective CBA. Policy-makers may require further
insights into the source of value attached to interventions in order to make informed decisions using a
CBA framework, and further research is required to identify these sources of value. Some hypotheses
for the high valuation of 6-month check-ups might include:
l Status quo bias, where respondents place a high value on services they usually receive.
l Omitted variable bias may occur if respondents place a value on some perceived outcomes that
were not included in the DCE, such as increased likelihood of detection of oral cancers, or an
assumption that check-ups come with scale and polish and associated aesthetic benefits.
l Supplier-induced demand where the population feel that they need to see the dentist every 6 months
because that is the expert advice they have received over a long period of time (even if it is not
evidence based).
l Reassurance provided by a consultation with a health professional.
Further work is required to more completely understand what it is that respondents explicitly value
about 6-month recalls.
Framework 3 (maximising dental health benefits) evaluated the most efficient dental recall strategy
in terms of maximising dental health benefit (i.e. through the DCE valuation of bleeding and caries
outcomes). For the group deemed eligible for 24-month recalls, differences in costs to the total NHS
dental budget (across the UK) are not statistically significantly different across the randomised arms;
however, substantial cost savings can be achieved from longer recall intervals when considering the
combined cost burden to both patients and the NHS. These savings can be achieved without adversely
affecting dental health outcomes. A 24-month recall has the greatest probability of positive net dental
health benefit, ranging between 65% and 99% across the full range of sensitivity analyses conducted.
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For the trial population as a whole (including both eligible and ineligible for 24-month recall strata),
there is substantial uncertainty regarding the most efficient strategy to maximise dental health benefit.
Risk-based recalls were more likely to generate positive net dental health benefit in Scotland than in
England, and when a wider perspective of the costing analysis was considered.
Comparison with other randomised clinical trials and studies
The Cochrane systematic review of dental recall, which was updated in 2013,72 reported insufficient
evidence to determine the effect of different recall intervals, with only one study included.125 The trial
population of the only included study125 comprised children or adolescents aged 3, 16 or 18 years at trial
entry. Wang et al.125 included 185 patients and compared recall intervals of 12 months and 24 months
over a 24-month follow-up period for the outcomes caries, as measured by decayed, missing and filled
surfaces of primary teeth (dmfs) increment, and decayed, missing and filled surfaces of permanent teeth
(DMFS) increment, and total time taken for examination and treatment. The authors of the Cochrane
review concluded that a very low-quality body of evidence from one RCT was insufficient to reach any
conclusions regarding the potential beneficial and harmful effects of varying recall intervals between
dental check-ups. The Cochrane review Recall intervals for oral health in primary care patients was updated
in 2020 by authors of the INTERVAL trial monograph, incorporating results from this study.126 The
updated search of 17 January 2020 identified the INTERVAL trial as the only new study eligible to
be included in the updated review and the only trial to include patient participants > 18 years at
trial entry. Given that different outcomes were reported in the two studies included in the updated
Cochrane review, it was not possible to synthesise the data. The forest plots from the INTERVAL trial
data are included to present the treatment effects across trial arm comparisons for the INTERVAL
trial-reported outcomes (Figures 21–23).
To our knowledge, this is the first RCT to fully integrate costs and benefits of different dental recall
intervals and, therefore, provides the best available evidence on the short-term cost-effectiveness of
different recall strategies proposed in the NICE guidance.127 The NICE guidance was informed by a
HTA report that developed a lifetime decision model to assess the cost-effectiveness of 3-, 6-, 12-, 18-,
24- and 36-month recall from a UK NHS perspective.71 The report found that the incremental cost per
decayed, missing, filled (DMF)-free tooth gained increased as recall intervals were narrowed; however,
given that there is no evidence or precedence regarding society’s WTP for a DMF-free tooth gained,
the results are difficult to interpret. Furthermore, the scope of costs was limited, and included only
check-ups and treatment for decay, omitting any other dental treatments that may be triggered by
recall. Finally, the results are of limited value to current decision-making as the payment system for
dentistry has been updated in England and Wales, since this review was carried out, to the current
banding system. To our knowledge, there are no other studies directly relevant to the cost-effectiveness
of routine dental checks or oral health reviews in a UK setting.
Strengths
The INTERVAL trial was a pragmatic trial in primary care dental practice designed to provide evidence
for the clinical and cost-effectiveness of variable recall intervals. The traditional view and ‘mantra’ of
6-month check-ups still exists among the majority of patients and dental professionals despite the
introduction of recommendations decades ago for a risk-based and variable approach to reviewing
patients.3 The design of INTERVAL was complex and unique in order to answer the commissioning
brief. A strength of the design was being able to compare three recall intervals and demonstrate the
ability of dentists to distinguish between high- and low-risk routine dental attenders. INTERVAL
included outcomes that were relevant and important to patients, clinicians and policy-makers. The
design enabled and ensured that the most robust measures were collected including independent
clinical assessments and access to national routine data.
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FIGURE 21 Forest plot for (a) the continuous outcomes; and (b) the outcome prevalence of extensive caries: risk-based vs. 6-month recall. M–H, Mantel–Haenszel.
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FIGURE 23 Forest plot for (a) the continuous outcomes; and (b) the outcome prevalence of extensive caries: risk-based vs. 24-month recall. M–H, Mantel–Haenszel.
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Surprisingly, there have been few high-quality studies comparing different recall intervals, whether
fixed or variable, according to risk. This is at a time when NHS resources are constrained, and there
are demands for realistic and patient-centred care across health care. The published studies evaluating
different recall intervals have involved few providers and most are in specialist settings that evaluate
the impact of complex interventions usually directed at preventing caries in high-risk children. The only
other trial undertaken was in a population of children and adolescents who received regular dental
care in a public dental clinic in Norway from one dentist and one dental hygienist.125 The trial inclusion
criteria were less pragmatic than in INTERVAL, with individuals considered at high risk of dental caries
excluded from the study. The commissioned call that INTERVAL answered presented a complex question
that required a novel trial design. The strength of the design was to include two strata to avoid allocating
participants to a 24-month recall for whom it was not clinically appropriate. A misinterpretation of
INTERVAL may come about if the design is not understood. A significant strength is that dentists in
INTERVAL applied their professional and clinical judgement before allocating a patient participant to
the stratum that included randomisation to 24-month recall.
A strength of INTERVAL was that it was a pragmatic trial allowing the dentists and patient participants
to respond to changes in circumstance. Changes in circumstance could have been logistics for allocating
a recall appointment, or not attending as scheduled because of holidays, or responses to change in
clinical condition. We predicted that the participants allocated to a 6-month recall would be most likely
to attend at 9 months, thereby taking into account the added duration of any course of treatment
following the previous check-up date and adjustments for the logistics or general life. A strength
of INTERVAL is that dentists did implement a different recall interval for the patient participants
randomised to the risk-based group in both strata of the trial. This overcame a potential risk at the
outset that we might not observe a difference in the number of check-ups experienced; however, a
surprising observation was that the time interval for the risk-based group was so close to the 6-month
recall group. In addition, for patients whom dentists felt were suitable not to be seen, unless needed,
for 24 months, dentists allocated a risk-based recall interval in between 6 months and 24 months,
which was, however, not closer to the latter. A further strength of INTERVAL is that because of its
pragmatic nature it has demonstrated that dentists can accurately and reliably assess risk as shown
by the difference in the recall behaviours of the two strata.
The strengths of the INTERVAL trial include the recruitment and retention of a large number of
centres (n = 51) and, to our knowledge, is the first dental trial to involve all the nations of the UK.
As the nations operate in different contractual systems, INTERVAL provides insight to the potential
impact that the system has on clinical decision-making and practice systems. The dental practices
represent a wide range of geographical locations including remote and rural settings, and a range
of characteristics including the number of dentists (average three), and whether or not they were a
training practice, or employed at least one hygienist (70%). INTERVAL was not powered to detect
differences across contractual systems and the numbers from Northern Ireland are too small to make
any conclusions, although there appears to be a difference in the determination of risk-based recall
interval for dentists in England and Scotland.
Recruitment and retention in trials is a frequent challenge, but an achievement for the INTERVAL trial
was the recruitment of 2372 of the potentially eligible patients, and their retention with provision of
data at 4 years from 1765 participants with 69% providing clinical data. This may be as a result of the
participants being routine dental attenders and, hence, interested in dental health, and it was possibly
their first invitation to participate in research. The randomised groups in both strata were balanced/similar
at baseline and the reasons for loss to follow-up were related to inability of the practice to contact its
patients; therefore, we were confident in the robustness of the results regardless of the missing data.
The dental behaviour and clinical characteristics of the participants mean that the findings of the INTERVAL
trial are generalisable to regular dental attenders across the UK in the NHS, and, therefore, also in similar
third-party funding systems. Applying a risk-based determination of recall interval is advocated in many
dental health-care systems and hence the findings of INTERVAL have relevance internationally.
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The INTERVAL trial found no evidence of a difference in oral health from a risk-based recall interval
compared with the traditional 6-month check-up. This also applied to patient participants whom the
dentist assessed as low risk and suitable for a check-up at 24 months. For this group, the INTERVAL
trial found no evidence of a difference between 24-month, risk-based or 6-month recall. The results
were robust to sensitivity analyses exploring the impact of missing data.
The pragmatic design of the trial did not prevent fidelity to the interventions with separation in the
frequency of dental check-ups between groups. We have evidence of intervention fidelity though
monitoring intended check-up appointments. Dentists participated in training and were asked to revisit
the e-learning tool, although compliance was variable. Conducting the trial in a primary care NHS setting
with a design that involved minimal requirements for the dental practices, blind outcome assessment
and access to routine data are strengths. The process undertaken to inform the determination of a risk-
based recall was not independently observed (i.e. information collection, assessment and consultation
with the patient); however, we believe the dentists performed this intervention as instructed in a way
with which they were confident. The evidence from the dentist experience questionnaire supports the
view that dentists who randomised participants to the 24-month stratum increased in confidence and
were more likely to adopt/maintain that behaviour. In contrast to those who did not, their concern/
anxiety increased by the end of the trial.
There was no evidence that different recall intervals made a difference to measures of patient quality of
life, anxiety and satisfaction with care. The strength of INTERVAL was that these measures were collected
annually during the 4 years of the trial. The reaction of some to them being considered suitable to have a
recall interval of 24 months was an indication of confidence in their ability to maintain their oral health.
The health economic analysis is based on best practice methodology for conducting economic evaluation
alongside RCTs. The analysis provides the only evidence that is relevant to decision-making in the UK
NHS regarding the most efficient dental recall interval, and is based on the current, most up-to-date
payment systems across the UK regions. The analysis is novel in implementing a CBA considering both
WTP for dental health outcomes and wider societal benefits. The use of a DCE to capture the value
placed on both the trial interventions and important dental health outcomes by the general population
is a distinct advantage and overcomes the problems with interpreting economic evaluation results from
other studies. The approach ensures consistency of methodology with recent economic evaluations of
routine dental interventions (e.g. the IQuaD study101). A further advantage of CBA is the simultaneous
valuation of multiple dental health outcomes within a single outcome measure (i.e. bleeding gums and
dental decay), representing an important advantage over more traditional, single outcome measure
cost-effectiveness studies (e.g. decayed teeth only) typically conducted in dentistry.
In terms of the within-trial analysis, we used best practice methodology, incorporating the most
advanced recommendations for analysis with the appropriate use of missing data models to minimise
the potential for bias.
Limitations
The INTERVAL trial experienced challenges throughout its course, some of which were anticipated and
others of which could not have been predicted. Recruitment of dentists and participants was a challenge
which was overcome, but this led to a considerable delay in the trial. The lack of research-experienced
practices and the fact that the dentists were responsible for recruiting and obtaining consent from
patient participants had an impact on our ability to reliably predict recruitment. INTERVAL was the first
in a series of trials that the research team have been involved with, and experience has shown that a
weakness was not having the research nurses supporting practices in person at dedicated recruitment
sessions to overcome this. We did not collect information on the total number of routine patients
approached as practices operated a process that complemented their practice management system;
therefore, the reasons why patients chose not to participate in INTERVAL are unknown.
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We experienced delays in analysis due to challenges encountered obtaining routine data. The process
and mechanisms for establishing permission for access to routine data did not exist for England and
Wales. Retrieving the routine data delayed analysis; the reasons for this included there not being
a system for information retrieval or sharing of dental data at NHS services in England and Northern
Ireland prior to INTERVAL.
A weakness was not collecting information on what factors were considered to inform the risk-based
interval and the interaction with the patient to both determine risk and negotiate the interval. A possible
weakness was the choice of the primary outcome as gingival bleeding on probing for which calibration is not
possible. The rationale for this decision was that it is a measurable and modifiable outcome that indicates
oral health in general. INTERVAL evaluated different recall intervals on maintaining oral health and no
difference in this disease measure would reflect the absence of either improvement or deterioration.
The other clinical outcomes were recorded, but the team’s experience and previous research confirmed
that the progression of caries and periodontal disease was going to be too slow in this population.
INTERVAL had a drop-out rate of 25–30% in the questionnaire data and 30–37% in attendance at
appointments, a higher value than expected at the design stage of the trial. However, the 95% CIs
for risk-based versus 6-month recall and risk-based versus 24-month recall precluded our predefined
clinical minimally important differences in gingival bleeding of 4.5% and 7.5%, respectively. In addition,
the drop-out rates were balanced between the arms, and sensitivity analyses using multiple imputation
showed that the results were robust.
The analysis is based on 4-year outcomes from the trial. It is important to extrapolate trial results
over a longer-term time horizon in order to fully capture all the costs and outcomes associated with
different interventions. This was outwith the scope of the current study. There is no evidence from
the trial to suggest differences in caries experience or bleeding across the different recall intervals,
and it is therefore unlikely that a decision model would lead to different conclusions regarding the
most efficient allocation of resources. There is a lack of good-quality information in dentistry to inform
decision analysis models, for example estimates of long-term baseline transition probabilities to
determine the life course of a tooth through different stages (well, decayed, root canal treatment
required, missing). Further research is urgently required to bridge this gap in the evidence base and
determine the economic value of long-term caries prevention.
There are different payment systems across the different UK regions. Dental check-ups are free of
charge in the fee-for-service system in Scotland, there are patient co-payments in the Northern Ireland
fee-for-service system, whereas England and Wales adopt a treatment banding approach. The method
of payment and the cross-region variation raise three specific issues for the economic evaluation:
1. The payment for dental care services is not necessarily a true reflection of the opportunity cost of
the resource required to deliver dental services. Owing to the practical barriers to conducting a
detailed micro-costing exercise, and the vast number of different possible treatments in primary
dental practice, we were not able to directly elicit opportunity costs in this study.
2. The different payment systems across the regions, and the process of submitting dental claims means
that the resource use data collected from the practices varies substantially, which limits comparability.
The quality of the data, in particular the detailed treatment information (e.g. check-ups and fillings)
obtained from the routine claims data, could also potentially vary across countries.
3. The different systems may induce different provider and consumer behaviours, and different
regional-specific incentives make direct comparability of results across the regions difficult.
However, results are unlikely to be biased at the average UK level because the proportion of
practices randomising to each group was approximately equal across the different regions.
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Clinical assessment
Overcoming the practical challenge of arranging the final clinical assessment visits for participants at
51 dental practices across the four nations of the UK relied on trust, respect and partnership working
between the research team and the general dental practices involved. Patient participants volunteered
around 30 minutes of their time for the clinical assessment by one of the blinded assessment teams.
The attendance of 1624 participants for their clinical assessments demonstrates their interest,
commitment and the value placed on seeking evidence for routine oral health care and the role of
practice-based dental research. The robust training undertaken prior to data collection and throughout
the assessment period ensured consistency between assessors. The fact that calibration was not
possible does not limit the findings, and we believe that no more could have been done to ensure
reliable measures.
Patient and public involvement and engagement
Prior to the start of the trial, advice on the design and conduct of the study was sought from members
of the Public Partnership Groups and from similar patient groups in other parts of the UK sourced
under guidance from INVOLVE.
These independent public partnership groups comprise volunteers who work in partnership with NHS
Tayside and aim to provide a conduit for the views of people about their local services.
Patient advisors were a valuable resource at the outset of the trial and they helped to ensure good
conduct and patient-friendly practice throughout the duration of the trial. Patient advisors were involved
with the trial design and provided invaluable feedback on trial recruitment and communication strategies.
Patient advisors also contributed to the content and layout of the trial invitation, trial newsletters and the
design of patient participant questionnaires. This ensured that trial participants could understand and
easily complete these materials. This input was obtained remotely and from individuals. In future studies,
we would recommend working with a group with some face-to-face interaction.
As quality of life was a primary outcome of the trial, patient advisors’ input to the proposed
questionnaire design was essential. Qualitative work with patients was carried out to ensure that
the outcome measures were patient-centred.
Lay representatives on the TSC and TMC actively contributed to trial oversight, processes and procedures,
including helping to interpret the trial findings, preparation of the monograph, and assisting with the
review of the Plain English summary.
The results were discussed with the four Chief Dental Officers of the UK to enable early consideration
of the implications for policy and practice.
Generalisability
The INTERVAL trial was designed pragmatically to investigate the effectiveness and cost–benefits
of three different recall intervals. The 51 recruiting dental practices were situated in England, Wales,
Northern Ireland and Scotland. On average, participating dentists had been qualified for 16 years and
had an approximate total list size of 5000 patients. The average number of dentists in their practices
was three and approximately 70% of practices employed at least one hygienist.
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As at 30 September 2018, 94% of the adult population in Scotland were registered with an NHS dentist.
Of these, 67% had attended their dentist at least once in the previous 2 years. The Adult Dental Health
Survey 2009114 reported that over half of the population in England, Wales and Northern Ireland had
attended a dental practice within the last 3 years. The INTERVAL trial recruited 2372 patient participants
who were regular attenders and had attended the dentist at least once in the previous 2 years, with 43%
recruited in England and Wales, 7% in Northern Ireland and 50% in Scotland.128
At baseline, the average age of participants was 45 years, 55% were female, 15% identified as smokers
and 55% used manual toothbrushes.
We are confident that the practices and participants recruited are a true representation of adults who
attend NHS dental practices across the UK.
Recommendation for research
Further research is required to:
l enhance and support the communication of a variable risk-based recall interval to patients and the
dental team, and the co-development of risk assessment tools
l develop recall interval quality management and improvement tools
l understand the role of risk-based recall and risk management of adults who are irregular
dental attenders
l better understand public perceptions of the value of 6-month fixed-period recall intervals to help
elucidate barriers to and facilitators of change
l inform methods for long-term decision modelling in dentistry utilising long-term dental cohort data
where possible
l better utilise routine claims data sets, including tooth-level treatment data, to create cohorts of data
to follow and predict individuals’ health and to understand and improve care pathways in dentistry.
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Appendix 1 Clinical effectiveness outcomes
TABLE 26 Patient-reported outcomes calculation
Outcomes Questions Scoring
Behaviour Section 2 Q1, Q3, Q9, Q11 Sum of the questionsa
Knowledge Section 2 Q2, Q4, Q10, Q12 Sum of the questionsa
Attitude Section 3 Q1 to Q7 Mean of all questions
PBC Section 3 Q8 to Q11 Mean of all questions
Satisfaction with care Section 3 Q12 to Q23 Mean of all questions
a The best value between flossing and interdental brushes was used as a measure of interdental cleaning behaviour.
TABLE 27 Dentist belief questionnaire outcomes calculation
Outcomes Description Questions Scoring
Attitude to the
6-month interval
Attitude to the 6-month interval. Higher scores represent a
positive attitude towards the 6-month interval
Q1, Q4, Q5, Q7, Q8,
Q9, Q10, Q12, Q13,
Q15, Q16, Q18
Mean of all
questions
Attitude to the
24-month interval
Attitude to the 24-month interval. Higher scores represent
a positive attitude towards the 24-month interval
Q3, Q14, Q17, Q19 Mean of all
questions
General attitude General attitude to the patient’s ability to maintain
self-care. Higher scores represent a positive attitude
Q2, Q6, Q11 Mean of all
questions
PBC Perceived ability to assess risk. Higher scores represent
greater PBC
Q20, Q21 (a) to (c) Mean of all
questions
TABLE 28 Recruitment by centre
Centre name
Strata
Total
Ineligible 24-month
recall
Eligible 24-month
recall
Six Gables Dental Practice, Cardiff 6 7 13
Craigmillar Dental Centre, Edinburgh 1 8 9
Colin C Yule & Associates, Forfar 1 59 60
Roseville Dental Practice, West Midlands 2 19 21
Cottam’s Dental, Implant & Orthodontic Practice, Birmingham 26 1 27
Walmley Dental Practice, Sutton Coldfield 18 12 30
Amblecote Dental Care, West Midlands 48 14 62
M&S Dental Care, Fort William 3 44 47
Southside Dental Care, Edinburgh 0 54 54
Kingsway Dental Practice, Dundee 38 38 76
Brightons Dental Surgery, Falkirk 14 38 52
continued
DOI: 10.3310/hta24600 Health Technology Assessment 2020 Vol. 24 No. 60
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Clarkson et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
111
TABLE 28 Recruitment by centre (continued )
Centre name
Strata
Total
Ineligible 24-month
recall
Eligible 24-month
recall
Montrose Dental Care, Montrose 5 47 52
Bayview Dental Practice, Banff 6 16 22
Young Smile Dental Care, Alford 38 17 55
Mount Florida Dental Care, Glasgow 40 15 55
Horizon Dental Clinic, Monkseaton 0 6 6
Horizon Dental Clinic, Blyth 0 4 4
Green Lane Dental, Birmingham 23 40 63
Aesthetics Dental and Implant Surgery, Birmingham 16 23 39
Platt & Common, Stirling 3 6 9
Chong Kwan Dental Centre, Dunfermline 0 79 79
Brunswick Dental Practice, Newcastle 4 75 79
Hazel House Dental Surgery, Inverness 11 5 16
Castle House Dental Practice, Inverness 10 30 40
PCK Wee Dental Surgery, London 1 110 111
Family Dental Care, London 1 5 6
Smiledent Dental Practice, London 4 33 37
Ballynahinch Dental Care, Belfast 47 2 49
Loughside Dental Practice, Belfast 30 22 52
Church Road Dental Care, Belfast 11 41 52
Anita Belbin Dental Surgery, Glasgow 2 50 52
N13 Dental Clinic, London 3 51 54
Mr I Lightfoot, Newcastle 0 28 28
Shotley Bridge Dental Care, Newcastle 6 44 50
Discovery Dental Care, Dundee 28 26 54
Nairn Dental Clinic, Inverness 15 41 56
My Dental Care, London 5 35 40
Salmon Lane Dental Care, London 3 49 52
Eastside Dental Practice, London 15 52 67
Bridge Dental Centre, London 4 52 56
Park View Family Dental, Newcastle 16 130 146
Dunbar Dental Practice, Dunbar 67 28 95
St Leonards Dental Practice, Glasgow 3 49 52
Woodside Dental Practice, Glasgow 4 11 15
Lochshell Dental Clinic, Wick 21 11 32
Bute Dental Surgery, Bute 14 39 53
Windsor Dental Practice, Salford 4 19 23
Windsor Dental Practice, Manchester 4 1 5
Kelvingrove Dental Care Ltd, Glasgow 0 100 100
Montgomery Street Dental Practice, Edinburgh 20 33 53
Collegiate Dental Practice, Manchester 7 5 12
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TABLE 29 Participant characteristics at baseline in Scotland by randomised group
Characteristic
Eligible 24-month recall Ineligible 24-month recall
Risk based 24 month 6 month Risk based 6 month
Randomised, n (%) 111 (100.0) 117 (100.0) 116 (100.0) 419 (100.0) 425 (100.0)
Baseline questionnaire
returned, n (%)
102 (91.9) 109 (93.2) 108 (93.1) 391 (93.3) 387 (91.1)
Age, mean (SD), n 42.4 (14.6), 111 47.2 (15.4), 117 46.6 (14.7), 116 49.1 (13.4), 419 49.9 (14.3), 425
Female participants, n (%) 70 (63.1) 66 (56.4) 66 (56.9) 245 (58.5) 248 (58.4)
Regular smoker, n (%) 19 (17.1) 18 (15.4) 17 (14.7) 88 (21.0) 60 (14.1)
Time since previous visit to dentist, n (%)
< 1 year 96 (86.5) 96 (82.1) 100 (86.2) 370 (88.3) 366 (86.1)
1–2 years 4 (3.6) 13 (11.1) 7 (6.0) 18 (4.3) 16 (3.8)
> 2 years 1 (0.9) – 1 (0.9) – –
Patient status, n (%)
NHS 89 (80.2) 97 (82.9) 93 (80.2) 347 (82.8) 325 (76.5)
Private 2 (1.8) 5 (4.3) 2 (1.7) 12 (2.9) 13 (3.1)
Combination 4 (3.6) 2 (1.7) 6 (5.2) 17 (4.1) 29 (6.8)
Type of toothbrush, n (%)
Manual 65 (58.6) 76 (65.0) 60 (51.7) 232 (55.4) 234 (55.1)
Electric 35 (31.5) 32 (27.4) 48 (41.4) 158 (37.7) 150 (35.3)
Regular attender:
self-report, n (%)
92 (82.9) 102 (87.2) 101 (87.1) 373 (89.0) 359 (84.5)
Difficulty travelling to
dentist, mean (SD), n
6.5 (1.2), 101 6.6 (1.0), 109 6.4 (1.2), 107 6.4 (1.1), 389 6.3 (1.2), 383
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TABLE 30 Participant characteristics at baseline in England by randomised group
Characteristic
Eligible 24-month recall Ineligible 24-month recall
Risk based 24 month 6 month Risk based 6 month
Randomised, n (%) 75 (100.0) 69 (100.0) 72 (100.0) 410 (100.0) 405 (100.0)
Baseline questionnaire
returned, n (%)
62 (82.7) 61 (88.4) 64 (88.9) 391 (95.4) 386 (95.3)
Age, mean (SD), n 43.9 (14.6), 75 39.8 (14.3), 69 40.0 (13.1), 72 49.8 (14.6), 410 50.7 (16.1), 405
Female participants, n (%) 45 (60.0) 40 (58.0) 43 (59.7) 236 (57.6) 221 (54.6)
Regular smokers, n (%) 9 (12.0) 7 (10.1) 12 (16.7) 53 (12.9) 65 (16.0)
Time since previous visit to dentist, n (%)
< 1 year 54 (72.0) 47 (68.1) 51 (70.8) 342 (83.4) 345 (85.2)
1–2 years 7 (9.3) 10 (14.5) 9 (12.5) 41 (10.0) 35 (8.6)
> 2 years – 4 (5.8) 2 (2.8) 4 (1.0) –
Patient status, n (%)
NHS 53 (70.7) 48 (69.6) 54 (75.0) 328 (80.0) 330 (81.5)
Private 2 (2.7) 5 (7.2) 2 (2.8) 17 (4.1) 15 (3.7)
Combination 5 (6.7) 4 (5.8) 4 (5.6) 34 (8.3) 24 (5.9)
Type of toothbrush, n (%)
Manual 39 (52.0) 47 (68.1) 44 (61.1) 238 (58.0) 244 (60.2)
Electric 22 (29.3) 13 (18.8) 20 (27.8) 151 (36.8) 136 (33.6)
Regular attender:
self-report, n (%)
52 (69.3) 49 (71.0) 54 (75.0) 340 (82.9) 348 (85.9)
Difficulty travelling to
dentist, mean (SD), n
6.3 (1.2), 61 6.1 (1.6), 61 6.3 (1.2), 64 6.3 (1.3), 388 6.3 (1.2),3 78
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TABLE 31 Participant characteristics at baseline in Northern Ireland by randomised group
Characteristic
Eligible 24-month recall Ineligible 24-month recall
Risk-based 24 month 6 month Risk based 6 month
Randomised, n (%) 31 (100.0) 30 (100.0) 27 (100.0) 32 (100.0) 33 (100.0)
Baseline questionnaire
returned, n (%)
17 (54.8) 16 (53.3) 15 (55.6) 28 (87.5) 30 (90.9)
Age, mean (SD), n 45.2 (18.3), 31 42.4 (14.5), 30 39.7 (14.6), 27 46.7 (17.8), 32 44.8 (16.6), 33
Female participants, n (%) 13 (41.9) 9 (30.0) 12 (44.4) 17 (53.1) 22 (66.7)
Regular smokers, n (%) 4 (12.9) 2 (6.7) 3 (11.1) 4 (12.5) 5 (15.2)
Time since previous visit to dentist, n (%)
< 1 year 15 (48.4) 14 (46.7) 14 (51.9) 25 (78.1) 30 (90.9)
1–2 years 2 (6.5) 1 (3.3) – 3 (9.4) –
> 2 years – – 1 (3.7) – –
Patient status, n (%)
NHS 10 (32.3) 9 (30.0) 8 (29.6) 20 (62.5) 22 (66.7)
Private 4 (12.9) 2 (6.7) 3 (11.1) 4 (12.5) 4 (12.1)
Combination 3 (9.7) 2 (6.7) 4 (14.8) 3 (9.4) 3 (9.1)
Type of toothbrush, n (%)
Manual 10 (32.3) 8 (26.7) 9 (33.3) 19 (59.4) 18 (54.5)
Electric 7 (22.6) 8 (26.7) 6 (22.2) 9 (28.1) 12 (36.4)
Regular attender:
self-report, n (%)
14 (45.2) 12 (40.0) 13 (48.1) 27 (84.4) 28 (84.8)
Difficulty travelling to
dentist, mean (SD), n
6.0 (1.3), 17 6.9 (0.3), 16 6.5 (1.2), 15 6.2 (1.5), 28 6.4 (1.1), 30
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TABLE 32 Participants’ oral health-related behaviour and knowledge at baseline in Scotland by randomised group
Oral health-related behaviour or
knowledge
Eligible 24-month recall Ineligible 24-month recall
Risk based
(N= 111)
24 month
(N= 117)
6 month
(N= 116)
Risk based
(N= 419)
6 month
(N= 425)
Frequency of brushing, n (%)
Twice a day 66 (59.5) 75 (64.1) 76 (65.5) 272 (64.9) 270 (63.5)
More than twice a day 14 (12.6) 9 (7.7) 6 (5.2) 42 (10.0) 43 (10.1)
How often should you be brushing? n (%)
Twice a day 81 (73.0) 85 (72.6) 89 (76.7) 271 (64.7) 281 (66.1)
More than twice a day 19 (17.1) 20 (17.1) 18 (15.5) 109 (26.0) 95 (22.4)
Duration of brushing, n (%)
2 minutes 49 (44.1) 58 (49.6) 49 (42.2) 183 (43.7) 178 (41.9)
> 2 minutes 16 (14.4) 16 (13.7) 19 (16.4) 71 (16.9) 61 (14.4)
How long should you brush for? n (%)
2 minutes 68 (61.3) 66 (56.4) 70 (60.3) 242 (57.8) 246 (57.9)
> 2 minutes 24 (21.6) 29 (24.8) 29 (25.0) 109 (26.0) 95 (22.4)
Spit not rinse after brushing, n (%) 51 (45.9) 44 (37.6) 47 (40.5) 140 (33.4) 126 (29.6)
Should spit not rinse after brushing, n (%) 59 (53.2) 59 (50.4) 57 (49.1) 161 (38.4) 154 (36.2)
TABLE 33 Participants’ oral health-related behaviour and knowledge at baseline in England by randomised group
Oral health-related behaviour or
knowledge
Eligible 24-month recall Ineligible 24-month recall
Risk based
(N= 75)
24 month
(N= 69)
6 month
(N= 72)
Risk based
(N= 410)
6 month
(N= 405)
Frequency of brushing, n (%)
Twice a day 45 (60.0) 40 (58.0) 48 (66.7) 271 (66.1) 294 (72.6)
More than twice a day 8 (10.7) 5 (7.2) 1 (1.4) 39 (9.5) 34 (8.4)
How often should you be brushing? n (%)
Twice a day 49 (65.3) 56 (81.2) 54 (75.0) 312 (76.1) 304 (75.1)
More than twice a day 11 (14.7) 5 (7.2) 7 (9.7) 65 (15.9) 66 (16.3)
Duration of brushing, n (%)
2 minutes 32 (42.7) 34 (49.3) 24 (33.3) 164 (40.0) 191 (47.2)
> 2 minutes 8 (10.7) 9 (13.0) 13 (18.1) 91 (22.2) 67 (16.5)
How long should you brush for? n (%)
2 minutes 42 (56.0) 42 (60.9) 45 (62.5) 222 (54.1) 226 (55.8)
> 2 minutes 14 (18.7) 12 (17.4) 13 (18.1) 114 (27.8) 99 (24.4)
Spit not rinse after brushing, n (%) 8 (10.7) 6 (8.7) 13 (18.1) 59 (14.4) 49 (12.1)
Should spit not rinse after brushing, n (%) 8 (10.7) 9 (13.0) 14 (19.4) 75 (18.3) 74 (18.3)
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TABLE 34 Participants’ oral health-related behaviour and knowledge at baseline in Northern Ireland by randomised group
Oral health-related behaviour
or knowledge
Eligible 24-month recall Ineligible 24-month recall
Risk based
(N= 31)
24 month
(N= 30)
6 month
(N= 27)
Risk based
(N= 32)
6 month
(N= 33)
Frequency of brushing, n (%)
Twice a day 12 (38.7) 13 (43.3) 8 (29.6) 17 (53.1) 23 (69.7)
More than twice a day 1 (3.2) 1 (3.3) 1 (3.7) 1 (3.1) 3 (9.1)
How often should you be brushing? n (%)
Twice a day 14 (45.2) 14 (46.7) 13 (48.1) 25 (78.1) 18 (54.5)
More than twice a day 1 (3.2) 2 (6.7) 0 (0) 3 (9.4) 12 (36.4)
Duration of brushing, n (%)
2 minutes 6 (19.4) 7 (23.3) 6 (22.2) 15 (46.9) 14 (42.4)
> 2 minutes 2 (6.5) 4 (13.3) 4 (14.8) 1 (3.1) 4 (12.1)
How long should you brush for? n (%)
2 minutes 7 (22.6) 9 (30.0) 10 (37.0) 18 (56.3) 17 (51.5)
> 2 minutes 3 (9.7) 4 (13.3) 3 (11.1) 6 (18.8) 9 (27.3)
Spit not rinse after brushing,
n (%)
5 (16.1) 3 (10.0) 4 (14.8) 14 (43.8) 15 (45.5)
Should spit not rinse after
brushing, n (%)
6 (19.4) 5 (16.7) 4 (14.8) 14 (43.8) 18 (54.5)
TABLE 35 Patient-reported outcomes at baseline in Scotland by randomised group
Patient-reported outcomes
Eligible 24-month recall, mean (SD),
count unless otherwise stated
Ineligible 24-month recall,
mean (SD), count unless
otherwise stated
Risk based
(n= 111)
24 month
(n= 117)
6 month
(n= 116)
Risk based
(n= 419)
6 month
(n= 425)
Baseline questionnaire returned 102 (91.9) 109 (93.2) 108 (93.1) 391 (93.3) 387 (91.1)
Attitude 4.2 (0.8), 101 4.3 (0.9), 109 4.2 (0.7), 108 4.1 (0.9), 388 4.1 (0.9), 383
PBC 5.3 (1.3), 100 5.2 (1.4), 109 5.1 (1.4), 107 5.0 (1.5), 362 5.1 (1.4), 357
Satisfaction 5.1 (0.8), 99 5.2 (0.7), 107 5.1 (0.7), 107 5.2 (0.6), 310 5.2 (0.7), 313
Anxiety 10.0 (4.4), 98 10.4 (4.4), 109 10.4 (4.8), 107 10.1 (4.6), 387 9.9 (4.6), 384
OHIP-14 4.4 (7.4), 99 5.5 (7.0), 107 4.5 (5.5), 104 5.5 (6.4), 374 5.9 (7.3), 375
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Description of the intervention by country
TABLE 37 Patient-reported outcomes at baseline in Northern Ireland by randomised group
Patient-reported outcomes
Eligible 24-month recall, mean (SD),
count unless otherwise stated
Ineligible 24-month recall,
mean (SD), count unless
otherwise stated
Risk based
(n= 31)
24 month
(n= 30)
6 month
(n= 27)
Risk based
(n= 32)
6 month
(n= 33)
Baseline questionnaire returned 17 (54.8) 16 (53.3) 15 (55.6) 28 (87.5) 30 (90.9)
Attitude 4.0 (0.5), 16 3.8 (0.9), 16 3.9 (0.5), 15 3.9 (0.6), 28 3.8 (0.7), 30
PBC 5.2 (1.8), 16 4.7 (1.9), 16 5.0 (1.4), 15 4.6 (1.6), 28 4.7 (1.6), 30
Satisfaction 5.4 (0.6), 16 5.1 (0.9), 16 5.2 (0.6), 15 5.4 (0.6), 28 5.4 (0.5), 30
Anxiety 11.1 (6.3), 16 9.7 (5.2), 16 9.8 (5.1), 14 11.5 (4.4), 28 11.0 (4.7), 30
OHIP-14 4.8 (8.5), 16 2.1 (2.5), 16 6.0 (11.5), 15 5.3 (6.8), 28 6.1 (6.6), 29
TABLE 36 Patient-reported outcomes at baseline in England by randomised group
Patient-reported outcomes
Eligible 24-month recall, mean (SD),
count unless otherwise stated
Ineligible 24-month recall,
mean (SD), count unless
otherwise stated
Risk based
(n= 75)
24 month
(n= 69)
6 month
(n= 72)
Risk based
(n= 410)
6 month
(n= 405)
Baseline questionnaire returned 62 (82.7) 61 (88.4) 64 (88.9) 391 (95.4) 386 (95.3)
Attitude 4.2 (0.8), 61 4.3 (0.8), 61 4.0 (0.7), 64 4.0 (0.8), 390 4.0 (0.9), 382
PBC 5.3 (1.3), 59 5.3 (1.4), 61 5.1 (1.5), 64 5.0 (1.5), 388 5.1 (1.5), 382
Satisfaction 5.3 (0.8), 32 5.3 (0.8), 30 5.4 (0.7), 36 5.4 (0.6), 365 5.3 (0.6), 358
Anxiety 10.8 (4.5), 62 11.4 (4.2), 61 11.0 (3.7), 64 10.1 (4.5), 386 10.2 (4.5), 384
OHIP-14 4.6 (6.0), 60 4.1 (5.9), 60 3.9 (5.1), 63 6.1 (7.5), 376 6.2 (8.1), 374
TABLE 38 Description of the intervention in Scotland: participants who attended clinical appointment
Number of check-ups, n (%)
Eligible for 24-month recall Ineligible for 24-month recall
Risk based
(N= 78)
24 month
(N= 76)
6 month
(N= 75)
Risk based
(N= 295)
6 month
(N= 308)
0 1 (1.3) 8 (9.8) 0 (0.0) 1 (0.3) 0 (0.0)
1 14 (17.7) 31 (37.8) 3 (3.9) 10 (3.3) 4 (1.3)
2 23 (29.1) 11 (13.4) 5 (6.5) 37 (12.3) 23 (7.3)
3 or more 40 (50.6) 26 (31.7) 67 (87.0) 247 (82.3) 281 (89.8)
Missing, n (%) 1 (1.3) 6 (7.3) 2 (2.6) 5 (1.7) 5 (1.6)
Number of check-ups,
mean (SD), n
3.0 (1.8), 78 2.3 (2.1), 76 4.3 (1.5), 75 3.9 (1.5), 295 4.4 (1.5), 308
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TABLE 39 Description of the intervention in England: participants who attended clinical appointment
Number of check-ups, n (%)
Eligible for 24-month recall Ineligible for 24-month recall
Risk based
(N= 45)
24 month
(N= 37)
6 month
(N= 266)
Risk based
(N= 266)
6 month
(N= 249)
1 1 (2.0) 11 (27.5) 3 (6.5) 4 (1.4) 3 (1.1)
2 2 (4.0) 9 (22.5) 4 (8.7) 7 (2.5) 7 (2.6)
3 or more 42 (84.0) 17 (42.5) 35 (76.1) 255 (89.8) 239 (89.5)
Missing 5 (10.0) 3 (7.5) 4 (8.7) 18 (6.3) 18 (6.7)
Number of check-ups
mean (SD), n
4.5 (1.8), 45 3.1 (2.6), 37 6.5 (5.9), 42 6.2 (2.4), 266 6.5 (2.0), 249
TABLE 40 Description of the intervention in Northern Ireland: participants who attended clinical appointment
Number of check-ups, n (%)
Eligible for 24-month recall Ineligible for 24-month recall
Risk based
(N= 14)
24 month
(N= 15)
6 month
(N= 11)
Risk based
(N= 21)
6 month
(N= 21)
1 1 (2.0) 11 (27.5) 3 (6.5) 4 (1.4) 3 (1.1)
2 2 (4.0) 9 (22.5) 4 (8.7) 7 (2.5) 7 (2.6)
3 or more 42 (84.0) 17 (42.5) 35 (76.1) 255 (89.8) 239 (89.5)
Missing 5 (10.0) 3 (7.5) 4 (8.7) 18 (6.3) 18 (6.7)
Number of check-ups
mean (SD), n
4.5 (1.8), 14 2.1 (1.5), 15 5.4 (2.2), 11 5.2 (1.5), 21 6.6 (1.2), 21
DOI: 10.3310/hta24600 Health Technology Assessment 2020 Vol. 24 No. 60
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Clarkson et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
119
Follow-up demographic characteristics
TABLE 41 Demographic characteristics year 1
Characteristic
Eligible for 24-month recall Ineligible for 24-month recall
Risk based 24 month 6 month Risk based 6 month
Regular smokers, n (%) 19 (13.1) 16 (10.3) 17 (11.2) 109 (17.1) 98 (15.3)
Missing 1 (0.7) 1 (0.6) 1 (0.7) 5 (0.8) 1 (0.2)
Time since previous visit to dentist, n (%)
< 1 year 122 (84.1) 97 (62.6) 143 (94.1) 600 (94.0) 629 (98.3)
1–2 years 21 (14.5) 56 (36.1) 8 (5.3) 31 (4.9) 9 (1.4)
Missing 2 (1.4) 2 (1.3) 1 (0.7) 7 (1.1) 2 (0.3)
Patient status, n (%)
NHS 69 (47.6) 60 (38.7) 91 (59.9) 410 (64.3) 431 (67.3)
Private 5 (3.4) 3 (1.9) 2 (1.3) 15 (2.4) 11 (1.7)
Combination 8 (5.5) 9 (5.8) 10 (6.6) 61 (9.6) 65 (10.2)
Missing 63 (43.4) 83 (53.5) 49 (32.2) 152 (23.8) 133 (20.8)
Type of toothbrush, n (%)
Manual 88 (60.7) 99 (63.9) 89 (58.6) 348 (54.5) 383 (59.8)
Electric 55 (37.9) 54 (34.8) 58 (38.2) 268 (42.0) 240 (37.5)
Toothbrush not used – – 1 (0.7) – –
Both 1 (0.7) 1 (0.6) 3 (2.0) 16 (2.5) 14 (2.2)
Missing 1 (0.7) 1 (0.6) 1 (0.7) 6 (0.9) 3 (0.5)
Regular attender: self-report,
n (%)
132 (91.0) 131 (84.5) 142 (93.4) 601 (94.2) 615 (96.1)
Missing 1 (0.7) 2 (1.3) 1 (0.7) 5 (0.8) 1 (0.2)
Difficulty travelling to dentist,
mean (SD), n
6.2 (1.3), 144 6.5 (1.0), 154 6.4 (1.2), 151 6.3 (1.2), 775 6.3 (1.3), 786
Replied to year 4 questionnaire,
n (%)
145 (100.0) 155 (100.0) 152 (100.0) 638 (100.0) 640 (100.0)
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TABLE 42 Demographic characteristics year 2
Characteristic
Eligible for 24-month recall Ineligible for 24-month recall
Risk based 24 month 6 month Risk based 6 month
Questionnaire returned, n (%) 135 (100.0) 144 (100.0) 142 (100.0) 610 (100.0) 619 (100.0)
Smoked in the last 12 months,
n (%)
12 (8.9) 16 (11.1) 20 (14.1) 96 (15.7) 76 (12.3)
Missing 1 (0.7) – – 6 (1.0) 3 (0.5)
Time since previous visit to dentist, n (%)
< 1 year 120 (88.9) 105 (72.9) 136 (95.8) 588 (96.4) 598 (96.6)
1–2 years 14 (10.4) 32 (22.2) 6 (4.2) 18 (3.0) 17 (2.7)
> 2 years – 6 (4.2) – 2 (0.3) 1 (0.2)
Missing 1 (0.7) 1 (0.7) – 2 (0.3) 3 (0.5)
Patient status, n (%)
NHS 84 (62.2) 73 (50.7) 89 (62.7) 415 (68.0) 425 (68.7)
Private 3 (2.2) 6 (4.2) 3 (2.1) 10 (1.6) 9 (1.5)
Combination 12 (8.9) 9 (6.3) 15 (10.6) 72 (11.8) 63 (10.2)
Missing 36 (26.7) 56 (38.9) 35 (24.6) 113 (18.5) 122 (19.7)
Type of toothbrush, n (%)
Manual 67 (49.6) 88 (61.1) 83 (58.5) 316 (51.8) 347 (56.1)
Electric 59 (43.7) 47 (32.6) 52 (36.6) 231 (37.9) 213 (34.4)
Toothbrush not used 1 (0.7) – – 1 (0.2) –
Toothbrush 7 (5.2) 8 (5.6) 7 (4.9) 57 (9.3) 56 (9.0)
Missing 1 (0.7) 1 (0.7) – 5 (0.8) 3 (0.5)
Regular attender: self-report,
n (%)
123 (91.1) 124 (86.1) 136 (95.8) 584 (95.7) 588 (95.0)
Missing 1 (0.7) – – 2 (0.3) 3 (0.5)
Difficulty travelling to dentist
mean (SD), n
6.4 (1.2), 134 6.5 (0.9), 143 6.3 (1.2), 141 6.3 (1.2), 742 6.3 (1.2), 751
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TABLE 43 Demographic characteristics year 3
Characteristic
Eligible for 24-month recall Ineligible for 24-month recall
Risk based 24 month 6 month Risk based 6 month
Questionnaire returned, n (%) 134 (100.0) 131 (100.0) 134 (100.0) 571 (100.0) 584 (100.0)
Smoked in the last 12 months,
n (%)
13 (9.7) 14 (10.7) 13 (9.7) 72 (12.6) 64 (11.0)
Missing 1 (0.7) – 1 (0.7) 4 (0.7) 2 (0.3)
Time since previous visit to dentist, n (%)
< 1 year 117 (87.3) 92 (70.2) 123 (91.8) 545 (95.4) 569 (97.4)
1–2 years 14 (10.4) 36 (27.5) 8 (6.0) 21 (3.7) 14 (2.4)
> 2 years 2 (1.5) 3 (2.3) 1 (0.7) 3 (0.5) –
Missing 1 (0.7) – 2 (1.5) 2 (0.4) 1 (0.2)
Patient status, n (%)
NHS 90 (67.2) 81 (61.8) 96 (71.6) 407 (71.3) 432 (74.0)
Private 4 (3.0) 4 (3.1) 4 (3.0) 10 (1.8) 19 (3.3)
Combination 18 (13.4) 14 (10.7) 17 (12.7) 65 (11.4) 62 (10.6)
Missing 22 (16.4) 32 (24.4) 17 (12.7) 89 (15.6) 71 (12.2)
Type of toothbrush, n (%)
Manual 68 (50.7) 77 (58.8) 66 (49.3) 304 (53.2) 316 (54.1)
Electric 58 (43.3) 46 (35.1) 58 (43.3) 227 (39.8) 234 (40.1)
Toothbrush not used 1 (0.7) – – – 1 (0.2)
Both 7 (5.2) 6 (4.6) 9 (6.7) 38 (6.7) 33 (5.7)
Missing – 2 (1.5) 1 (0.7) 2 (0.4) –
Regular attender: self-report,
n (%)
119 (88.8) 108 (82.4) 129 (96.3) 543 (95.1) 558 (95.5)
Missing – 1 (0.8) 1 (0.7) 3 (0.5) 3 (0.5)
Difficulty travelling to dentist
mean (SD), n
6.4 (1.2), 134 6.6 (0.9), 131 6.3 (1.2), 133 6.4 (1.1), 703 6.3 (1.2), 715
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Follow-up behaviour and knowledge related to oral health
TABLE 44 Behaviours/knowledge year 1
Behaviours/knowledge
Eligible for 24-month recall Ineligible for 24-month recall
Risk based 24 month 6 month Risk based 6 month
Responded 145 (100.0) 155 (100.0) 152 (100.0) 638 (100.0) 640 (100.0)
Frequency of brushing
Once a day 20 (13.8) 32 (20.6) 36 (23.7) 112 (17.6) 100 (15.6)
Twice a day 99 (68.3) 110 (71.0) 104 (68.4) 449 (70.4) 461 (72.0)
More than twice a day 22 (15.2) 11 (7.1) 7 (4.6) 69 (10.8) 63 (9.8)
Missing 2 (1.4) 1 (0.6) 3 (2.0) 4 (0.6) 10 (1.6)
How often should you be brushing?
Once a day 1 (0.7) 3 (1.9) 3 (2.0) 10 (1.6) 5 (0.8)
Twice a day 111 (76.6) 125 (80.6) 118 (77.6) 481 (75.4) 483 (75.5)
More than twice a day 31 (21.4) 25 (16.1) 28 (18.4) 138 (21.6) 143 (22.3)
Missing 2 (1.4) 2 (1.3) 2 (1.3) 9 (1.4) 9 (1.4)
Duration of brushing
1–2 minutes 44 (30.3) 48 (31.0) 48 (31.6) 195 (30.6) 208 (32.5)
2 minutes 73 (50.3) 75 (48.4) 71 (46.7) 304 (47.6) 315 (49.2)
> 2 minutes 19 (13.1) 24 (15.5) 23 (15.1) 112 (17.6) 86 (13.4)
Missing 2 (1.4) 3 (1.9) 3 (2.0) 6 (0.9) 8 (1.3)
How long should you brush for?
1–2 minutes 15 (10.3) 12 (7.7) 15 (9.9) 65 (10.2) 69 (10.8)
2 minutes 97 (66.9) 104 (67.1) 102 (67.1) 394 (61.8) 401 (62.7)
> 2 minutes 29 (20.0) 36 (23.2) 32 (21.1) 164 (25.7) 156 (24.4)
Missing 3 (2.1) 2 (1.3) 2 (1.3) 10 (1.6) 11 (1.7)
After brushing
Rinse with water 56 (38.6) 78 (50.3) 69 (45.4) 306 (48.0) 308 (48.1)
Rinse with mouthwash 20 (13.8) 18 (11.6) 18 (11.8) 98 (15.4) 98 (15.3)
Spit not rinse 67 (46.2) 57 (36.8) 61 (40.1) 224 (35.1) 222 (34.7)
Missing 2 (1.4) 2 (1.3) 4 (2.6) 10 (1.6) 12 (1.9)
After brushing should you . . . ?
Rinse with water 29 (20.0) 40 (25.8) 39 (25.7) 200 (31.3) 210 (32.8)
Rinse with mouthwash 33 (22.8) 35 (22.6) 30 (19.7) 145 (22.7) 157 (24.5)
Spit not rinse 79 (54.5) 76 (49.0) 79 (52.0) 276 (43.3) 261 (40.8)
Missing 4 (2.8) 4 (2.6) 4 (2.6) 17 (2.7) 12 (1.9)
continued
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TABLE 44 Behaviours/knowledge year 1 (continued )
Behaviours/knowledge
Eligible for 24-month recall Ineligible for 24-month recall
Risk based 24 month 6 month Risk based 6 month
Frequency of flossing
At least once a week 33 (22.8) 20 (12.9) 27 (17.8) 128 (20.1) 128 (20.0)
At least once a month 13 (9.0) 17 (11.0) 17 (11.2) 86 (13.5) 76 (11.9)
Never 35 (24.1) 51 (32.9) 48 (31.6) 188 (29.5) 176 (27.5)
Missing 41 (28.3) 42 (27.1) 40 (26.3) 114 (17.9) 119 (18.6)
How often should you floss?
At least once a week 8 (5.5) 6 (3.9) 5 (3.3) 24 (3.8) 14 (2.2)
At least once a month 15 (10.3) 29 (18.7) 29 (19.1) 103 (16.1) 88 (13.8)
Never 75 (51.7) 69 (44.5) 68 (44.7) 353 (55.3) 374 (58.4)
Missing 44 (30.3) 44 (28.4) 45 (29.6) 137 (21.5) 139 (21.7)
Frequency of using interdental brushes
At least once a week 10 (6.9) 7 (4.5) 8 (5.3) 73 (11.4) 60 (9.4)
At least once a month 4 (2.8) 8 (5.2) 14 (9.2) 49 (7.7) 43 (6.7)
Never 78 (53.8) 86 (55.5) 73 (48.0) 291 (45.6) 308 (48.1)
Missing 45 (31.0) 41 (26.5) 46 (30.3) 134 (21.0) 133 (20.8)
How often should you use interdental brushes?
At least once a week 5 (3.4) 10 (6.5) 3 (2.0) 29 (4.5) 24 (3.8)
At least once a month 18 (12.4) 14 (9.0) 18 (11.8) 79 (12.4) 61 (9.5)
Never 19 (13.1) 17 (11.0) 17 (11.2) 95 (14.9) 101 (15.8)
Missing 98 (67.6) 104 (67.1) 106 (69.7) 401 (62.9) 411 (64.2)
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TABLE 45 Behaviours/knowledge year 2
Behaviours/knowledge
Eligible for 24-month recall Ineligible for 24-month recall
Risk based 24 month 6 month Risk based 6 month
Responded 135 (100.0) 144 (100.0) 142 (100.0) 610 (100.0) 619 (100.0)
Frequency of brushing
Once a day 24 (17.8) 37 (25.7) 27 (19.0) 103 (16.9) 99 (16.0)
Twice a day 95 (70.4) 96 (66.7) 105 (73.9) 443 (72.6) 443 (71.6)
More than twice a day 15 (11.1) 10 (6.9) 9 (6.3) 55 (9.0) 64 (10.3)
Missing 1 (0.7) 0 (0.0) 0 (0.0) 3 (0.5) 5 (0.8)
How often should you be brushing?
Once a day 1 (0.7) 1 (0.7) 1 (0.7) 11 (1.8) 8 (1.3)
Twice a day 106 (78.5) 120 (83.3) 118 (83.1) 455 (74.6) 471 (76.1)
More than twice a day 27 (20.0) 22 (15.3) 23 (16.2) 137 (22.5) 130 (21.0)
Missing 1 (0.7) 1 (0.7) 0 (0.0) 7 (1.1) 9 (1.5)
Duration of brushing
1–2 minutes 41 (30.4) 45 (31.3) 43 (30.3) 178 (29.2) 210 (33.9)
2 minutes 72 (53.3) 74 (51.4) 73 (51.4) 323 (53.0) 304 (49.1)
> 2 minutes 16 (11.9) 22 (15.3) 22 (15.5) 88 (14.4) 83 (13.4)
Missing 1 (0.7) 0 (0.0) 1 (0.7) 3 (0.5) 2 (0.3)
How long should you brush for?
1–2 minutes 9 (6.7) 13 (9.0) 10 (7.0) 59 (9.7) 68 (11.0)
2 minutes 93 (68.9) 105 (72.9) 98 (69.0) 401 (65.7) 409 (66.1)
> 2 minutes 31 (23.0) 24 (16.7) 34 (23.9) 138 (22.6) 135 (21.8)
Missing 1 (0.7) 2 (1.4) 0 (0.0) 10 (1.6) 6 (1.0)
After brushing
Rinse with water 49 (36.3) 64 (44.4) 46 (32.4) 264 (43.3) 275 (44.4)
Rinse with mouthwash 19 (14.1) 15 (10.4) 19 (13.4) 100 (16.4) 90 (14.5)
Spit not rinse 66 (48.9) 65 (45.1) 74 (52.1) 239 (39.2) 247 (39.9)
Missing 1 (0.7) 0 (0.0) 3 (2.1) 7 (1.1) 7 (1.1)
After brushing should you . . .?
Rinse with water 19 (14.1) 33 (22.9) 31 (21.8) 159 (26.1) 171 (27.6)
Rinse with mouthwash 27 (20.0) 27 (18.8) 29 (20.4) 143 (23.4) 130 (21.0)
Spit not rinse 85 (63.0) 83 (57.6) 78 (54.9) 292 (47.9) 297 (48.0)
Missing 4 (3.0) 1 (0.7) 4 (2.8) 16 (2.6) 21 (3.4)
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TABLE 46 Behaviours/knowledge year 3
Behaviours/knowledge
Eligible for 24-month recall Ineligible for 24-month recall
Risk based 24 month 6 month Risk based 6 month
Responded 134 (100.0) 131 (100.0) 134 (100.0) 571 (100.0) 584 (100.0)
Frequency of brushing
Once a day 22 (16.4) 29 (22.1) 29 (21.6) 98 (17.2) 88 (15.1)
Twice a day 100 (74.6) 91 (69.5) 99 (73.9) 414 (72.5) 438 (75.0)
More than twice a day 11 (8.2) 10 (7.6) 5 (3.7) 53 (9.3) 50 (8.6)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.4) 2 (0.3)
How often should you be brushing?
Once a day 1 (0.7) 1 (0.8) 1 (0.7) 6 (1.1) 9 (1.5)
Twice a day 111 (82.8) 108 (82.4) 110 (82.1) 448 (78.5) 457 (78.3)
More than twice a day 22 (16.4) 22 (16.8) 22 (16.4) 112 (19.6) 115 (19.7)
Missing 0 (0.0) 0 (0.0) 1 (0.7) 5 (0.9) 2 (0.3)
Duration of brushing
1–2 minutes 44 (32.8) 33 (25.2) 42 (31.3) 175 (30.6) 187 (32.0)
2 minutes 68 (50.7) 76 (58.0) 68 (50.7) 296 (51.8) 316 (54.1)
> 2 minutes 17 (12.7) 18 (13.7) 23 (17.2) 83 (14.5) 65 (11.1)
Missing 0 (0.0) 1 (0.8) 1 (0.7) 4 (0.7) 2 (0.3)
How long should you brush for?
1–2 minutes 14 (10.4) 6 (4.6) 4 (3.0) 59 (10.3) 73 (12.5)
2 minutes 93 (69.4) 95 (72.5) 100 (74.6) 384 (67.3) 396 (67.8)
> 2 minutes 26 (19.4) 30 (22.9) 29 (21.6) 121 (21.2) 111 (19.0)
Missing 0 (0.0) 0 (0.0) 1 (0.7) 4 (0.7) 4 (0.7)
After brushing
Rinse with water 38 (28.4) 59 (45.0) 44 (32.8) 236 (41.3) 263 (45.0)
Rinse with mouthwash 21 (15.7) 13 (9.9) 13 (9.7) 76 (13.3) 72 (12.3)
Spit not rinse 74 (55.2) 59 (45.0) 75 (56.0) 254 (44.5) 243 (41.6)
Rinse with both water and
mouthwash
1 (0.7) 0 (0.0) 2 (1.5) 2 (0.4) 1 (0.2)
Missing 0 (0.0) 0 (0.0) 0 (0.0) 3 (0.5) 5 (0.9)
After brushing should you . . .?
Rinse with water 22 (16.4) 34 (26.0) 33 (24.6) 140 (24.5) 162 (27.7)
Rinse with mouthwash 26 (19.4) 21 (16.0) 20 (14.9) 112 (19.6) 121 (20.7)
Spit not rinse 84 (62.7) 76 (58.0) 81 (60.4) 309 (54.1) 289 (49.5)
Missing 2 (1.5) 0 (0.0) 0 (0.0) 10 (1.8) 12 (2.1)
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TABLE 47 Behaviours/knowledge year 4
Behaviours/knowledge
Eligible for 24-month recall Ineligible for 24-month recall
Risk based 24 month 6 month Risk based 6 month
Responded 151 (100.0) 153 (100.0) 156 (100.0) 650 (100.0) 655 (100.0)
Frequency of brushing
Once a day 27 (17.9) 31 (20.3) 32 (20.5) 112 (17.2) 94 (14.4)
Twice a day 103 (68.2) 103 (67.3) 112 (71.8) 463 (71.2) 491 (75.0)
More than twice a day 21 (13.9) 16 (10.5) 8 (5.1) 66 (10.2) 62 (9.5)
Missing 0 (0) 0 (0) 1 (0.6) 4 (0.6) 2 (0.3)
How often should you be brushing?
Once a day 3 (2.0) 3 (2.0) 1 (0.6) 6 (0.9) 6 (0.9)
Twice a day 121 (80.1) 123 (80.4) 125 (80.1) 512 (78.8) 515 (78.6)
More than twice a day 26 (17.2) 27 (17.6) 27 (17.3) 129 (19.8) 128 (19.5)
Missing 1 (0.7) 0 (0) 2 (1.3) 3 (0.5) 4 (0.6)
Duration of brushing
1–2 minutes 52 (34.4) 51 (33.3) 44 (28.2) 192 (29.5) 210 (32.1)
2 minutes 79 (52.3) 76 (49.7) 82 (52.6) 318 (48.9) 341 (52.1)
> 2 minutes 17 (11.3) 23 (15.0) 28 (17.9) 114 (17.5) 78 (11.9)
Missing 0 (0) 1 (0.7) 1 (0.6) 5 (0.8) 4 (0.6)
How long should you brush for?
1–2 minutes 19 (12.6) 9 (5.9) 10 (6.4) 66 (10.2) 56 (8.5)
2 minutes 104 (68.9) 113 (73.9) 106 (67.9) 432 (66.5) 452 (69.0)
> 2 minutes 24 (15.9) 30 (19.6) 39 (25.0) 142 (21.8) 137 (20.9)
Missing 3 (2.0) 1 (0.7) 1 (0.6) 8 (1.2) 6 (0.9)
After brushing
Rinse with water 49 (32.5) 63 (41.2) 55 (35.3) 261 (40.2) 264 (40.3)
Rinse with mouthwash 22 (14.6) 13 (8.5) 11 (7.1) 91 (14.0) 76 (11.6)
Spit not rinse 80 (53.0) 74 (48.4) 87 (55.8) 276 (42.5) 300 (45.8)
Rinse with both water and
mouthwash
0 (0) 0 (0) 2 (1.3) 13 (2.0) 12 (1.8)
Missing 0 (0) 3 (2.0) 1 (0.6) 9 (1.4) 3 (0.5)
After brushing should you . . .?
Rinse with water 30 (19.9) 29 (19.0) 31 (19.9) 158 (24.3) 166 (25.3)
Rinse with mouthwash 27 (17.9) 26 (17.0) 23 (14.7) 124 (19.1) 119 (18.2)
Spit not rinse 91 (60.3) 92 (60.1) 98 (62.8) 344 (52.9) 346 (52.8)
Rinse with both water and
mouthwash
0 (0) 2 (1.3) 1 (0.6) 6 (0.9) 6 (0.9)
Missing 3 (2.0) 4 (2.6) 3 (1.9) 18 (2.8) 18 (2.7)
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Clinical outcomes
The following tables and graphs present the clinical outcomes at 4 years for the overall sample.
TABLE 48 Clinical outcomes at 4 years post randomisation for the whole sample
Clinical outcome, mean (SD), n Risk based 6 month
Percentage of sites bleeding 33.8 (21.6), 741 33.3 (22.0), 731
Calculus 36.7 (27.5), 746 37.9 (27.3), 733
Mean pocket depth (mm) 2.2 (0.5), 736 2.2 (0.4), 727
Number of teeth 23.9 (4.7), 749 23.5 (5.0), 737
Caries category, n (%)
Sound surfaces 4 (0.5) 8 (1.1)
Initial lesions 122 (16.3) 140 (19.0)
Moderate lesions 491 (65.6) 463 (62.8)
Extensive caries or treatment needed 130 (17.4) 120 (16.3)
Missing 2 (0.3) 6 (0.8)
Maximum caries score per mouth, n (%)
1 4 (0.5) 10 (1.4)
2 118 (15.8) 130 (17.6)
3 167 (22.3) 171 (23.2)
4 324 (43.3) 292 (39.6)
5 110 (14.7) 102 (13.8)
6 20 (2.7) 18 (2.4)
Missing 2 (0.3) 6 (0.8)
Root caries, n (%)
Yes 146 (19.5) 154 (20.9)
No 509 (68.0) 481 (65.3)
Missing 94 (12.6) 102 (13.8)
Effect sizes adjusted for minimisation variables; linear mixed-effects model for continuous outcomes; ordinal logistic
mixed-effects model for caries category (effect size is odds ratio) and logistic mixed effects for root caries (effect size is
odds ratio).
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Clinical outcomes by country
Scotland
TABLE 49 Clinical data at 4 years: Scotland
Clinical outcome, mean (SD), n
Eligible for 24-month recall Ineligible for 24-month recall
Risk based 24 month 6 month Risk based 6 month
Attended/randomised 79/111 82/117 77/116 300/419 313/425
Bleeding score 30.9 (18.0), 78 30.9 (19.9), 81 32.5 (20.8), 76 33.6 (22.9), 295 37.2 (22.8), 310
Calculus 40.3 (27.4), 78 45.9 (28.3), 82 43.8 (25.0), 76 32.2 (26.0), 299 36.0 (26.9), 312
Mean pocket depth (mm) 2.2 (0.5), 78 2.2 (0.4), 81 2.1 (0.4), 75 2.1 (0.4), 293 2.2 (0.4), 309
Number of teeth 23.6 (4.8), 79 22.8 (5.2), 82 24.0 (4.1), 77 23.5 (4.9), 300 22.7 (5.3), 313
Caries category, n (%)
Sound surfaces 0 (0.0) 0 (0.0) 0 (0.0) 3 (1.0) 1 (0.3)
Initial lesions 12 (15.2) 14 (17.1) 13 (16.9) 53 (17.7) 49 (15.7)
Moderate lesions 57 (72.2) 53 (64.6) 56 (72.7) 186 (62.0) 199 (63.6)
Extensive caries or treatment
needed
9 (11.4) 15 (18.3) 7 (9.1) 58 (19.3) 62 (19.8)
Missing 1 (1.3) 0 (0.0) 1 (1.3) 0 (0.0) 2 (0.6)
Root caries, n (%)
Yes 26 (18.2) 21 (15.2) 17 (12.6) 120 (19.8) 137 (22.8)
No 96 (67.1) 100 (72.5) 96 (71.1) 413 (68.2) 385 (64.0)
Missing 21 (14.7) 17 (12.3) 22 (16.3) 73 (12.0) 80 (13.3)
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England
TABLE 50 Clinical data at 4 years: England
Clinical outcome, mean (SD), n
Eligible for 24-month recall Ineligible for 24-month recall
Risk based 24 month 6 month Risk based 6 month
Attended/randomised 50/75 40/69 46/72 284/410 267/405
Percentage of sites bleeding 43.4 (18.0), 50 39.7 (19.6), 40 39.4 (22.8), 46 32.2 (21.4), 282 27.6 (20.1), 265
Calculus 26.1 (22.3), 50 25.5 (25.8), 40 27.9 (22.3), 45 42.7 (29.1), 283 40.4 (28.9), 266
Mean pocket depth (mm) 2.2 (0.4), 50 2.1 (0.2), 40 2.2 (0.5), 46 2.2 (0.5), 279 2.2 (0.5), 263
Number of teeth 25.5 (4.1), 50 25.5 (2.1), 40 25.8 (3.8), 46 24.3 (4.4), 284 23.8 (5.0), 267
Caries category, n (%)
Sound surfaces 1 (2.0) 0 (0.0) 0 (0.0) 0 (0.0) 7 (2.6)
Initial lesions 9 (18.0) 11 (27.5) 15 (32.6) 43 (15.1) 51 (19.1)
Moderate lesions 29 (58.0) 24 (60.0) 27 (58.7) 191 (67.3) 165 (61.8)
Extensive caries or treatment
needed
10 (20.0) 5 (12.5) 3 (6.5) 50 (17.6) 42 (15.7)
Missing 1 (2.0) 0 (0.0) 1 (2.2) 0 (0.0) 2 (0.7)
Root caries, n (%)
Yes 26 (18.2) 21 (15.2) 17 (12.6) 120 (19.8) 137 (22.8)
No 96 (67.1) 100 (72.5) 96 (71.1) 413 (68.2) 385 (64.0)
Missing 21 (14.7) 17 (12.3) 22 (16.3) 73 (12.0) 80 (13.3)
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Northern Ireland
Subgroup analyses
Interaction coefficients for bleeding
TABLE 51 Clinical data at 4 years: Northern Ireland
Clinical outcome, mean (SD), n
Eligible for 24-month recall Ineligible for 24-month recall
Risk based 24 month 6 month Risk based 6 month
Attended/randomised 14/31 16/30 12/27 22/32 22/33
Percentage of sites bleeding 34.1 (21.4), 14 39.0 (19.5), 16 40.5 (21.3), 12 46.6 (18.8), 22 33.5 (21.7), 22
Calculus 27.9 (21.4), 14 30.7 (21.6), 16 32.4 (23.0), 12 37.4 (22.2), 22 37.1 (26.3), 22
Mean pocket depth (mm) 2.1 (0.7), 14 1.9 (0.2), 16 2.0 (0.2), 12 2.0 (0.2), 22 2.0 (0.3), 22
Number of teeth 22.5 (6.4), 14 26.1 (2.0), 16 26.2 (2.8), 12 23.0 (4.0), 22 24.5 (3.4), 22
Caries category, n (%)
Sound surfaces 0 (0.0) 1 (6.3) 0 (0.0) 0 (0.0) 0 (0.0)
Initial lesions 1 (7.1) 3 (18.8) 5 (41.7) 4 (18.2) 7 (31.8)
Moderate lesions 12 (85.7) 10 (62.5) 4 (33.3) 16 (72.7) 12 (54.5)
Extensive caries or treatment
needed
1 (7.1) 2 (12.5) 3 (25.0) 2 (9.1) 3 (13.6)
Root caries, n (%)
Yes 26 (18.2) 21 (15.2) 17 (12.6) 120 (19.8) 137 (22.8)
No 96 (67.1) 100 (72.5) 96 (71.1) 413 (68.2) 385 (64.0)
Missing 21 (14.7) 17 (12.3) 22 (16.3) 73 (12.0) 80 (13.3)
TABLE 52 Coefficient for interaction in subgroup for bleeding
Characteristic
Eligible for 24-month recall (24 month vs. 6 month),
mean difference (99% CI); p-value
Overall (risk based vs. 6 month),
mean difference (99% CI); p-value
Age
< 45 years 3.50 (–4.59 to 11.58); 0.27 0.53 (–3.80 to 4.86); 0.75
45–64 years –9.23 (–21.01 to 2.55); 0.04 –1.18 (–6.89 to 4.52); 0.59
≥ 65 years –0.22 (–19.86 to 19.43); 0.98 4.47 (–3.28 to 12.23); 0.14
Country
Scotland –2.02 (–9.37 to 5.33); 0.48 –3.36 (–6.90 to 0.18); 0.01
England 3.47 (–9.00 to 15.94); 0.47 8.34 (3.11 to 13.57); < 0.001
Northern Ireland 1.94 (–17.16 to 21.05); 0.79 9.63 (–2.53 to 21.79); 0.04
Do you pay for treatment?
Yes –0.90 (–10.69 to 8.88); 0.81 –1.35 (–6.06 to 3.35); 0.46
No 0.35 (–11.69 to 12.39); 0.94 2.96 (–2.65 to 8.57); 0.17
A positive mean difference favours the 6-month-based recall group.
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Interaction coefficients for caries
Patient-reported outcomes
Oral Health Impact Profile-14
TABLE 53 Coefficient for interaction in subgroup for caries
Characteristic
Eligible for 24-month recall
(24 month vs. 6 month),
odds ratio (99% CI); p-value
Overall (risk based vs 6 month),
odds ratio (99% CI); p-value
Age
< 45 years 1.14 (0.37 to 3.53); 0.77 1.57 (0.89 to 2.79); 0.04
45–64 years 0.91 (0.16 to 5.07); 0.89 0.70 (0.32 to 1.51); 0.23
≥ 65 years 4.27 (0.20 to 88.96); 0.22 0.74 (0.24 to 2.28); 0.49
Country
Scotland 0.96 (0.30 to 3.02); 0.92 0.88 (0.53 to 1.45); 0.51
England 1.52 (0.26 to 8.87); 0.54 1.89 (0.91 to 3.91); 0.03
Northern Ireland 2.89 (0.21 to 39.89); 0.30 3.98 (0.76 to 20.69); 0.03
Do you pay for treatment?
Yes 1.23 (0.30 to 4.98); 0.71 1.53 (0.78 to 3.00); 0.11
No 1.04 (0.19 to 5.84); 0.95 0.77 (0.35 to 1.70); 0.39
An odds ratio > 1 favours the 6-month-based recall group.
TABLE 54 Oral Health Impact Profile-14 over the years in the trial
Time point
Eligible for 24-month recall, mean (SD), n Ineligible for 24-month recall, mean (SD), n
Risk based 24 month 6 month Risk based 6 month
Baseline 4.5 (7.0), 175 4.7 (6.4), 183 4.4 (6.1), 182 5.8 (6.9), 778 6.1 (7.7), 778
Year 1 3.7 (5.4), 141 4.4 (5.6), 152 4.8 (6.4), 145 5.6 (7.6), 617 5.4 (7.4), 623
Year 2 4.4 (5.7), 128 4.6 (6.4), 143 5.2 (7.1), 137 5.6 (7.4), 585 5.1 (7.3), 599
Year 3 3.9 (5.3), 131 4.6 (5.6), 129 4.1 (5.5), 129 5.4 (6.9), 551 5.7 (8.1), 566
Year 4 4.1 (5.7), 145 4.8 (6.4), 153 4.8 (6.2), 152 5.5 (6.8), 624 5.8 (8.3), 630
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Attitude and satisfaction with care
Anxiety
TABLE 55 Participants’ views over the years in the trial
Patient-reported outcome Time point
Eligible for 24-month recall, mean (SD), n
Ineligible for 24-month recall,
mean (SD), n
Risk based 24 month 6 month Risk based 6 month
Attitude Baseline 4.2 (0.8), 178 4.3 (0.9), 186 4.1 (0.7), 187 4.1 (0.9), 806 4.0 (0.9), 795
Year 1 4.4 (0.8), 143 4.2 (1.0), 154 4.2 (0.8), 150 4.1 (0.9), 635 4.1 (0.8), 635
Year 2 4.2 (0.8), 134 4.2 (0.9), 144 4.2 (0.8), 142 4.1 (0.9), 608 4.1 (0.8), 616
Year 3 4.2 (0.7), 134 4.2 (0.8), 131 4.0 (0.8), 134 4.1 (0.9), 570 4.0 (0.8), 583
Year 4 4.3 (0.9), 151 4.3 (0.9), 153 4.1 (0.8), 155 4.1 (0.9), 647 4.1 (0.8), 654
Satisfaction
with care
Baseline 5.2 (0.8), 147 5.2 (0.8), 153 5.2 (0.7), 158 5.3 (0.6), 703 5.3 (0.6), 701
Year 1 5.1 (0.7), 143 5.0 (0.8), 153 5.1 (0.8), 150 5.1 (0.7), 620 5.2 (0.7), 623
Year 2 5.1 (0.7), 134 4.9 (0.7), 144 5.1 (0.6), 142 5.2 (0.7), 609 5.2 (0.7), 616
Year 3 5.0 (0.7), 134 5.0 (0.7), 131 5.1 (0.7), 134 5.2 (0.6), 570 5.2 (0.7), 583
Year 4 5.2 (0.7), 151 5.0 (0.7), 153 5.1 (0.7), 155 5.3 (0.6), 647 5.2 (0.6), 654
TABLE 56 Anxiety over time by randomised group
Anxiety measure Time point
Eligible for 24-month recall, mean (SD), n
Ineligible for 24-month recall,
mean (SD), n
Risk based 24 month 6 month Risk based 6 month
Overall anxiety (score from
5 to 25), mean (SD), n
Baseline 10.4 (5), 176 10.7 (4), 186 10.5 (4), 185 10.2 (5), 801 10.1 (5), 798
Year 1 10.2 (4), 145 10.7 (5), 154 10.5 (4), 150 10.4 (4), 635 10.3 (4), 637
Year 2 10.1 (4), 133 10.5 (5), 144 10.4 (4), 142 10.3 (5), 608 10.3 (4), 617
Year 3 10.6 (5), 134 10.9 (5), 131 10.7 (4), 134 10.4 (5), 568 10.4 (5), 582
Year 4 10.5 (5), 150 10.9 (5), 153 11.0 (5), 155 10.3 (5), 645 10.5 (5), 649
High-anxiety patients
(score ≥ 19), n (%)
Baseline 12 (6.8) 12 (6.5) 13 (7.0) 53 (6.6) 53 (6.6)
Year 1 9 (6.2) 13 (8.4) 10 (6.7) 46 (7.2) 38 (6.0)
Year 2 7 (5.3) 12 (8.3) 10 (7.0) 42 (6.9) 40 (6.5)
Year 3 13 (9.7) 11 (8.4) 6 (4.5) 38 (6.7) 45 (7.7)
Year 4 9 (6.0) 12 (7.8) 11 (7.1) 40 (6.2) 46 (7.1)
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Dentist belief questionnaire
TABLE 57 Dentist beliefs at baseline, follow-up and change from baseline by whether or not they deemed at least one of
their patients eligible for 24-month recall
Dentist belief
Baseline, mean (SD), n Follow-up, mean (SD), n
Change follow-up–baseline,
mean (SD), n
Deemed at
least one
patient eligible
for 24-month
recall
Deemed all
ineligible for
24-month
recall
Deemed at
least one
patient eligible
for 24-month
recall
Deemed all
ineligible for
24-month
recall
Deemed at
least one
patient eligible
for 24-month
recall
Deemed all
ineligible for
24-month
recall
Attitude regarding a
24-month recall
3.7 (1.2), 40 4.3 (1.1), 6 4.4 (1.2), 43 4.4 (1.5), 6 0.7 (1.1), 40 0.1 (1.4), 6
Attitude regarding a
6-month recall
3.6 (1.0), 40 4.5 (0.5), 6 3.9 (1.2), 43 4.1 (0.6), 6 0.3 (0.9), 40 –0.4 (0.7), 6
General attitude 4.5 (1.1), 40 4.7 (0.7), 6 3.9 (1.1), 43 4.6 (1.0), 6 –0.6 (1.4), 40 –0.2 (1.2), 6
PBC risk 4.0 (0.9), 40 4.9 (0.6), 6 4.1 (1.1), 43 3.9 (1.1), 6 0.1 (1.1), 40 –1.0 (1.1), 6
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Appendix 2 Health economics outcomes
Discrete choice experiment subgroup analyses
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TABLE 58 Discrete choice experiment subgroup results
Attribute level Base case Female Scotland Smoker Employed Low income Pay private 6-month check up Decay experience
Main effects
Recall (12 month) –0.015 –0.017 0.002 –0.038 –0.017 –0.019 –0.010 –0.042 –0.016
Recall (6 month) 0.348 *** 0.351 *** 0.359 *** 0.373 *** 0.351 *** 0.335 *** 0.350 *** 0.282 *** 0.331 ***
Recall (risk based) 0.089 ** 0.090 ** 0.088 ** 0.079 * 0.097 *** 0.094 ** 0.086 ** 0.108 ** 0.087 **
Bleed hardly ever 0.099 ** 0.100 ** 0.080 0.066 0.107 ** 0.096 ** 0.113 ** 0.014 0.109 *
Bleed occasional 0.089 ** 0.091 ** 0.072 0.075 0.099 ** 0.087 ** 0.081 * 0.076 0.091 *
Bleed fairly often –0.127 ** –0.125 ** –0.142 ** –0.149 ** –0.129 ** –0.127 ** –0.135 ** –0.213 *** –0.153 **
Bleed very often –0.268 *** –0.277 *** –0.272 ** –0.238 ** –0.297 *** –0.257 ** –0.279 ** –0.103 –0.258 *
Early decay 0.058 * 0.059 * 0.050 0.054 0.057 0.046 0.070 * –0.010 0.008
Moderate decay –0.241 *** –0.239 *** –0.245 *** –0.192 *** –0.238 *** –0.252 *** –0.270 *** –0.278 *** –0.230 ***
Advanced decay –0.382 *** –0.384 *** –0.382 *** –0.379 *** –0.400 *** –0.400 *** –0.399 *** –0.408 *** –0.295 ***
Annual cost –0.006 *** –0.006 *** –0.006 *** –0.006 *** –0.006 *** –0.006 *** –0.005 *** –0.007 *** –0.005 ***
ASC 1.484 *** 1.482 *** 1.446 *** 1.490 *** 1.513 *** 1.465 *** 1.565 *** 1.203 *** 1.412 ***
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Attribute level Base case Female Scotland Smoker Employed Low income Pay private 6-month check up Decay experience
Interaction terms
Recall (12 month) 0.075 ** 0.040 –0.042 0.009 –0.036 0.005 0.036 < 0.001
Recall (6 month) 0.010 0.025 0.043 –0.010 –0.058 0.003 0.096 * 0.043
Recall (risk based) –0.046 –0.008 –0.017 –0.035 0.021 –0.010 –0.021 0.010
Bleed hardly ever –0.045 –0.045 –0.067 –0.036 –0.030 0.044 0.121 * –0.026
Bleed occasional –0.043 –0.046 –0.036 –0.063 –0.049 –0.030 0.025 –0.009
Bleed fairly often 0.105 * –0.030 –0.049 –0.003 –0.042 –0.018 0.109 0.033
Bleed very often 0.053 –0.013 0.106 0.159 0.164 –0.028 –0.236 * –0.023
Early decay –0.076 ** –0.010 –0.014 0.041 –0.055 0.027 0.101 ** 0.091 **
Moderate decay 0.065 * –0.003 0.085 ** –0.011 0.003 –0.111 *** 0.043 –0.058
Advanced decay 0.132 *** –0.003 –0.004 0.074 –0.098 * –0.055 0.032 –0.173 ***
Annual cost < 0.001 > –0.001 < 0.001 0.001 *** –0.001 *** 0.002 *** 0.002 *** –0.001 ***
ASC –0.125 –0.111 –0.015 –0.056 –0.240 *** 0.200 ** 0.428 *** 0.147
LR tests
Log-likelihood –3856 –3839 –3849 –3850 –3845 –3835 –3821 –3829 –3840
AIC 7739 7730 7751 7752 7742 7722 7694 7711 7733
BIC 7837 7926 7948 7949 7939 7919 7891 7907 7930
LR test (chi sq) 34.92 13.61 12.12 22.05 42.59 70.14 53.91 31.80
LR test (p-value) < 0.001 0.001 0.002 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001
*p < 0.1, **p < 0.05, ***p < 0.01.
BIC, Bayesian information criterion; LR, likelihood ratio.
Region (1 = England; –1= rest of UK); sex (1 = female; –1=male); income (1 = low income < £20,800 per year; –1= all other reported incomes); smoker (1= current smoker;
–1 = never smoked or previous smoker); 6-month recall (1 = usually attends the dentist for a check-up at least every 6 months; –1 = usually attends a check-up less than every
6 months); experience of decay (1 = any dental decay; –1= never); pay private (1 = usually pays out of pocket or through insurance; –1= usually obtains free or NHS-subsidised
dental care).
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TABLE 59 Descriptive data from multiple imputation data set
Variable
M= 0 M= 1 M= 2 M= 3 M= 4 M= 5
n Mean SD n Mean SD n Mean SD n Mean SD n Mean SD n Mean SD
WTP
WTP (constant) 2372 £948 £0 2372 £947.51 £0.00 2372 £947.51 £0.00 2372 £947.51 £0.00 2372 £947.51 £0.00 2372 £947.51 £0.00
WTP (recall) 2209 –£48 £203 2358 –£47.84 £202.77 2358 –£50.49 £203.65 2358 –£47.18 £202.67 2358 –£49.38 £202.16 2358 –£50.22 £203.15
WTP (bleeding) 1642 £67 £55 2357 £65.78 £56.34 2357 £65.00 £57.57 2357 £66.26 £57.47 2357 £66.09 £56.82 2357 £65.62 £55.80
WTP (caries) 2063 –£144 £63 2371 –£142.97 £64.49 2371 –£143.24 £63.89 2371 –£143.07 £64.85 2371 –£142.31 £64.49 2371 –£143.41 £63.20
EQ-5D-3L utilities
Utility (baseline) 1606 0.905 0.198 2359 0.909 0.190 2359 0.909 0.193 2359 0.908 0.191 2359 0.905 0.202 2359 0.909 0.193
Utility (1 year) 1670 0.889 0.203 2358 0.894 0.202 2358 0.891 0.202 2358 0.889 0.204 2358 0.889 0.207 2358 0.890 0.206
Utility (2 year) 1618 0.850 0.210 2358 0.849 0.215 2358 0.848 0.213 2358 0.849 0.216 2358 0.846 0.217 2358 0.852 0.208
Utility (3 year) 1525 0.819 0.208 2358 0.821 0.209 2358 0.821 0.209 2358 0.818 0.211 2358 0.821 0.207 2358 0.822 0.206
Utility (4 year) 1735 0.784 0.210 2358 0.783 0.211 2358 0.783 0.214 2358 0.782 0.212 2358 0.780 0.215 2358 0.784 0.211
NHS costs
NHS dental 2209 £113.13 £173.29 2358 £112.94 £173.69 2358 £111.88 £170.19 2358 £114.03 £174.73 2358 £112.57 £172.41 2358 £112.53 £172.08
NHS GP 990 £29.94 £62.65 2357 £32.30 £64.99 2357 £32.25 £65.54 2357 £33.38 £70.81 2357 £31.24 £63.35 2357 £30.65 £65.64
NHS inpatient 1153 £8.32 £75.18 2357 £7.87 £73.19 2357 £8.60 £75.86 2357 £9.32 £79.52 2357 £9.17 £78.29 2357 £9.00 £78.08
NHS outpatient 1003 £7.29 £56.29 2357 £9.04 £66.76 2357 £9.86 £68.83 2357 £8.13 £57.22 2357 £7.28 £57.46 2357 £9.04 £63.73
NHS accident and
emergency
1003 £0.90 £10.80 2357 £1.03 £11.46 2357 £1.50 £13.92 2357 £1.09 £11.84 2357 £1.32 £13.07 2357 £0.92 £10.87
Participant
Time and travel 2128 £92.22 £50.58 2358 £89.74 £51.55 2358 £89.40 £51.61 2358 £89.82 £51.46 2358 £89.35 £51.35 2358 £89.02 £51.25
Patient co-charges 2209 £98.88 £120.69 2358 £100.07 £122.59 2358 £98.93 £119.80 2358 £99.32 £120.35 2358 £98.89 £121.08 2358 £98.59 £119.94
Private dental 1022 £84.25 £660.22 2357 £109.04 £849.88 2357 £63.28 £499.06 2357 £84.98 £728.30 2357 £66.04 £625.52 2357 £66.34 £531.18
Manual toothbrush 747 £20.09 £9.90 2357 £19.46 £10.14 2357 £19.76 £10.07 2357 £19.68 £10.03 2357 £19.51 £9.99 2357 £19.34 £10.03
Electric toothbrush 526 £38.61 £55.08 2357 £37.02 £53.56 2357 £35.55 £50.66 2357 £35.34 £51.21 2357 £36.49 £54.15 2357 £34.06 £48.40
Replacement heads 572 £15.40 £11.09 2357 £13.88 £11.15 2357 £13.86 £11.25 2357 £13.50 £10.84 2357 £13.82 £11.12 2357 £13.85 £11.17
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